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ABSTRACT 
It has been hypothesised that the melanoma tumour antigen p97 (MTf) may participate in 
melanoma progression due to the fact that the MTf plays a vital role in proliferation and 
tumorigenesis. This suggestion has been supported by the high levels of MTf expression in 
melanoma cells and the fact that previous studies demonstrated silencing MTf decreased melanoma 
tumour xenograft growth in vivo. On the other hand, N-myc downstream regulated gene 1 
(NDRG1), is a potent metastasis suppressor and acts to inhibit several oncogenic pathways, such 
as WNT, PI3K/AKT, etc. This thesis sought to elucidate the mechanism of MTf activity as a novel 
pro-oncogenic signalling protein involved in melanoma pathogenesis and whose molecular 
mechanism(s) of action remain unclear. 
 
Since metastasis accounts for most cancer deaths and is a major problem in melanoma, it was 
critical to further discover the molecular mechanisms that underlie NDRG1’s ability to inhibit 
progression and metastasis of melanoma. Furthermore, this thesis examined a promising anti-
metastatic therapeutic strategy by assessing the novel, clinically trialed, anti-cancer agent, namely 
di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), which potently up-
regulates NDRG1 in a variety of tumour cells. 
 
This dissertation consists of 6 chapters: A comprehensive literature review (Chapter 1: 
Introduction); a general materials and methods chapter (Chapter 2: Materials and Methods); 3 
results chapters (Chapters 3-5); and a general discussion of findings and future directions 
(Chapter 6: Discussion). 
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Chapter 3: A persistent mystery in the melanoma field has been the molecular function of one of 
the first melanoma tumour antigens characterised, namely the pro-oncogenic protein, MTf. The 
current study hypothesised that MTf may participate in melanoma progression since MTf plays a 
vital role in melanoma cell proliferation and tumourigenesis in vivo in melanoma tumours. On the 
other hand, NDRG1 is a potent growth and metastasis suppressor and acts to inhibit multiple 
oncogenic pathways, such as PI3K/AKT, WNT, etc. The expression of NDRG1 in a variety of 
melanoma cells suggests a potential role in inhibiting metastasis, and the aim of this study was to 
investigate the functional role of MTf in oncogenesis and its relationship with NDRG1. For the 
first time, Chapter 3 demonstrates that MTf over-expression markedly down-regulates NDRG1 
expression in multiple melanoma cell models. Conversely, silencing MTf expression increased 
NDRG1 levels. On the other hand, silencing NDRG1 increased MTf expression, while NDRG1 
over-expression decreased MTf. These observations indicate a negative feedback loop exists 
between these proteins in a “Yin-Yang” relationship.  
 
Mechanistically, silencing NDRG1 led to nuclear MTf accumulation and up-regulation of 
oncogenic β-catenin and its downstream targets, cyclin D1 and c-Myc. The increase in c-Myc may 
be responsible for the down-regulation of NDRG1 by MTf, as c-Myc is known to suppress NDRG1 
transcription. These studies revealed a mechanism by which MTf is able to down-regulate NDRG1 
through c-Myc.  In fact, the Yin-Yang relationship between MTf and NDRG1 was broken after c-
Myc silencing, suggesting that c-Myc plays a major role in the inter-relationship between MTf and 
NDRG1. MTf over-expression was demonstrated to activate the oncogenic PI3K/AKT pathway 
and this was associated with increased β-catenin levels and nuclear translocation of β-catenin, 
indicating a key role for MTf in regulating key pro-oncogenic signalling pathways.  
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Investigation of melanoma patient specimens also demonstrated a strong Yin-Yang relationship 
between MTf and NDRG1 expression and this was particularly notable examining the relationship 
between melanoma progression and the NDRG1/MTf ratio. These investigations demonstrated a 
key role of MTf as a pro-oncogenic signalling protein that displays an inverse inter-relationship 
with NDRG1. This finding could be important for the development of a prognostic marker and 
novel treatments. In fact, apart from up-regulating NDRG1, the novel anti-cancer agent, DpC, was 
demonstrated to significantly decreased MTf and cyclin D1 expression. Collectively, for the first 
time, the studies in Chapter 3 contribute a novel body of evidence demonstrating the role of MTf 
as a pro-oncogenic signalling protein that down-regulates the metastasis suppressor, NDRG1, in 
vitro and in vivo. 
 
Chapter 4:  To investigate the hypothesis that the pro-oncogenic effects of MTf result from its 
ability to up-regulate common oncogenic up-stream signalling, the role of MTf on the expression 
of key signalling molecules was assessed. These included the WNT co-receptor, lipoprotein 
receptor-related protein 6 (LRP6) and β-catenin, as well as members of the receptor tyrosine kinase 
(RTK) family, particularly c-Met and the vascular endothelial growth factor receptor 2 (VEGFR2). 
These proteins were investigated as MTf was demonstrated in Chapter 3 to down-regulate 
NDRG1, which has been demonstrated to inhibit the expression of WNT, PI3K, and AKT pathway 
proteins, as well as other RTKs. Furthermore, MTf over-expression significantly increased LRP6 
and c-Met and their activation, as well as VEGFR2 levels. In contrast, silencing MTf had the 
opposite effect. On the other hand, silencing NDRG1 demonstrated a significant increase of LRP6, 
c-Met, and VEGFR2, and the activated forms of LRP6 and c-Met.  
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Using fractionation and/or confocal immunofluorescence microscopy, LRP6, β-catenin, c-Met, 
and VEGFR2, as well as the activated forms of LRP6 and c-Met, were internalised in SK-MEL-
28 cells upon MTf over-expression. Moreover, the translocation of these proteins into the 
cytoplasm and nucleus was significantly increased with MTf expression, while MTf silencing had 
the opposite effect. This was important, as further studies demonstrated that MTf associated with 
these proteins in a potential complex by co-immunoprecipitation (co-IP) and/or confocal 
microscopy, suggesting either of these proteins could play co-chaperone roles. This mechanism 
may provide an explanation of the pro-oncogenic activity of MTf.  
 
Finally, the anti-cancer drug, DpC, effectively up-regulated anti-oncogenic NDRG1 and mitogen-
inducible gene 6 (MIG6), while suppressing pro-tumourigenic MTf, LRP6 and LRP6 activation. 
These findings highlight that DpC effectively targets NDRG1 to suppress the oncogenic activity 
of MTf and its oncogenic partners. 
 
Chapter 5: c-Myc is known to transcriptionally repress the potent metastasis suppressor, NDRG1. 
Studies in Chapter 3 demonstrated that MTf over-expression induced nuclear translocation of c-
Myc, and this was potentially responsible for the decreased NDRG1 expression in MTf over-
expressing cells. Further studies demonstrated that the Yin-Yang relationship between MTf and 
NDRG1 was broken after c-Myc silencing, suggesting a crucial role of c-Myc in the inter-relating 
regulation of MTf and NDRG1. Therefore, Chapter 5 examined in melanoma cells the effect of 
silencing c-Myc on the protein expression of LRP6, c-Met and VEGFR2, as well as the activation 
of LRP6 and c-Met, in addition to β-catenin, cyclin D1 and the tumour suppressor, MIG6.  
 
xiii 
 
Upon c-Myc silencing there was significant increase in plasma membrane and cytoplasmic β-
catenin expression, as well as a decrease of nuclear β-catenin, which may be a consequence of 
NDRG1 up-regulation due to the ablation of c-Myc transcriptional repression. These studies also 
demonstrated that MTf, c-Met, activated c-Met, VEGFR2 and cyclin D1 were increased upon c-
Myc silencing, which can be speculated to be a compensatory oncogenic response. On the other 
hand, the WNT co-receptor LRP6 and its activated form were significantly decreased after c-Myc 
silencing. This response suggested an involvement of NDRG1 on LRP6 down-regulation, as 
NDRG1 was also up-regulated after c-Myc loss and is known to bind to, and inhibit, LRP6.  
 
In conclusion, this dissertation has markedly expanded knowledge regarding the molecular 
mechanisms involved in MTf pro-oncogenic activity. For the first time, it has been demonstrated 
that MTf down-regulates the potent metastasis suppressor, NDRG1, in melanoma cells, indicating 
a negative feedback loop between these two proteins. In addition, MTf was demonstrated to be 
also localised in the nucleus and cytoplasm and co-localised with several major oncogenic proteins 
e.g., c-Met, LRP6, β-catenin, etc., that are involved in melanoma pathogenesis. In fact, co-IP 
confirmed this, suggesting a potential co-chaperone role for MTf and its partners. Collectively, the 
results from this dissertation have demonstrated that MTf is a pro-oncogenic signalling protein 
involved in melanoma pathogenesis. 
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INTRODUCTION 
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Emerging Players in Melanoma Progression and Oncogenic Signaling Biochim Biophys Acta 
– Mol Cell Res (Invited Review of the Literature; Impact factor 5.1). 1863:770-84. 
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1.1 General Introduction: Melanoma  
Melanoma is one of the most aggressive and treatment-resistant human cancers, having increased 
radically worldwide during the past several decades in the Caucasian population (1). With an 
overall mortality rate of around 20%, it is responsible for the 80% of skin cancer-related deaths 
worldwide, which is largely due to its propensity to metastasize to other organs (1,2). In fact, 
metastatic melanoma is the 4th most common cancer in Australia and the 6th most common cancer 
in the USA (3,4). Although early-stage melanoma can be effectively treated with surgery, 
metastatic melanoma is highly resistant to conventional therapies (3).  
 
Unfortunately, the annual incidence rates of melanoma worldwide are increasing rapidly each year, 
and at a greater rate than any other major cancer (1). According to recent studies, 1- and 2- year 
survival rates in patients with metastatic melanoma were ~25% and 10%, respectively, with a 
median overall survival of 6 months (1). There is a consensus that ultraviolet (UV)-induced DNA 
damage is a major etiological factor in the pathogenesis of these tumours (5). Indeed, UVA 
(wavelength range: 315 to 400 nm) and UVB (wavelength range: 280 to 315 nm) promote 
deleterious effects on biomolecules and can also trigger DNA damage through UV-induced 
reactive oxygen species (ROS) production, which directly damages DNA, causing genetic 
alterations (6). UVB is thought to be more carcinogenic than UVA, as it induces the formation of 
cyclobutane pyrimidine dimers (CPD) and pyrimidine(6-4)pyrimidone photoproducts and 
development of oxidative stress (7), while UVA generally is found to produce mainly oxidative 
stress (8). Considering these multiple effects, UV radiation may be conducive to melanoma 
development via combined genotoxic and mitogenic effects in melanocytes (6).  
 
3 
 
1.1.1 Melanoma Progression: From Melanocytes to Melanoma 
 
1.1.1.1 Melanocyte Development: An Overview 
Melanoma originates from neural-crest derived melanocytes, which are pigment-producing cells 
located in various anatomic sites, such as the base layer (stratum basale) of the skin’s epidermis, 
the uvea of the eyes, the inner ear, meninges, bones and heart (9). During embryonic development, 
multipotent trunk neural crest cells undergo lineage specification to form melanocyte precursors 
(viz., melanoblasts) (10). After migration and proliferation between the somites and ectoderm, and 
later invasion into the ectoderm, melanoblasts differentiate into melanocytes (Figure 1.1) (11). 
Following the maturation of melanocytes, melanin production starts in special organelles, namely 
melanosomes (Figure 1.1), via a biochemical process known as melanogenesis, which involves 
tyrosine oxidation products that are polymerized to form melanin (12). Finally, the mature 
melanosomes (filled with granules of melanin) are transported to keratinocytes and the life cycle 
of melanocytes (hair melanocytes) ends with eventual cell death (12). 
 
The transformation of melanocytes into melanoma cells is a multi-step process that begins with 
the horizontal or radial growth phase, which then progresses towards the invasive phenotype (10). 
Indeed, the development of melanoma from melanocytes occurs via a stepwise mechanism 
involving clonal succession and acquisition of deleterious genomic alterations (3). Following the 
vertical growth phase, the tumour cells invade deeply into the dermis/hypodermis, and eventually 
penetrate the endothelium of capillaries and enter the blood stream, allowing them to form distant 
metastases (10). Integral to the progression of metastatic melanoma is a complex series of 
molecular events that include multiple and sequential genetic lesions (e.g., driver mutations) that 
result in an invasive phenotype. 
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Figure 1.1: Schematic of the Structure and Function of Melanocytes. Melanocytes are located 
at the stratum basale and produce melanin with melanosomes. Melanin itself can be transferred to 
the neighbouring keratinocytes and protects the cells in the skin from the hazardous effect of UV 
radiation.  
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1.1.1.2 Some key ‘driver’ Mutations in Melanoma Development 
Genome-wide sequencing approaches have identified remarkable genetic complexity in 
melanoma, comprising thousands of mutations, deletions, amplification, translocations and 
changes in DNA methylation within a single tumour (13). Despite this abundance and complexity 
of genetic lesions, many of which are so-called ‘passenger’ mutations, several key genetic 
alterations in melanoma tumourigenesis have been identified that are known as ‘driver’ mutations 
(for recent reviews, see (3,14)). 
 
Perhaps the best studied oncogenic mutation in melanoma is that of v-Raf murine sarcoma viral 
oncogene (BRAF) that encodes a serine/threonine protein kinase, which acts in the RAS-RAF-
MEK-ERK mitogen-activated protein kinase (MAPK) pathway (for review see: (3)). Activating 
mutations in BRAF occur in >50% of melanomas, with the most common mutation leading to a 
Val-to-Glu substitution at position 600 (p.V600E; (3)). While the wild-type BRAF kinase is 
typically activated by KRAS, the p.V600E mutation confers BRAF with unregulated kinase 
activity, leading to constitutive activation of MEK that drives the growth-promoting ERK pathway 
(3). Interestingly, melanomas that possess wild-type BRAF typically have mutations in key genes 
encoding upstream proteins of the MAPK pathway, including NRAS, KIT, GNAQ, and GNA11 (3). 
This observation strongly suggests the centrality of over-activation of the RAS-RAF-MEK-ERK 
pathway in melanoma pathogenesis. Moreover, activating BRAF mutations are frequently found 
in benign and dysplastic nevi, and the activation of BRAF leads to nevus development through a 
process known as oncogene-induced senescence (3). Despite the over-activation of BRAF in these 
nevi, there is induction of cell cycle arrest resulting from the expression of the key cyclin-
dependent kinase inhibitor, p16INK4A (15) (see below for further discussion). Nonetheless, BRAF 
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mutations are considered to be common early stage genetic mutations in melanoma progression 
(3). However, activating mutations in BRAF alone are insufficient to cause melanoma. Indeed, 
additional genetic alterations in BRAF-mutant cells are required to elicit a fully cancerous 
phenotype (14). 
 
One such further genetic lesion that cooperates with activating BRAF mutations, and represents 
another high-penetrance genetic alteration in melanoma, is the loss or inactivating mutation of the 
cyclin-dependent kinase inhibitor 2A (CDKN2A) locus (16,17). Notably, this locus is located on 
chromosome 9p21 and encodes two tumour suppressor proteins, p16INK4A and p14ARF (differing in 
post-translational modifications), which both function to arrest the cell cycle. Importantly, the 
CDKN2A locus is the most frequently deleted region in melanoma (18), occurring in 16-41% of 
sporadic melanomas and with high penetrance in familial melanoma (10,14). As alluded to above, 
p16INK4A is a key negative regulator of the cell cycle that binds to and inhibits the cyclin-dependent 
kinase (CDK4), thereby activating the retinoblastoma (RB) protein (i.e., by preventing its 
phosphorylation) and preventing cell cycle progression at the G1-S checkpoint (19). On the other 
hand, p14ARF acts as a positive regulator of p53 by inhibiting its major negative regulator, the 
nuclear-localised E3 ubiquitin ligase, murine double minute 2 (MDM2) (10,14). For this reason, 
an inactivation of CDKN2A through deletion, promoter silencing or mutation leads to uncontrolled 
cell proliferation (10).  
 
Interestingly, sustained expression of oncogenic BRAFV600E in melanocytes induces the expression 
of p16INK4A, which does not appear to involve telomere attrition and loss of replicative potential 
(15). This so-called “oncogene-induced senescence” barrier in melanocytes promotes nevus 
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development and is controlled by the p16INK4A-cyclin D/CDK4-RB cell cycle checkpoint (3,15). 
In normal melanocytes, the induction of p16INK4A by the MAPK pathway typically involves the 
activation of microphthalmia-associated transcription factor (MITF) (20). Crucially, amplification 
of the MITF locus is found in 20-30% of melanomas, and is frequently accompanied by activating 
BRAF mutations and p16INK4A loss (20). Such observations underscore the importance of this 
oncogene-induced senescence checkpoint as a gatekeeper of melanoma progression (21,22). 
 
Another genetic lesion associated with melanoma is amplification or mutations in CDK4, which 
is associated with a small number of cases of familial melanoma (23,24). CDK4 is located on 
chromosome 12q13 and is the binding partner of p16INK4a. Mutations of CDK4 are often found in 
its binding domain, making this protein incapable of binding to functional p16INK4A (23,24). 
Indeed, the CDK4 pathway is dysregulated in most melanomas as a result of hyper-activation of 
extracellular signal regulated kinase (ERK) or loss of p16INK4A (see above; (3)). Both high-
penetrance genes, CDKN2A and CDK4 are involved in cell cycle control, as both mutations, which 
affect p16INK4A and CDK4, respectively, disturb the G1/S phase check point (23,24).  
 
It is worth emphasizing here that, although promotion of the cell cycle by activation of the RAS-
RAF-MEK-ERK pathway is a major contributor to melanoma pathogenesis and progression 
(discussed further in section 1.2.1), other dysregulated signalling pathways also play a significant 
etiological role. Indeed, due to the large number of driver genes involved in melanoma progression 
(3), subsequent sections of this Chapter will deal primarily with the major signalling pathways that 
are dysregulated in melanoma. For more comprehensive reviews of the driver mutation 
“landscape” in melanoma, we refer readers to recent reviews on this topic (see (3,14)).  
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1.1.2 Key Oncogenic Signalling Pathways Involved in Melanoma 
 
Cancer results from abnormal cellular growth and proliferation, which is uncoordinated with that 
of the normal tissues around it and is caused by a combination of genetic and epigenetic 
modifications that lead to neoplastic transformation (25). In the past years, several key molecular 
pathways have been uncovered that are involved in melanoma onset, progression and proliferation 
(26). Notably, melanoma metastasis is typically linked with an activation of signalling pathways 
that are responsible for embryogenesis (27). The following section will expound the most crucial 
oncogenic signalling pathways involved in this disease. 
 
1.1.2.1 MAPK Signalling Pathway 
The mitogen-activated protein kinase (MAPK) signal transduction pathway has been the focus of 
intense investigation in oncology, as it is known to regulate cell growth, proliferation, 
differentiation, migration and apoptosis (28). In the field of melanoma biology, the MAPK 
pathway has been of interest since the discovery of frequent activating mutations of the BRAF 
kinase in melanoma and nevi (29).  
 
Initiated either by receptor tyrosine kinases (RTKs) binding to their cognate ligands, or integrin 
adhesion of the extracellular matrix and the cell membrane, MAPK signalling involves the 
transmission of activation signals via Rat sarcoma (RAS) GTPase, which is associated with the 
inner leaflet of the plasma membrane (Figure 1.2) (29). In its active GTP-bound state, RAS can 
bind and activate RAF (RAF-1, BRAF and ARAF) by a complex sequence of events (28). The 
signalling cascade culminates in MEK1/2 dual-specificity protein kinases phosphorylating and 
activating the ERK1 and ERK2 MAPKs, which are then able to translocate to the nucleus and 
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regulate several transcription factors (Figure 1.2) (28,30,31). As a result, gene expression patterns 
are altered by an increased expression of nuclear transcription factors, such as c-Myc and MITF 
etc., leading to cell proliferation (28,30,31). Additionally, MAPK signalling can lead to increased 
expression of cyclin D1, which then interacts with CDK4/6 to promote phosphorylation and 
inhibition of the retinoblastoma family of transcriptional repressors, ultimately leading to the 
enhancement of E2F-dependent transcription of S-phase genes (32). 
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Figure 1.2: Schematic of Cellular Events During MAPK Signalling. MAPK signalling is 
initiated with the activation of the Receptor Tyrosine Kinase (RTK) for example via growth factors 
(GF). Activation of RTKs stimulates the conversion of RAS from a GDP-bound state to GTP-
bound (i.e., active) state via the activity of guanine nucleotide exchange factors (GEF). Activated 
RAS can then phosphorylate RAF, leading to its activation. Once active, RAF can phosphorylate 
and activate MEK1 and MEK2 that then subsequently activate ERK1/2 resulting in the 
translocation and regulation of several transcription factors in the nucleus, such as cyclin D1, c-
MYC and MITF. Besides initiation of MAPK signalling, RAS-GDP is also able to promote 
survival through the PI3K signalling pathway, by activating AKT. 
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More recently, and as alluded to above, BRAF has attracted special interest, as it was found to be 
mutated in 66% of malignant melanomas (28,33). Importantly, the V600E somatic missense 
mutation in BRAF results in a conformational change in the activation loop between kinase 
subdomains VII and VIII (28). This mutation induces a constitutive and unregulated activation of 
kinase activity that leads to hyper-activation of MAPK signalling (28,31). Interestingly, this 
mutation is not a typical UV “fingerprint” mutation as it is more common in melanomas occurring 
on intermittently sun-exposed skin than melanomas in unexposed or chronically sun-damaged skin 
(acral and mucosal melanomas), and is often accompanied by amplification of the mutant allele 
(25). These and other observations suggest that complex genetic interactions promote BRAF 
mutations rather than physicochemical mechanisms (34) and further indicate that BRAF mutations 
are normally lethal unless a certain genetic and biochemical microenvironment allows those cells 
to survive and proliferate (28).  
 
1.1.2.2 WNT Signalling Pathway 
The WNT signalling pathway controls crucial processes, such as cell fate determination, cell 
polarity, proliferation and migration (35). The WNT family of proteins are secreted glycoproteins 
that bind to the seven-transmembrane Frizzled receptor (FZD) proteins to initiate intracellular 
signal transduction (35). Following the binding of WNT to FZD, three possible signalling 
pathways are activated: (i) a canonical β-catenin-dependent pathway; (ii) a non-canonical β-
catenin-independent pathway for cell polarity signalling; and (iii) a WNT-dependent, protein 
kinase-C (PKC)-dependent pathway (Figures 1.3 & 1.4) (36). 
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Figure 1.3: Schematic Representation of the Canonical WNT Signal Transduction Cascade. 
A: In absence of WNT ligands, β-catenin is normally bound to E-cadherin as part of the adherens 
junction complex. Dissociated from the E-cadherin complex, β-catenin is bound by the destruction 
complex of Axin, GSK3, CK1α and APC in the cytosol. Hyper-phosphorylation of β-catenin by 
CK1α and GSK3 facilitates its targeted degradation mediated by β-TrCP. B: WNT stimulation 
causes inhibition of GSK3 via disheveled protein (DVL), followed by inhibition of the 
GSK3/Axin/APC complex. Both PI3K and MAPK pathways also contribute to inhibiting the 
GSK3/Axin/APC complex. DVL itself gets activated by PAR-1, a kinase that phosphorylates DVL 
directly. As a result, free β-catenin accumulates in the cytoplasm and is then able to translocate to 
the nucleus where it complexes with T cell factor (TCF) to mediate transcriptional activation of 
oncogenic target genes, such as cyclin D1, c-Myc and ZEB-1. 
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Figure 1.4: Schematic Representation of the Non-Canonical WNT Signal Transduction 
Cascade. After the activation of FZD receptors by WNT5A, Wnt11 ligands, or rat Fz2 (RFz-2) 
protein the dissociation of heterotrimeric G-protein into Gα- and Gβ/γ-subunits releases 
intracellular Ca2+ from the ER. Increased intracellular calcium promotes activation of protein 
kinase C (PKC) and calcium/calmodulin-dependent kinase II (CamKII). On the other hand, 
CamKII activates the nuclear factor associated with T-Cell (NFAT) transcription factor and also 
the TGF-β activated kinase (TAK1) and Nemo-like kinase (NLK) that antagonizes β-catenin/TCF 
signalling. 
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Abnormal activation of the WNT pathway is considered to be one of the key signalling cascades 
that results in melanoma development (37). Indeed, the canonical and non-canonical WNT 
signalling cascades are thought to affect different stages of tumour progression, as the canonical 
pathway contributes to melanoma formation, while the non-canonical pathways is involved in 
metastasis (37). 
 
1.1.2.2.1 The Canonical WNT Pathway  
The key role of this pathway is the accumulation and translocation of the adherens junction 
complex molecule, β-catenin, into the nucleus, where it cooperates with other transcription factors 
to activate WNT target gene expression (Figure 1.3) (35). As part of its normal activity, β-catenin 
functions as an anchor to the actin cytoskeleton by directly linking it with a single-span, trans-
membrane glycoprotein, namely E-cadherin, via α-catenin (35). In fact, β-catenin is, in general, 
bound at the cell membrane to the intracellular domain of E-cadherin as part of the adherens 
junction complex (38).  
 
In the absence of WNT signalling (Figure 1.3A), a β-catenin destruction complex comprised of 
Axin, adenomatous polyposis coli (APC), glycogen synthase kinase 3β (GSK3β) and casein kinase 
1α (CK1α) causes hyper-phosphorylation of β-catenin by casein kinase and GSK3β, targeting it 
for ubiquitination and subsequent degradation by the proteasome (35). Binding of WNT (Figure 
1.3B) to its receptor, FZD, and to the co-receptor low-density-lipoprotein-related proteins 5/6 
(LRP5/6), leads to the release of β-catenin from E-cadherin and the stabilisation of β-catenin within 
the cytoplasm (35). As a result, β-catenin then translocates into the nucleus, where it acts as a co-
activator of the TCF/LEF transcription factors to up-regulate WNT-responsive genes, including c-
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Myc, cyclin D1 and ZEB-1, which promote proliferation, cell cycle progression and inhibition of 
E-cadherin expression, respectively, in melanoma and other cancers (39-41).  
 
1.1.2.2.2 The Non-Canonical WNT /Ca2+ Pathway  
In general, the non-canonical pathway can be divided into two separate branches: the planar cell 
polarity (PCP) pathway and the WNT/Ca2+ pathway, the latter of which is often denoted as the β-
catenin-independent pathway (Figure 1.4) (35). The PCP pathway is distinguished by its 
regulation of the actin cytoskeleton (for a review see (35)). However, this review will focus on the 
WNT/Ca2+ pathway, as it is the branch of non-canonical WNT signalling that is most likely to be 
involved in melanoma development (42,43).  
 
The non-canonical WNT/Ca2+ pathway modulates canonical WNT signalling for dorsal axis 
formation, as well as the PCP pathway for cellular movement during gastrulation (35). This Ca2+-
dependent pathway was identified following findings that the interaction of several WNT ligands 
with FZD receptors could stimulate intracellular Ca2+ release from the ER (35). Notably, the 
WNT5a and WNT11 ligands, as well as the rat FZD2 (RFz-2) proteins, are capable of stimulating 
the intracellular release of Ca2+ from the ER without affecting β-catenin stabilisation (44). The 
intracellular Ca2+ release from the ER results from the dissociation of heterotrimeric G-proteins 
into Gα- and Gβ/γ-subunits after binding of specific WNT ligands to FZD receptors (35). The 
increase of intracellular calcium, in turn, promotes activation of various Ca2+-sensitive proteins, 
such as protein kinase C (PKC) and calcium/calmodulin-dependent kinase II (CamKII) (Figure 
1.4) (35). CamKII has been demonstrated to activate the nuclear factor associated with T-cell 
(NFAT) transcription factor and also the TGFβ activated kinase (TAK1) and Nemo-like kinase 
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(NLK), that can antagonise β-catenin/TCF signalling (35). In general, the non-canonical 
WNT/Ca2+ pathway appears to function to modulate both the PCP pathway and the canonical WNT 
pathway (44-46). However, the mechanism of this modulation remains to be fully elucidated (35).  
 
1.1.2.3 WNT Signalling and its Role in Melanoma 
Although WNT signalling is considered to be an important driver of oncogenesis in diverse 
cancers, the precise role of WNT/β-catenin signalling in melanoma remains unclear (37,47,48). 
Nevertheless, immunohistochemical detection of nuclear β-catenin has provided evidence for the 
activation of the canonical WNT/β-catenin pathway in a subclass of primary melanomas, 
suggesting a role for this pathway in melanoma development (47). Additionally, constitutively 
activated canonical WNT signalling via β-catenin acts synergistically with the MAPK cascade, 
with both signalling pathways resulting in the induction of melanoma formation and development 
(49). 
 
Normally, WNT signalling is required for the development of melanocytes from their neural crest 
precursors (50). This is mediated by β-catenin-dependent up-regulation of transcriptional targets, 
such as the homeobox gene, MITF, which encodes the transcription factor, MITF that promotes 
pigment cell formation (50). MITF modulates the expression of several cell-cycle progression and 
differentiation genes, such as CDK2, as well as the expression of melanomagenic proteins (51). 
Hence, it is recognized as the master regulator of melanocyte development, survival and function 
(51,52). In addition, β-catenin increases the growth and proliferation of melanoma cells via up-
regulating the POU domain transcription factor, BRN2, which has been implicated in controlling 
proliferation of melanoma cells (53). 
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An interesting recent study by Grossmann and colleagues has provided a functional connection 
between the canonical WNT signalling pathway and the non-canonical pathway via its ligand 
WNT5A in melanoma metastasis (54). Non-canonical WNT signalling contributes to tumour 
metastasis after its activation by WNT5A (55). As part of this mechanism, the binding of the 
WNT5A ligand to the FZD4-LRP6 receptor complex at the cell surface of melanoma cells leads 
to activation of the small GTPase, ARF6, which releases β-catenin from its interaction with N-
cadherin, thereby increasing: (i) the pool of free β-catenin; (ii) β-catenin-mediated transcription, 
and (iii) invasion. WNT5A signals via protein kinase C (PKC) and calcium-dependent enzymes 
independently of β-catenin, leading to melanoma cell migration and metastasis (54). In fact, 
WNT5A gene over-expression is commonly linked with high grade melanomas (42,56). 
Interestingly, WNT5A can promote the canonical WNT pathway by interacting with FZD and 
LRP6 to increase β-catenin signalling (54). However, while this latter induction of canonical WNT 
signalling by WNT5A has been demonstrated in non-melanoma cell types, such as HEK293 and 
mouse L cell lines, it is yet to be examined in melanoma (57). Notably, Weeraratna and colleagues 
have established that WNT/PKC stimulates cell motility via the regulation of genes involved with 
the epithelial to mesenchymal transition (EMT), including up-regulation of E-cadherin and down-
regulation of vimentin and SNAIL in melanoma cells (56) (see 1.2.5 for further discussion of the 
EMT in melanoma). 
 
In summary, WNT signalling in melanoma is extremely complex and requires the differential 
involvement and coordinated expression of multiple intracellular molecules and interacting 
pathways throughout the progression of the disease. Although, WNT signalling is a key driver of 
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melanoma progression, the precise functions of the WNT pathways in melanoma remain to be 
fully elucidated.   
 
1.1.2.4 PI3K Signalling Pathway 
Another signalling pathway known to be crucially involved in melanoma is the 
phosphatidylinositol-3-kinase (PI3K) pathway (58). Belonging to a conserved group of lipid 
kinases, PI3K is involved in various functions within the cell, such as cell growth, proliferation 
and metabolism (59). There are three subgroups of these enzymes: class 1, 2 and 3, with class 1 
being the most extensively characterised (60). PI3Ks are canonically activated by insulin growth 
factor 1 (IGF-1) binding to the IGF-1 receptor (60). The central role of class 1 PI3Ks is the catalysis 
of phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate 
(PIP3), which then functions as a docking site for 3-phosphoinositide-dependent protein-kinase 1 
(PDK1) to activate the protein kinase (59). 
 
PDK1 is able to phosphorylate the serine-threonine-specific kinase, AKT (also known as protein 
kinase B), leading to its activation (59). The active p-AKT then has the potential to phosphorylate 
up to 100 target proteins (59). One of these substrates is GSK3β, which is inhibited when 
phosphorylated by p-AKT (61). Indeed, as a result of GSK3β inhibition, free β-catenin is able to 
accumulate and translocate to the nucleus, where it can up-regulate expression of oncogenic genes, 
such as c-Myc and cyclin D1 (Figure 1.5) (35). In addition, phosphorylation of ERK by p-AKT 
causes increased expression of c-Myc by activating the mammalian target of rapamycin (mTOR) 
(62). Through these regulatory mechanisms, p-AKT elicits a strong anti-apoptotic effect and 
promotes cancer progression (63). 
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Figure 1.5: Schematic of the PI3K Signalling Pathway and its Effects on β-catenin. PI3K 
phosphorylates PIP2 to PIP3, which leads to the phosphorylation of AKT. Active p-AKT then acts 
like an oncogenic signalling kinase that promotes tumour progression by inhibiting GSK3β and 
allowing β-catenin to accumulate and move to the nucleus. As a result, β-catenin up-regulates the 
oncogenic expression of c-Myc, cyclin D1 and ZEB-1. Furthermore, p-AKT activates mTOR, 
which then leads to increased levels of c-Myc, a nuclear transcription factor that promotes 
proliferation. 
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1.1.2.5 PI3K Signalling Pathway and its Role in Melanoma 
Oncogenic RAS, which is involved in MAPK signalling (see above), is also known to be a positive 
upstream regulator of the PI3K pathway (64). Hence, activation of RAS transcription leads to 
downstream activation of two different, but interconnected pathways: the RAF-MEK-ERK 
pathway and the PI3K-AKT signalling pathway, the latter of which leads to activation of AKT and 
its downstream targets (31). While both cause cell proliferation, dissemination and survival, the 
PI3K-AKT signalling pathway also promotes anabolism, whereas the RAF-MEK-ERK pathway 
is more active in proliferation and invasion (31,65). 
 
As a PI3K pathway inhibitor, the phosphatase and tensin homologue deleted on chromosome 10 
(PTEN), catalyses the de-phosphorylation reaction of PIP3 back to PIP2 via its lipid phosphatase 
activity, resulting in reduced p-AKT levels and inhibition of the PI3K signalling pathway (Figure 
1.5) (60). Moreover, PTEN is able to target and dephosphorylate other proteins, such as focal 
adhesion kinase (FAK), resulting in inhibition of focal adhesions and a decrease in cellular 
migration (66,67). Interestingly, PTEN is also thought to interact with MAPK signalling by 
dephosphorylating adapter proteins, leading to decreased MEK1/2 and ERK1/2 phosphorylation 
(68). 
 
Uncontrolled signalling through the PI3K pathway results from PTEN loss/inactivation (69) and 
notably, the loss of tumour suppressor genes on chromosome 10, including PTEN, is detected in 
30% to 60% of non-inherited melanomas (70). Importantly, a loss of PTEN expression has been 
observed in 30% to 50% of established melanoma cell lines and 5% to 20% of primary melanomas 
(68). Notably, both BRAF and PTEN mutations have been found to occur concomitantly at high 
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rates in melanoma, while N-RAS was found to be mutated in mutual exclusivity with mutations in 
BRAF and PTEN (29).  
 
1.1.2.6 The EMT 
 
A crucial enabling process that is involved in melanoma development and progression is the EMT. 
Under normal physiological conditions, the EMT is vital during cellular development, and is 
characterised by rapid and often reversible changes in cellular phenotype (71). It is not only 
required for embryonic development, tissue remodelling and wound repair, but is also initially 
responsible for cell migration, invasion and metastasis (71-73). During the EMT, epithelial cells 
lose their cell-cell adherens junctions, reorganise their cytoskeleton, alter their polarity and gain 
mesenchymal characteristics via a switch in expression from keratin- to vimentin-type filaments 
(Figure 1.6) (71). In association with the over-expression of N-cadherin, the mesenchymal marker 
vimentin is also increased in cancer cells undergoing the EMT (74). Moreover, vimentin is an 
intermediate filament and plays a multifunctional role in cancer cell motility and mesenchymal 
cell shape (75).  
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Figure 1.6: Schematic of Cellular Events During EMT. The onset of EMT is associated with 
loss of epithelial cell-cell contacts. These involve adherens junctions that are connected to the actin 
cytoskeleton, tight junctions and gap junctions, which allow direct chemical interactions with 
neighbouring cells and desmosomes. As a result, the epithelial actin architecture is reorganised 
and matrix metalloproteinases (MMP) are expressed, leading to the degradation of extracellular 
matrix (ECM) proteins to release epithelial cells from the surrounding tissue and to maintain the 
mesenchymal phenotype. Once migrated to their target destinations, the tumour cells may return 
to their original epithelial phenotype via a process known as mesenchymal-epithelial transition 
(MET). 
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Having migrated to their target destinations, it is likely that tumour cells may revert to their original 
epithelial phenotype through a process known as mesenchymal-epithelial transition (MET), 
leading to the formation of secondary cancers (Figure 1.7). This reverse process illustrates an 
inherent plasticity of the epithelial phenotype (71).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Schematic of the Development from Normal Epithelium to Secondary 
Carcinomas via EMT and MET. During EMT, transformed and cancerous cells with 
mesenchymal phenotypes are able to enter the lymph/blood vessel through the basement 
membrane and disseminate to distant organs. In the second step, metastatic cancer cells exit the 
lymph/blood vessels and enter organs to form micro-metastases, which can transform to macro-
metastases via the mesenchymal-epithelial transition (MET). 
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E-Cadherin, a single-span, trans-membrane glycoprotein expressed in all epithelia, has been 
demonstrated to act as a tumour suppressor through its ability to bind in trans to E-cadherin from 
neighbouring cells through homotypic interactions, thereby promoting cell to cell adhesion and 
preventing metastasis (Figure 1.8) (76). Furthermore, E-cadherin forms a complex with β-catenin, 
p120 and α-catenin, which in turn connect this complex with the actin cytoskeleton, allowing the 
cell to be anchored to the neighbouring cells and to maintain the epithelial phenotype (35). 
However, loss of E-cadherin releases free β-catenin into the cytoplasm, which is then able to act 
as a coactivator of the TCF/LEF transcription factors by entering the nucleus (Fig. 5) (35). The 
down-regulation of E-cadherin is accompanied by an increase of mesenchymal neural cadherin 
(N-cadherin), in what is termed the “cadherin switch”, which alters cell adhesion by facilitating 
cell migration and invasion (71). N-cadherin is connected to the cytoskeleton via α- and β-catenin 
and also interacts with p120 catenin, signalling mediators and receptor tyrosine kinases (RTKs) 
(71).  
 
Moreover, in contrast to E-cadherin, which is ubiquitously expressed, N-cadherin is only expressed 
in neural tissue and muscle under normal conditions (71,77). Interestingly, through this “cadherin 
switch”, transitioning cells obtain a greater affinity for mesenchymal cells, while losing their 
association with epithelial cells via homotypic N-cadherin interactions (71). Considering that these 
latter interactions are weaker than the homotypic E-cadherin interactions, this further facilitates 
cell migration and invasion (71). Studies have demonstrated that this switch is more evident in 
metastatic than in primary tumours, leading to the hypothesis that N-cadherin itself can promote 
tumour progression and metastasis (74). In fact, the decrease in E-cadherin during tumour 
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development was observed in several different tumour types, such as malignant melanoma, and is 
correlated with poor patient prognosis (78). 
 
 
Figure 1.8: Schematic of the Adherens Junction. β-catenin and α-catenin function like a bridge 
between E-cadherin and the cytoskeleton. The extracellular domains of E-cadherin interact with 
those of the adjacent cells, mediating cell-cell adhesion. 
 
 
While the expression of the E-cadherin gene, CDH1, can be downregulated by promoter 
hypermethylation in a subset of pancreatic cancers (79), several inducible transcription factors are 
well-described to suppress expression of CDH1 by binding to the promoter region via their 
carboxyl terminal zinc fingers (for reviews, see (80) and (71)). These include the SNAIL family 
members, SNAIL1 and SNAIL2 (also known as SLUG), which are homologous zinc finger 
transcriptional repressors that function to activate the EMT (81,82). This group of EMT-inducing 
transcription factors repress epithelial genes, such as E-cadherin, by binding to E-box DNA in the 
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promoter region of CDH1 (71). However, while acting as a direct repressor of genes involved in 
maintenance of the epithelial phenotype, SNAIL proteins can directly upregulate the expression 
of genes involved in promoting a mesenchymal phenotype (80). In fact, besides acting as a 
suppressor of E-cadherin, SNAIL is also well-known to regulate several aspects of the EMT 
phenotype, including the down-regulation of epithelial markers, such as claudins, occludins and 
cytokeratins, and the up-regulation of matrix metalloproteinase (MMP) levels and expression of 
mesenchymal cell/fibroblast makers, such as fibronectin and vitronectin (Figure 1.6) (81). 
Importantly, MMPs can target transmembrane proteins, such as stromelysin-1, leading to the 
release of the extracellular domain of E-cadherin, resulting in loss of the adherens junction (83). 
 
SNAIL1 and SLUG can be induced by a variety of signalling pathways, including bone 
morphogenetic protein (BMP) and transforming growth factor-β (TGF-β) signalling, as well as 
RAS-dependent signalling through the RAF-MEK-ERK and PI3K-AKT pathways (84). In the case 
of melanoma, loss or inactivity of PTEN correlated with a switch from E-cadherin to N-cadherin 
expression during melanoma progression that could be reversed by reintroduction of PTEN or 
pharmacologic blockade of PI3K activity (85). This cadherin switch in melanoma cells was found 
to be mediated by the PI3K-dependent transcriptional up-regulation of SNAIL, and another E-
cadherin transcriptional repressor, twist-related protein 1 (TWIST1) (85). Moreover, a recent study 
has indicated that PI3K-AKT signalling in melanoma can lead to upregulation of SLUG 
expression, which appears to be driven by osteonectin (also known as SPARC), a secreted 
extracellular matrix-associated factor that promotes the EMT (86). 
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Activation of NRAS and BRAF has recently been found to mediate an EMT switch in late-stage 
melanoma that relies on TWIST1, another transcriptional repressor, ZEB1, and E-cadherin loss, 
resulting in enhanced invasion (6). TWIST1 is a crucial basic helix loop helix transcription factor 
in embryological morphogenesis, and is over-expressed in various tumour-types, including 
prostate (87), breast  and gastric (88) cancers, and acts to repress E-cadherin and simultaneously 
activate mesenchymal gene expression by inducing N-cadherin expression (71,89). Intriguingly, a 
recent study by Caramel and colleagues indicates that a switch in expression of embryonic EMT-
inducing transcription factors drives the development of malignant melanoma, and predicts a poor 
outcome in melanoma patients (90). Strikingly, SLUG and ZEB2 are expressed in normal 
melanocytes where they act as onco-suppressive proteins by activating MITF-dependent 
differentiation. However, in response to NRAS or BRAF activation in late stage melanoma, 
TWIST1 and ZEB1 are preferentially expressed, leading to the promotion of a reversible de-
differentiation and neoplastic transformation (90). 
 
As such, the WNT-signalling pathway is one of the key regulators that drives EMT and plays an 
important role in the promotion of melanoma progression and EMT-dependent metastasis (91). 
 
1.2 Other Pathways and Molecules Under Investigation in Melanoma 
Pathogenesis 
The exemplified key molecular pathways described above are involved in melanoma onset, 
progression and proliferation (26). In addition to these oncogenic pathways, a number of molecules 
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including p53, c-KIT,  and melanoma tumour antigen p97 (melanotransferrin; MFI2/MTf) also 
play vital roles in melanoma progression. 
 
1.2.1 p53 and Melanoma 
 
As discussed above, the most crucial DNA-damaging stress in melanogenesis is UV radiation (29). 
In fact, the cellular stress caused by UV light compromises the fidelity of DNA replication, 
genomic stability, chromosome repair and cell division (92-94). The tumour suppressor, p53, is a 
master regulator of the cellular stress response to DNA damage, and can function as a transcription 
factor to upregulate genes that accelerate DNA repair and inhibit cell cycle progression, or, in the 
case of extensive DNA damage, can initiate cell senescence or apoptosis (95). However, p53 is 
frequently found to be inactivated or mutated in most human cancers (96,97). Interestingly, it has 
been estimated that nearly 90% of human melanomas contain inactivated, functionally defective 
or hypo-expressed p53, although the mechanisms leading to this inactivation and/or hypo-
expression are varied (98-100). A recent study has indicated that p53 function in melanoma may 
be able to be restored by simultaneously blocking the p53 E3 ligase, MDM2, and the p53 inhibitor, 
inhibitor of apoptosis-stimulating protein of p53 (iASPP) (98). Indeed, this study demonstrated 
that reactivation of p53 by this strategy, together with inhibition of BRAFV600E, induced apoptosis 
and suppressed melanoma growth (98).  
 
1.2.2 c-KIT and Melanoma 
c-KIT is a receptor tyrosine kinase for the stem cell factor (SCF), and is essential for proliferation, 
melanocyte development, differentiation, survival, and migration (101). Interestingly, its 
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downstream effectors include MAPK and PI3K cascades (101) and MITF (102). SCF on the other 
hand is responsible for increased melanin production in normal melanocytes, and hence, their 
survival is dependent on c-KIT signalling (101). Pathogenic mutations of KIT have been found in 
a large number of tumours and notably, these mutations were found in 39% of mucosal melanomas, 
36% of acral melanomas, 28% of melanomas on chronically sun damaged skin, but 0% of 
melanomas on skin without sun damage, suggesting an active role of UV radiation in mutations of 
KIT (103).  
 
1.2.3 p97/melanotransferrin and Melanoma 
 
Another molecule linked with melanoma development is one of the first tumour antigens described 
for this tumour-type (104), namely MTf. Indeed, MTf plays a vital role in cell proliferation and 
migration, endothelial migration and angiogenesis, differentiation and tumourigenesis (Figure 
1.9) (105). To date, the function of MTf remains unclear, but several investigations have suggested 
its involvement in physiological and pathological processes, including arthritis (106), 
chondrogenesis (107), Alzheimer’s disease (108,109), eosinophil differentiation (110), 
angiogenesis (111) and plasminogen activation (112). A soluble and actively secreted form of MTf 
(sMTf) has been reported to be increased in patients with Alzheimer’s disease or arthritis and may 
modulate angiogenesis, cell migration and plasminogen activation (111-114). Interestingly, it has 
also been demonstrated that MTf can interact with an unidentified member of the lipoprotein 
receptor-related protein (LRP) family, followed by the internalisation of MTf (112,115), although 
the molecular function of this process remains unclear. 
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Figure 1.9: Summary of the Potential Function(s) of MTf.  One of the first identified cell 
surface markers of melanoma is the membrane-bound form of melanoma tumour antigen p97 
(mMTf). MTf plays a vital role in cell proliferation and migration, endothelial migration and 
angiogenesis, differentiation and tumourigenesis. A soluble and actively secreted form of MTf 
(sMTf) has been reported to be increased in patients with Alzheimer’s disease or arthritis and may 
modulate angiogenesis, cell migration and plasminogen activation. To date, the mechanism of how 
MTf is involved in melanoma remains unclear and requires further investigation. 
 
The highest levels of MTf expression are found in malignant melanoma cells, although it was also 
found in small quantities in normal tissues (116,117). Selectively down-regulating MTf expression 
resulted in inhibition of migration, invasion, proliferation and growth of melanoma in vitro (118). 
Furthermore, silencing of MTf expression in melanoma cells resulted in considerably decreased 
cell proliferation, melanoma xenograft growth, DNA synthesis, cellular migration and reduced 
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tumour initiation in nude mice (105).  In more recent studies, it has been shown that the down-
regulation of MTf in mice results in up-regulation of myocyte enhancer factor 2a (Mef2a), 
transcription factor 4 (Tcf4) and glutaminase (Gls), whereas the apolipoprotein D (Apod) gene 
was down-regulated (105,106). Both, Mef2a and Tcf4 are linked with cell proliferation and 
survival and are known transcription factors (119,120). The Mef2a transcription factor is found to 
be strongly expressed in muscle tissues and is involved in foetal cardiac development, MAPK 
signalling and calcium signalling (119-123). Interestingly, the Tcf4 gene product is a transcription 
factor that physically interacts with β-catenin and is crucially involved in the WNT signalling 
pathway (124), as well as the regulation of melanocyte differentiation (123). Moreover, Tcf4 is 
highly expressed in some cancers and plays an important role in cell proliferation (120).  
 
Recent observations suggest that melanoma cells can drive the progression of the disease by 
“switching” between proliferative and invasive states (potentially utilising EMT and MET 
reversals) that involves WNT signalling (125). This phenotypic switching behaviour was found to 
crucially involve changes in the expression of TCF4, and another β-catenin-binding transcription 
factor, LEF1 (125). Specifically, LEF1 was preferentially expressed in differentiated and rapidly 
proliferating melanoma cells, while TCF4 was preferentially expressed in de-differentiated and 
invasive melanoma cells (125). Taken together, such findings are strongly suggestive of a role for 
MTf in modulating the WNT signalling pathway. 
 
In contrast, the MTf regulated molecules, Apod and Gls, show differential expression and encode 
proteins that are important in proliferation, namely Apod and glutaminase, respectively (105). In 
fact, Apod inhibits proliferation and is linked with transporting sterols, steroids and arachidonic 
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acid for tissue repair (126,127). Conversely, glutaminase has been established to be highly 
expressed in mitochondria of tumour cells immediately before the maximum rate of proliferation 
is attained (128-130). Hence, the down-regulation of Apod and up-regulation of Gls by MTf 
deletion in mice supports a role for this latter protein in proliferation (105). 
 
Interestingly, a group of receptors receptor tyrosine kinases (RTKs), such as c-Met, vascular 
endothelial growth factor receptor (VEGFR2) and fibroblast growth factor receptor 1 (FGFR1) are 
known to induce e.g. EMT and PI3K pathways. Moreover, their dysregulation was linked to 
development and progression of several cancer types (131-133) including melanoma (134-137). 
Considering this in conjunction with the common localisation of c-Met, VEGFR2, FGFR1 and 
MTf at the plasma membrane and also the previously reported interaction of 
glycosylphosphatidylinositol-anchored proteins with PTKs (138), it is crucial to conduct further 
studies to investigate their potential relationship. These group of RTK’s will be further discussed 
in Section 4.3.7. 
 
At present, metastatic melanoma is almost completely resistant to available therapies and is linked 
with poor patient prognosis. Hence, a new and expanded knowledge of novel prognostic markers 
that can affect melanoma metastasis, such as MTf, may be crucial for the development of new and 
more effective treatment strategies.  
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1.3 Current Drugs and Drug Targets in Melanoma 
Since most of the activating mutations (>70%) in the BRAF gene are V600E and because mutated 
BRAF leads to activation of the MAPK signalling pathway, much of the current research has 
focused on inhibiting the constitutively active BRAF protein kinase in melanoma patients 
(139,140). Melanoma in the metastatic stage (stage III and IV) is exceptionally resistant to many 
types of treatments, and hence, new therapeutics that are able to target metastatic melanoma are 
crucial, as these patients have very low survival rates (6-10 months) (34). 
 
Before 2011, neither administration of the cytokine, IL-2, nor the chemotherapeutic agent, 
dacarbazine (DTIC), were able to improve the overall survival rate (OR) of melanoma patients 
(34). While DITC usage is limited by an insufficient OR of 8 months and low response rate (RR; 
5-15 %), high-dose IL-2 is limited by a low RR of 6-10% as well as a short duration of response 
in most patients and is associated with severe side effects (141). Since 2011, several novel anti-
melanoma agents have received FDA approval, and these include: (1) vermurafenib, which targets 
melanomas with mutated BRAFV600E; (2) ipilimumab, a therapeutic anti-CTLA-4 monoclonal 
antibody; and (3) the PEGylated form of interferon α-2b (PEG-IFN), currently used as adjuvant 
treatment for stage III melanoma (142). Additionally, besides vermurafenib, other agents, such as 
dabrafenib and trametinib have been approved for melanomas with the BRAF V600E mutation (34). 
 
Mutated BRAF leads to activation of the MAPK signalling pathway and therefore, intense research 
has focused on inhibiting BRAF in melanoma patients (139,140). However, due to the off-target 
effects induced via inhibition of wild-type BRAF, the results were ineffective (140). Only 
vermurafenib was capable of silencing mutant BRAFV600E without interfering with the wild-type 
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BRAF (140). As such, vermurafenib represents an excellent model for successful targeted anti-
cancer therapy for patients with the BRAF V600E mutation (140,143). Nevertheless, as a highly 
selective mutant BRAFV600E inhibitor, the single use of vermurafenib is not as efficient in patients 
who have mutations other than V600E (e.g., V600K, which is present in 5-20% patients with 
melanoma), and hence, these patient have a correspondingly low RR (140,144). 
Immune check point inhibitors are also emerging as highly promising novel drug targets for 
melanoma (34,145,146). As a negative regulator of T-cells, the T-cell receptor, programmed cell 
death-1 (PD-1), acts to limit T-cell cytotoxic activity via interacting with its two ligands, PD-L1 
and PD-L2, which can be highly expressed by melanoma cells (34). Hence, this modulator is an 
interesting target for investigations of innovative immune-based therapy drugs by developing 
agents that can block these receptors, thereby leading to re-activation of T-cells, and hence, the 
restoration of anti-tumour activity (34,145). In fact, malignant skin cancer cells use this inhibitory 
mechanism to prevent effective anti-tumour responses by “turning off” T-cell activation and 
furthermore PD-1 is present on the surface of activated T, pro-B, NK cells and monocytes (34). 
With a high affinity for PD-1, Nivolumab and pembrolizumab (monoclonal immunoglobulin G4 
antibodies) act to prevent PD-1 interaction with its ligands (PD-L1 and PD-L2) in the tumour 
microenvironment (147,148). In fact, the expression of PD-L1 on cancer cells may be enhanced 
by BRAFV600E signalling via the MAPK pathway, which stimulates production of IL-1 and PD-1 
ligands that depress T-cell activity and promote tumour growth (34).  
 
To date, nivolumab and pembrolizumab have both shown high activity in multiple clinical trials, 
inducing responses in 20-40% of patients, with less than 10% of patients experiencing a grade 3/4 
adverse event (34). Moreover, nivolumab and pembrolizumab are both linked with an acceptable 
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tolerance and have a long-standing safety profile (34). Notably, PD-1 blockade occurs in 
melanomas without mutated BRAF, highlighting the emerging importance of the PD-1/PD-L1 
pathway in malignant melanoma (34). 
 
As one of the major key pathways involved in melanoma, PI3K is known to cause cell 
proliferation, anabolism, dissemination and tumour survival (31,65). Hence, investigations have 
focused on PI3K signalling targets in melanoma. Due to the fact that mTOR is a serine/threonine 
kinase downstream of AKT that modulates angiogenesis, protein synthesis and cell cycle 
progression (69), mTOR inhibitors may be rational therapeutic agents in melanoma (29,69). In 
fact, studies undertaken by Karbowniczek et al. demonstrated that mTOR activation is strongly 
associated with melanocytic lesions in vivo (149). Moreover, the inhibition of mTOR prevented 
the proliferation of melanoma-derived cell lines (149). The agents, Temsirolismus (CCI-779; 
Wyeth-Ayerst, Madison, NJ), Everolismus (Novartis) and AP-23573 (Ariad Pharmaceuticals, 
Cambridge, MA), are among the current mTOR inhibitors with clinical potential (29). In a two-
stage phase II trial with the single-agent, Everolismus, 7 of 20 patients (35%) demonstrated stable 
disease at 16 weeks in stage IV melanoma (29). 
 
Considering the importance of deregulated WNT signalling activation in the pathogenesis of 
melanoma, a range of new strategies in terms of cancer pharmacopoeia have been assessed. In fact, 
since the late 1990s, intense interest in developing effective WNT pathway inhibitors (150,151) 
has led to non-steroidal anti-inflammatory drugs (NSAIDS) and vitamin derivatives that directly 
or indirectly suppress the dysregulated WNT pathway (152). However, no effective treatment has 
resulted.   
36 
 
 
As most of the more recently developed anti-cancer drugs focus on highly specific molecular 
targets to modulate an explicit abnormal pathway, it is not surprising that these drugs result in 
treatment failure (153). In this case, selection pressure by a single target chemotherapeutic results 
in tumour clones that demonstrate resistance (153). In diseases such as cancer, where multiple 
pathways are dysregulated and involve both independent and overlapping molecular targets, a 
polypharmacologic strategy that focuses on a range of key molecules may be more beneficial and 
may prevent cancer cells from adapting and developing into more resistant cancer phenotype 
(154). This is especially important as cancer is a disease that progresses with some molecular 
targets becoming more crucial than others at different stages (155).  
 
1.3.1 Possible Novel Strategies for Melanoma Treatment: The di-2-
pyridylketone thiosemicarbazones 
 
A novel class of agents that demonstrate polypharmacology are the di-2-pyridylketone 
thiosemicarbazones (DpT series), including the lead compounds of this series, di-2-pyridylketone 
4,4-dimethyl-3-thiosemicarbazone (Dp44mT) and di-2-pyridylketone 4-cyclohexyl-4-methyl-3-
thiosemicarbazone (DpC) (153). Tumours require a greater amount of iron and copper for their 
rapid growth and proliferation than normal cells (156-158). Interestingly, the DpT series of agents 
target these metal ions, leading to the formation of redox active iron or copper complexes that 
generate ROS (159,160). Furthermore, it has been demonstrated that the DpT agents are also able 
to inhibit multiple oncogenic pathways, such as MAPK (161), RAD/ERK (162), PI3K (162,163), 
SRC (164), STAT3 (165) and the transforming growth factor-β signalling pathways (162). In 
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addition, these agents have also been shown to inhibit the EMT that is responsible for metastasis 
(72,166), while also leading to dysfunctional pro-survival autophagy (167,168). Moreover, a 
recent study on Dp44mT demonstrated that this agent could overcome drug resistance mediated 
by the drug efflux pump, P-glycoprotein (P-gp) (169). Considering that P-gp is an important 
contributor to multidrug resistance in metastatic melanoma (170), these novel agents may be 
highly effective in treating advanced and multi-drug resistant melanoma.  
 
Dp44mT and its analogues have shown effective anti-tumour activity in vitro and in vivo against 
numerous aggressive tumour xenografts, such as neuroepithelioma, pancreatic lung carcinoma, 
hepatoma, breast and melanoma (72,169,171-179). In fact, Dp44mT demonstrated more potent 
activity in vivo than a 16-fold higher dose of the clinically-trialled thiosemicarbazone, Triapine 
(171,172). Moreover, this agent demonstrated marked activity at inhibiting the dissemination of 
breast cancer cells in vivo (164,176). The ligand, DpC, is a newer analogue of the DpT series that 
is highly potent and does not induce cardiotoxicity in mice, even when used at markedly higher 
doses than Dp44mT (174,175). Indeed, studies have demonstrated that Dp44mT causes cardiac 
fibrosis at high non-optimal doses (171) and also the formation of methemoglobin (metHb) and 
metmyoglobin (metMb) in vivo in mice (180). On the contrary, DpC has been demonstrated to 
significantly reduce these adverse effects and have higher activity than Dp44mT in inhibiting 
pancreatic tumour growth in vivo in nude mice (181) and in lung cancer cells (182).  
 
Metastasis is a major clinical problem that is responsible for 90% of cancer deaths, and hence, 
development of drugs that target proteins, which inhibit metastasis has become an important 
therapeutic strategy (155,183,184). One of these proteins is N-Myc downstream regulated gene-1 
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(NDRG1) (174,185,186). This potent metastasis suppressor has been found to play an important 
role in decreasing metastases and inhibiting angiogenesis by inhibiting multiple oncogenic 
pathways that are relevant to melanoma, such as the WNT- and PI3K signalling pathway (72,187-
189). In addition, recent studies have demonstrated that NDRG1 also negatively regulates several 
RTKs that play key roles in the pathogenesis of other tumours (190,191). Hence, NDRG1 is a 
promising therapeutic target for the treatment of cancer (72,162). 
 
Interestingly, it has been shown that cellular iron-depletion markedly up-regulates expression of 
the potent metastasis suppressor, NDRG1, at both the mRNA and protein levels in various cancer 
cell types (192). Indeed, both Dp44mT and DpC are able to up-regulate NDRG1 expression and 
also have the ability to increase the phosphorylation of NDRG1 at Serine-330 and Threonine-346 
(174). These sites are crucial for the anti-tumour activity of NDRG1 in pancreatic cancer (193).  
 
Considering the positive anti-cancer effects of the DpT compounds, a polypharmacological 
strategy could be highly beneficial in melanoma chemotherapy, decreasing the capability of 
melanoma cells to adjust and escape a therapeutic insult. Hence, this approach may revolutionize 
drug design strategies (153), especially in melanoma. 
 
1.4 Summary of Chapter 1 
The growing understanding of pathways involved in melanoma progression and development has 
led to the identification of some interesting new molecules that might be crucial for clinical 
development of new treatments in the future. However, treatment options for metastatic melanoma, 
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which is responsible for the majority of melanoma related deaths, remain limited. In terms of 
treatment, a new polypharmacological strategy might be more effective than focusing on one 
particular pathway or molecular target in melanoma. Indeed, the progression of malignant 
melanoma involves a very complex series of events, which includes many pathways and key 
oncogenic targets that interact together. Hence, elucidating the intricate mechanisms that initiate 
and drive this disease is crucial and likely to lead to more effective treatment strategies for 
melanoma.  
 
1.4.1 Aims of Thesis  
 
As described in Section 1.2.3, MTf plays a vital role in cell proliferation and migration, endothelial 
migration and angiogenesis, differentiation and tumourigenesis  and several investigations have 
suggested its involvement in physiological and pathological processes, including arthritis (106), 
chondrogenesis (107), Alzheimer’s disease (108,109), eosinophil differentiation (110), 
angiogenesis (111) and plasminogen activation (112). However, the molecular mechanism behind 
the pro-proliferating and tumour-progression ability of MTf remains unclear. In contrast, NDRG1 
was confirmed to function as a potent metastases suppressor via inhibiting a range of oncogenic 
pathways including the WNT and PI3K signalling pathways in pancreatic and prostate cancers 
(72,162,163,186,190,194). Considering, the effect of a novel class of anti-cancer agent, namely 
the thiosemicarbozones, that up-regulate NDRG1 markedly and induce potent inhibition of 
melanoma growth (171), NDRG1 became an important molecular target for cancer therapies. 
Hence, a new and expanded knowledge of novel prognostic markers that can affect melanoma 
metastasis, such as MTf and NDRG1, may be crucial for new tractable targets and the development 
of novel and more effective treatment strategies in melanoma. 
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As a result, the aims of this thesis were:   
 
1. To determine the inter-relationship between NDRG1 and MTf in vitro and in human 
melanoma samples as well as uncovering their potential link in melanoma. Furthermore, 
the effect of MTf and NDRG1 on oncogenic downstream key targets were assessed that 
are involved in WNT- and PI3K-signalling. The ability of the novel thiosemicarbazone, 
DpC on MTf, NDRG1 and cyclin D1 was also examined. 
 
2. To explore the role of MTf to up-regulated WNT- and PI3K signalling in melanoma, the 
effect of MTf on the crucial upstream receptors was examined, namely LRP6, c-Met, 
VEGFR2 and FGFR1. Moreover, the localisation and interaction between MTf, LRP6, c-
Met and VEGFR2 was investigated. DpC was also assessed for its effect on regulating 
LRP6, p-LRP6 (Ser1490) and the tumour suppressor MIG6. 
 
 
3. To investigate the mechanism involved in up-regulation of MTf and NDRG1 upon c-Myc 
silencing. Considering c-Myc is known to act as a transcriptional activator of a wide 
number of oncogenes, as well as suppressing NDRG1, the aim of this study was to further 
advance the understanding of how MTf is driving proliferation and activates certain 
oncogenic pathways including WNT- and PI3K signalling when c-Myc was silenced.   
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CHAPTER 2 
 
 
MATERIAL AND METHODS 
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2.1 Materials 
2.1.1 Chemicals and General Reagents 
 
Commonly used chemicals and reagents for experiments are listed below in Table 2.1 
Table 2.1: Chemicals and General Reagents 
Reagent Source 
Agarose 
Acrylamide 
Ammonium persulphate (APS) 
β-mercaptoethanol 
BCA protein assay reagent 
Bovine serum albumin (BSA) 
Chloroform 
Copper sulfate 
Dimethylsulphoxide (DMSO) 
ECL chemiluminescence reagent 
Ethanol (Spectrasol grade) 
Ethylenediaminetetraaceticaicd (EDTA) 
Glycine 
Hydrochloric acid (HCl) 
IP Lysis buffer 
Isopropanol 
Lipofectamine® 2000 
Amresco 
Bio-Rad 
Sigma Aldrich 
Sigma Aldrich 
Progen Biosciences 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Merck Millipore 
Labtech 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Pierce  
Sigma Aldrich 
Life Technologies 
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Lipofectamine® RNAiMAX 
Methanol 
Paraformaldehyde (PFA)  
Protease inhibitor cocktail 
Phosphatase inhibitor 
Phosphate-buffered saline (PBS) powder 
ProLong® Gold Antifade Reagent with DAPI 
Sodium chloride 
Sodium dodecyl sulphate (SDS) 
Sodium hydroxide 
TEMED (N, N, N’, N’-tetramethylethylenediamine) 
Tris(hydroxymethyl)aminomethane (Tris) 
Triton X-100 
TRIzol® 
Trypan blue 
Tween-20 
Life Technologies 
LabServ 
Diploma 
Sigma Aldrich 
Roche 
Roche 
Sigma Aldrich 
Life Technologies 
Sigma Aldrich 
Amresco 
Sigma Aldrich 
Bio-Rad 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
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2.1.2 Cell Culture Reagents 
Table 2.2: Cell Culture Reagents Used 
Reagent Source 
Eagle’s Minimum Essential Medium (MEM) 
Foetal bovine serum (FBS) 
Fungizone™ 
G418 
Non-Essential Amino Acids (NEAA) 
Penicillin/Streptomycin with L-glutamine 
Sodium pyruvate 
Sigma Aldrich 
Sigma Aldrich 
Invitrogen 
Alexis Biochemicals  
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
 
 2.1.3 Buffers 
Table 2.3: Buffers 
 
Buffers Composition 
Cell lysis buffer 150 mM NaCl, 10 mM Tris-HCl (pH 7.4), 1.5% 
Triton X100, 0.5% SDS, 1 mM EDTA, 0.04 mM NaF, 
Protease inhibitor cocktail, Phosphatase inhibitor   
SDS-PAGE running buffer (10x) 247.65 mM Tris, 1.92 M Glycine, 34.68 mM SDS, 
adjust to pH 8.3  
Separating gel buffer 749.55 mM Tris, 6.94 mM SDS, pH 8.8 
Stacking gel buffer 250.12 mM Tris, 6.94 mM SDS, pH 6.8 
Transfer buffer (10x) 247.65 mM Tris, 1.92 M Glycine 
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Tris-buffered saline (TBS; 20x) 1x TBS, 0.1% (v/v) Tween-20 
Tris-acetate EDTA (TAE) buffer (20x) 800 mM Tris, 2.2% glacial acetic acid, 100 mM 
EDTA 
 
2.1.4 Compounds and Inhibitors 
 
Table 2.4: Compounds and Inhibitors 
 
Compounds and inhibitors Type Source 
Di-2-pyridylketone 4cyclohexyl-4-methyl-
3thiosemicarbazone (DpC) 
Metal Chelator Synthesised in lab 
(175) 
 
 
2.2 Cell culture  
The human melanoma cell lines, SK-MEL-28 and SK-MEL-2, were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA). Cell lines were authenticated by the provider 
and this was based on viability, recovery, growth, morphology, cytogenetic analysis, antigen 
expression, DNA profile and iso-enzymology. Both SK-MEL-28 and SK-MEL-2 were cultured in 
Eagle’s Minimum Essential Medium (MEM; Sigma Aldrich, VIC, Australia) supplemented with 
10% foetal calf serum (FCS; Sigma-Aldrich; St. Louise, MO), penicillin streptomycin glutamine 
(100 μg/mL; Invitrogen), sodium pyruvate (1 mM; Sigma Aldrich), non-essential amino acids (0.1 
mM; Sigma Aldrich) and 0.28 ng/mL Fungizone™ (Invitrogen). Over-expression of MTf was 
accomplished by stably transfecting SK-MEL-28 cells with human MTf cDNA or with the empty 
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pCMV-Script® (Stratagene, CA, USA) vector alone (195). The over-expressing clones are termed, 
hIF and hIE, and their vector control as VA, and maintained in the media above in G418 (1000 
μg/ml; Alexis Biochemicals, Switzerland) (195).  
 
In terms of stable MTf down-regulation model, SK-MEL-28 cells were stably transfected with the 
expression vector, pSilencer 3.1-H1 neo (Ambion, Texas) (105). These clones were referred to as 
the B1 and B2 clones, and as a control, the cells were transfected with the same vector (SCR) 
containing a scrambled, non-specific siRNA insert (pS-scrambled; Ambion) (105). The B1 clone 
demonstrated superior silencing of MTf and was used in preference in most experiments. The same 
procedure was used to down-regulate MTf expression in the SK-MEL-2 cells and are referred to 
as ‘A3’ with an appropriate SCR control (195). These stably transfected cells were selected and 
maintained in G418 (1000 μg/ml; Alexis Biochemicals, Lausen, Switzerland) (195).  
 
The pancreatic cancer cell line PANC-1 was a generous gift from Prof. Andrew Biankin (Garvan 
Institute, NSW, Australia) and was grown in Dulbecco’s Modified Eagle Medium (DMEM; 
Gibco). For NDRG1 over-expression, the cells were stably transfected with pCMV-taq2-Flag-
NDRG1 (GenHunter, Nashville, TN, USA), namely N1 and N2 or the empty pCMV-taq2-FLAG 
(Stratagene, Santa Clara, CA, USA) vector (VC) to serve as a negative control (162). All 
transfected cells were selected using G418, as described above. Cells were all cultured in an 
incubator (Forma Scientific, Ohio, USA) at 37°C in a humidified atmosphere of 5% CO2 and 95% 
air. 
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2.3 Reagent Preparation 
The thiosemicarbazone, DpC was synthesised and characterised using standard methods (196). 
DpC was freshly prepared in DMSO at concentrations of 10 mM and further diluted in media to 
its final desired concentrations. Briefly, at ~80% confluence, cells were incubated with the 
compound concentration (1, 5 and 10 μM) for 24 h in 37°C.  
 
2.4 Gene Silencing by Small Interfering RNA (siRNA)  
Two specific siRNAs for NDRG1, were used, namely, siNDRG1 (Cat.#: s20336; Life 
Technologies) and siNDRG1II (Cat.#: s20334; Life Technologies). These were compared to non-
targeting negative control siRNA (siControl; Life Technologies). The siRNA was reverse 
transiently transfected into SK-MEL-28 and SK-MEL-2 cells using Lipofectamine RNAiMAX® 
(Life Technologies) following the manufacturer's instructions and incubated for 72 h/37oC, 
respectively. siRNAs specific for MTf (siMTf; Life Technologies), c-Myc (si-c-Myc, Cat.#: 6341S; 
Cell Signaling) and MIG6 (siMIG6, Cat.#: AM16706; Thermofisher) were compared to non-
targeting negative control siRNA (siControl; Life Technologies). The siRNAs were reverse 
transiently transfected into SK-MEL-28 cells using Lipofectamine RNAiMAX® (Life 
Technologies) following the manufacturer's instructions and incubated for 72 h/37oC, respectively.  
Western blotting was then performed, as described in Section 2.6.  
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2.5 Protein extraction  
2.5.1 Whole protein  
 
Media was discarded from the plates and cells were harvested using the IP Lysis buffer (Pierce) 
containing protease inhibitor cocktail (4% (v/v); Cat. # 11836170001; Roche, Basel, Switzerland) 
and phosSTOP phosphatase inhibitor (10% (v/v); Cat. # 04906845001; Roche). Cells were 
detached from the plastic substratum using a cell scraper and the cell suspension was rotated for 
20 min on 4°C. The cells were then centrifuged at 11 000 x g for 10 min at 4°C, and the supernatant 
collected. The protein concentration was then measured using BCA Protein Assay (Thermofisher 
Scientific, USA) and a UV spectrophotometer (UV-1800, Shimadzu, Japan), measuring 
absorbance at 562nm.   
  
2.5.2 Cytoplasmic and nuclear fractionation  
 
Cytoplasmic and nuclear fractions were extracted from cells using NE-PER® Nuclear and 
Cytoplasmic extraction reagents (Thermo Fisher Scientific) according to the manufacturer’s 
instructions. Media was discarded from the plates and cells were harvested using the Cytoplasmic 
Extraction Reagent I (CER I) solution containing protease inhibitor cocktail (4% (v/v); Cat. # 
11836170001; Roche, Basel, Switzerland) and phosSTOP phosphatase inhibitor (10% (v/v); Cat. 
# 04906845001; Roche) and left to incubate for 10 min on ice. Cytoplasmic extraction Reagent II 
(CER II) was added to each sample, vortexed and incubated on ice for 1 min, then re-vortexed and 
centrifuged (16 000 x g, 5 min). The supernatant (cytoplasmic fraction) was then collected. The 
remaining pellet was re-suspended in the Nuclear Extraction Reagent (NER) solution. This was 
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vortexed for 30 s every 10 min for a total of 40 min. Following this, the sample was centrifuged 
(16 000 x g/10 min/4°C), and the supernatant (nuclear fraction) collected.  
  
2.6 Western blot analysis  
Protein lysates were heated for 3-4 min at 95°C on a heating block in the presence of β-
mercaptoethanol.  Kaleidoscope Precision Plus™ protein molecular weight standards (Bio-Rad 
Laboratories, Inc., CA, USA) and proteins (20-50 μg) were loaded onto a polyacrylamide gel (8 - 
12% resolving [1.5 M Tris-HCl pH 8.8] and a 4% stacking [0.5 M Tris-HCl pH 6.8]) in running 
buffer (120 V, 2 h). The separated proteins were transferred onto a PVDF membrane (0.45 μM 
pore size; Millipore, Billerica, MA) in transfer buffer for 14 h at 30 V/4°C. The membrane was 
soaked in methanol for 30 s and dried at 37oC/2 h. Membranes were then blocked in 5% skim milk 
or Bovine Serum Albumin (BSA) in TBST [12.1 g/L Tris. 40 g/L NaCl. pH 7.6, 0.1% (v/v) Tween 
20] for 30 min at room temperature.  Primary antibodies were diluted in 5% skim milk or BSA in 
TBST overnight at 4°C on a rocker. Membranes were then washed in TBST 3 times/10 min, 
followed by incubation with secondary antibody diluted in 5% skim milk at room temperature for 
1 h, followed by the same round of washes.  The antigen antibody complex was visualised using 
ECL Immobilon Western HRP Substrate (Merck Millipore, MA, USA) according to the 
manufacturer’s instructions, and then then exposed using a ChemiDoc™ (Bio-Rad, CA, USA).   
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2.7 MTT cellular proliferation assay  
Cellular proliferation was determined using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium, Sigma] assay by methods described in (197). In proliferating cells, mitochondrial 
dehydrogenases reduce yellow tetrazolium salt to a purple coloured formazan. This allows cell 
viability to be assessed by a colorimetric assay. Cells were seeded on 96-well plates containing 
appropriate medium, and allowed to attach overnight. The next day, a 5 mg/mL solution of MTT 
in PBS was added to each well and incubated for 2 h at 37 °C. The cells were then solubilised by 
adding dimethyl sulfoxide (DMSO) and the plate was read at 570 nm on a multi-well 
spectrophotometer (Wallac 1420 Victor3™, PerkinElmer, MA, USA). The results were expressed 
as a percentage of the control.  
  
2.8 Co-immunoprecipitation   
Co-immunoprecipitation was performed using Dynabeads Protein G (Life Technologies, Inc.) 
following the manufacturer's instructions. Briefly, cells were washed with PBS and lysed using 
the IP Lysis buffer (Pierce) containing protease inhibitor cocktail (4% (v/v); Cat. # 11836170001; 
Roche, Basel, Switzerland) and phosSTOP phosphatase inhibitor (10% (v/v); Cat. # 04906845001; 
Roche).  Protein (400 μg) was incubated with the antibody of choice overnight at 4 °C on a rotator. 
Following day, this mixture was added to 30 μl of Dynabeads Protein G and incubated for 3 h at 4 
°C on rotator. The beads were then washed three times with IP Lysis buffer, loading buffer was 
added and samples were heated for 95 °C/5 min. Samples were then placed on a magnet, and equal 
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amounts of supernatant were loaded and separated on a gel. Proteins were detected using standard 
Western Blot protocols described in Section 2.6. 
  
2.9 Immunofluorescence and Confocal Microscopy 
Cells were seeded and grown for 24-72h onto sterile coverslips and left to attach. Cells were then 
washed with sterile PBS and fixed with 4% (w/v) paraformaldehyde for 10 min. This was followed 
by 3 washes with sterile PBS. The cells were then permeabilised with 0.01% Triton X-100 in sterile 
PBS/10 min, followed by a further 3 washes with sterile PBS. Cells were then blocked in a 5% 
BSA in sterile PBS solution for 1 h, following incubation in primary antibody in a 1% BSA in 
sterile PBS solution overnight. The following day, the cells were washed 3 times with sterile PBS, 
and then incubated in secondary Alexa Fluor 594 and/or 488 (Invitrogen) for 1 h at room 
temperature in the dark with gentle rocking. Following 3 washes with sterile PBS, coverslips were 
mounted onto glass slides using an anti-fade mounting solution containing 4ʹ,6-diamidino-2-
phenylindole (DAPI, Invitrogen). Images were captured via a Zeiss LSM 510 Meta Spectral 
confocal microscope and also a ZEISS LSM 800 plus Airyscan Spectral confocal microscope using 
a 63× objective (Zeiss, Jena, Germany). Raw images were analysed using AxioVision (Carl Zeiss, 
Australia) and ImageJ software (National Institutes of Health). Confocal images analysed using 
the Plot Profile and Co-Masking Analysis functions in ImageJ.  
 
2.10 Statistics and densitometry  
Densitometry was performed using Quantity One software (Bio-Rad) and normalised using the  
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relative β-actin loading control. Experimental data were compared using Student’s paired t-test 
and presented as mean ± standard deviation. Data was considered statistically significant when p 
< 0.05.  In figures, (*) refers to p<0.05, (**) refers to p<0.01, and (***) refers to p<0.001. Gene 
Expression Omnibus (GEO) and mIHC data were compared using one-way ANOVA and the 
Mann-Whitney U test, respectively. 
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CHAPTER 3 
 
 
Identification of MTf as a Pro-Proliferative Signalling 
Protein Involved in the WNT Pathway in Melanoma Cells: 
The Yin-Yang Relationship Between MTf and NDRG1. 
 
 
 
 
 
 
 
 
 
This chapter contains work prepared in the manuscript: 
 
Paluncic, J., Lane, D.J., Skoda, J., Bae, D.H., Scolyer, R., Wilmott, Loh, K., Jansson P.J., Huang 
M.L., Kovacevic, Z. and Richardson, D.R. (2019) In Preparation 
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3.1 Introduction 
Melanoma is one of the most aggressive and treatment-resistant human cancers, having increased 
radically worldwide during the past several decades in Caucasian population (198). Due to its 
propensity to metastasise, its overall mortality rate is approximately 20%, and is responsible for 
80% of skin cancer-related deaths worldwide (26,198). Although early-stage melanoma can be 
effectively treated with surgery, metastatic melanoma is highly resistant to conventional therapies 
(26,198). Melanotransferrin (MTf) or melanoma tumour antigen p97 is one of the first well 
characterised tumour antigens described in melanoma (104,198,199). The highest MTf expression 
was demonstrated in malignant melanoma cells, although it is also found in small quantities in 
normal tissues (116,117,198,200,201). The protein is a transferrin (Tf) homolog that binds one 
iron atom and is mainly membrane bound via a glycosylphosphatidylinositol (GPI) anchor 
(106,198). However, comprehensive studies by our laboratory using human melanoma cells in 
vitro (200,202) and also knockout and transgenic mice in vivo (105,203,204), demonstrated that 
MTf plays no role in iron transport or metabolism. However, silencing of MTf expression in 
melanoma cells resulted in markedly decreased proliferation, melanoma xenograft growth in vivo, 
DNA synthesis, cellular migration and reduced tumour initiation in mice (105,195).
 
 
 
Across five models of MTf expression, it was demonstrated that three genes involved in 
proliferation were modulated by MTf, including ATP-binding cassette subfamily B member 5 
(ABCB5), thiamine triphosphatase (Thtpa) and transcription factor 4 (TCF4) (195). TCF4 is a 
transcription factor that interacts with β-catenin and is involved in WNT signalling (124), 
melanocyte differentiation (123,124) and proliferation (120). Further, MTf can interact with an 
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unidentified member of the lipoprotein receptor-related protein family, followed by MTf 
internalisation (112,115). However, despite the broad expression of MTf in melanoma cells and 
patient melanoma samples (104,116,117), its exact molecular function remains unclear, as does its 
role in melanoma pathogenesis. 
 
Recent observations suggest melanoma cells can drive disease progression by “switching” between 
proliferative and invasive states that involves WNT signalling (125). This phenotypic switching 
involves changes in TCF4 expression, and another β-catenin-binding transcription factor, LEF1 
(125). Considering the marked regulation of TCF4 by MTf, this suggests a role for MTf in 
modulating WNT signalling, which may be important in proliferation, metastasis and invasion. 
 
N-myc downstream regulated gene 1 (NDRG1) is a potent metastasis suppressor involved in 
inhibiting the spread of prostate, pancreatic cancer, colon cancer, etc. (187-189), although a role 
in malignant melanoma has yet to be intensively investigated. Interestingly, NDRG1 has been 
demonstrated to play a role in a range of signalling pathways including those involving: 
transforming growth factor-β, ROCK-MLC2, NFкB, Src, AKT/PI3K, EGFR, WNT, etc. 
(72,162,163,190,194). In fact, NDRG1 inhibits a key step in metastasis, namely the epithelial 
mesenchymal transition (EMT), by stabilising plasma membrane β-catenin expression (72) and 
preventing its nuclear translocation (72). 
 
The current study hypothesised that MTf may participate in melanoma progression due to the fact 
that MTf plays a vital role in melanoma cell proliferation and migration and tumourigenesis in 
vivo in melanoma tumours. On the other hand, N-myc down-stream regulated gene 1 (NDRG1) is 
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a potent growth and metastasis suppressor and acts to inhibit multiple oncogenic pathways, such 
as PI3K/AKT, WNT, etc. The expression of NDRG1 in a variety of melanoma cells suggests a 
potential role in inhibiting metastasis, and the aim of the current study was to investigate the 
functional role of MTf in oncogenesis and its relationship with NDRG1. For the first time, we 
demonstrate that MTf down-regulates NDRG1, in multiple melanoma cell models, and conversely, 
that silencing MTf expression increased NDRG1 levels. On the other hand, silencing NDRG1 
increased MTf expression. These observations suggest a negative feedback loop between these 
proteins. Mechanistically, silencing NDRG1 led nuclear MTf accumulation and up-regulation of 
oncogenic β-catenin and its downstream targets, cyclin D1 and c-Myc. The increase in c-Myc may 
be responsible for the down-regulation of NDRG1 by MTf, as c-Myc is known to suppress NDRG1 
transcription (205). MTf also activated the oncogenic PI3K/AKT pathway, which was associated 
with increased β-catenin levels and nuclear translocation of β-catenin, indicating a key role in 
cellular signalling. Investigation of melanoma patient specimens similarly demonstrated a strong 
negative relationship between MTf and NDRG1 expression and particularly the NDRG1/MTf 
ratio. These investigations demonstrate MTf’s key role as a pro-oncogenic signalling protein that 
displays a Yin-Yang relationship with the potent metastasis suppressor, NDRG1, which could be 
important for treatment and development of a prognostic marker.  
 
For the first time, we demonstrate that MTf plays a role as a pro-proliferative protein in melanoma 
cells that stimulates WNT signalling and inhibits the anti-oncogenic metastasis suppressor, 
NDRG1, in multiple cell-types and human patient melanoma samples. In fact, a Yin-Yang 
relationship exists between MTf and NDRG1 expression, which is important in terms of 
implementing novel agents that up-regulate NDRG1 to suppress melanoma tumourigenesis. 
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3.2 Material and Methods  
3.2.1 Cell Culture  
 
The human melanoma cell lines, SK-MEL-28 and SK-MEL-2, were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA). Cell lines were authenticated by the provider 
and this was based on viability, recovery, growth, morphology, cytogenetic analysis, antigen 
expression, DNA profile and iso-enzymology. Cells were routinely examined for mycoplasma 
contamination using standard methods (206). Both SK-MEL-28 and SK-MEL-2 were cultured in 
Eagle’s Minimum Essential Medium (MEM; Gibco, VIC, Australia) supplemented with 10% 
foetal calf serum (FCS; Sigma-Aldrich; St. Louise, MO), penicillin streptomycin glutamine (100 
μg/mL; Invitrogen), sodium pyruvate (1 mM; Invitrogen) and non-essential amino acids (0.1 mM; 
Invitrogen). Over-expression of MTf was accomplished by stably transfecting SK-MEL-28 cells 
with human MTf cDNA or with the empty pCMV-Script® (Stratagene, CA, USA) vector alone 
(195). The hyper-expressing clones are termed, hIF and hIE, and their vector control as VA, and 
maintained in the media above in G418 (1000 μg/ml; Alexis Biochemicals, Switzerland) (195).  
 
In terms of stable MTf down-regulation model, SK-MEL-28 cells were stably transfected with the 
expression vector, pSilencer 3.1-H1 neo (Ambion, Texas) (105). These clones were referred to as 
the B1 and B2 clones, and as a control, the cells were transfected with the same vector (SCR) 
containing a scrambled, non-specific siRNA insert (pS-scrambled; Ambion) (105). The B1 clone 
demonstrated superior silencing of MTf and was used in preference in most experiments. The same 
procedure was used to down-regulate MTf expression in the SK-Mel-2 cells and are referred to as 
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‘A3’ with an appropriate SCR control (195). These stably transfected cells were selected and 
maintained in G418 (1000 μg/ml; Alexis Biochemicals, Lausen, Switzerland) (195).  
 
The pancreatic cancer cell line PANC-1 was a generous gift from Prof. Andrew Biankin (Garvan 
Institute, NSW, Australia) and was grown in Dulbecco’s Modified Eagle Medium (DMEM; 
Gibco). For NDRG1 over-expression, the cells were stably transfected with pCMV-taq2-Flag-
NDRG1 (GenHunter, Nashville, TN, USA), namely N1 and N2 or the empty pCMV-taq2-FLAG 
(Stratagene, Santa Clara, CA, USA) vector (VC) to serve as a negative control (162). All 
transfected cells were selected using G418, as described above.  
 
3.2.2 Protein Extractions, Western Blot and Antibodies  
 
Total protein was extracted using standard procedures in our laboratory (72). Western analysis was 
performed as described previously (207). The following primary antibodies were used: MTf 
(Sigma Aldrich Cat#: HPA004880; 1:1000, 1:300 for IF), NDRG1 (Abcam, Cambridge, MA, 
USA; ab37897, 1:2000), NDRG1 XP (Cell Signaling Technology, Danvers, MA, USA; Cat#: 
9485S; 1:150 for IF), p-NDRG1 S330 (Cell Signaling Technology, Danvers, MA, USA; Cat#: 
11899S; 1:2000, 1:200 for IF), p-NDRG1 Thr346 (Cell Signaling Technology, Danvers, MA, 
USA; Cat#: 5482S; 1:3000, 1:250 for IF), β-catenin (Abcam, Cambridge, MA, USA; ab32572, 
1:10,000), c-Myc (Cell Signaling Technology, Danvers, MA, USA; Cat#: 5605S; 1:1000; 1:300 
for IF), cyclin D1 (Cell Signaling Technology, Danvers, MA, USA; Cat#: 2922S; 1:1000; 1:300 
for IF), mTOR (Cell Signaling Technology, Danvers, MA, USA; Cat#: 2983S; 1:1000), p-mTOR 
(Cell Signaling Technology, Danvers, MA, USA; Cat#: 5536S; 1:1000), PI3K p85 (Cell Signaling 
Technology, Danvers, MA, USA; Cat#: 4257S; 1:1000), p-PI3K p85 (Cell Signaling Technology, 
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Danvers, MA, USA; Cat#: 4228S; 1:1000), PI3K 110β (Cell Signaling Technology, Danvers, MA, 
USA; Cat#: 3011S; 1:1000), p-AKT (Abcam, Cambridge, MA, USA; Cat#: ab81283; 1:1000), 
AKT (Abcam, Cambridge, MA, USA; Cat#: ab54752, 1:1000), HDAC (Cell Signaling 
Technology, Danvers, MA, USA; Cat#: 2062S; 1:1000) GAPDH (Cell Signaling Technology, 
Danvers, MA, USA; Cat#: 5174S; 1:10,000) and β-actin (Sigma Aldrich;  St. Louis, MO; 
1:10,000), which was used as a protein-loading control. The secondary antibodies implemented 
were anti-goat, anti-rabbit and anti-mouse (Sigma-Aldrich, St. Louis, MO; 1:10,000). 
 
3.2.3 Cytoplasmic and Nuclear Fractionation  
Cytosolic and nuclear fractions were prepared from cultured cells using NE-PER nuclear and 
cytosolic extraction reagents (Thermo Fisher Scientific, Waltham, MA). Fractionation was 
performed according to the kit instructions. The lysates were then supplemented with a 1× solution 
of protease inhibitor (Roche Diagnostics) and 1× solution of PhosSTOP. 
 
3.2.4 Gene Silencing by Small Interfering RNA (siRNA)  
 
Two specific siRNAs for NDRG1, were used, namely, siNDRG1 (Cat.#: s20336; Life 
Technologies) and siNDRG1II (Cat.#: s20334; Life Technologies). These were compared to non-
targeting negative control siRNA (siControl; Life Technologies). The siRNA was reverse 
transiently transfected into SK-MEL-28 and SK-MEL-2 cells using Lipofectamine RNAiMAX® 
(Life Technologies) following the manufacturer's instructions and incubated for 72 h/37oC, 
respectively. siRNAs specific for MTf (siMTf; Life Technologies), c-Myc (si-c-Myc, Cat.#: 6341S; 
Cell Signaling) were compared to non-targeting negative control siRNA (siControl; Life 
Technologies). The siRNAs were reverse transiently transfected into SK-MEL-28 cells using 
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Lipofectamine RNAiMAX® (Life Technologies) following the manufacturer's instructions and 
incubated for 72 h/37oC, respectively.  Western blotting was then performed, as described in 
Section 2.6.  
 
3.2.5 Immunofluorescence and Confocal Microscopy 
 
Immunofluorescence was performed as described (72) and Chapter 2 (Section 2.9). Images were 
captured using a Zeiss LSM 510 Meta Spectral confocal microscope and also a ZEISS LSM 800 
plus Airyscan Spectral confocal microscope using a 63×objective (Zeiss, Jena, Germany). Raw 
images were analysed using AxioVision (Carl Zeiss, Australia) and ImageJ software (National 
Institutes of Health). Confocal images analysed using the Plot Profile and Co-Masking Analysis 
functions in ImageJ.  
 
3.2.6 MTT Cellular Proliferation Assay  
 
Cellular proliferation was determined using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium, Sigma] assay by methods described in (197) and in Section 2.7.  
 
3.2.7 RNA Extraction and Semi-Quantitative RT-PCR Analysis 
 
Cells were seeded onto tissue culture plates in MEM media (Gibco) and after 24 h, media was 
removed, and cells were rinsed with sterile PBS. RNA was extracted using TRIzol (Invitrogen) 
following manufacturers’ instructions. Briefly, 2 mL TRIzol was added to each plate to lyse the 
cells and the contents then transferred to a sterile microfuge tube. After adding 250 µL chloroform 
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to each sample, the mixture was vigorously shaken and then incubated for 15 min followed by 
centrifuging at 12.000 g for 15 min at 4°C. For the isopropanol precipitation, the aqueous phase 
was transferred to a new microfuge tube and 500 µL isopropanol added to precipitate the RNA 
from the solution. The solution was incubated for further 10 min and centrifuged at 12.000 g for 
15 min at 4°C. After removing the supernatant, the RNA pellet was washed with 75% (v/v) ethanol 
and centrifuged at 7.500 g for 5 min, followed by air drying. The pellet was dissolved in 
diethylpyrocarbonate (DEPC) treated water and heated to 55oC for 10 minutes. RNA was 
quantified using a spectrophotometer (Nanodrop 1000, Thermo Scientific, Wilmington, DE, USA) 
at wavelengths of 280 and 260 nm.  
Primers were designed and checked for specificity using the National Center for Biotechnology 
Information BLAST search tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Real time 
PCR quantification of MTf, NDRG1 and c-Myc, genes was carried out using standard procedures 
as described in (192) with gene-specific primers (Table 3). β-actin was used as a loading control.  
Table 3.1: Sequences for the sense and antisense primers used 
Primer Sense Antisense 
MTf 5’CTCTGTGGCTGCTCCTGGCTCTG’3 5’CTCTCCAGGGGGCTCTTGTCACA’3 
NDRG1 5’TCACCCAGCACTTTGCCGTCT’3 5’GCCACAGTCCGCCATCTT’3 
c-Myc 5’ACTGCGACGAGGAGGAGAAC’3 5’ACAGTCCTGGATGATGATGTTTT’3 
β-actin 5’CCCGCCGCCAGCTCACCATGG’3 5’AAGGTCTCAAACATGATCTGGGTC’3 
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The following thermocycling optimization protocol was used: 56°C for 30 min, 94°C for 2 min 
and 15 sec, 58°C for 30 sec followed by the appropriate number of cycles for each primer (Table 
3.2) at 94°C for 15 sec per cycle. For the elongation step, the samples were heated at 68°C for 5 
min and finally cooled to 4°C. The following thermocycling optimisation protocol was used: 56°C 
for 30 min, 94°C for 2 min and 15 sec, 58°C for 30 sec followed by the appropriate number of 
cycles for each primer (Table 3.2) at 94°C for 15 sec per cycle. For the elongation step, the samples 
were heated at 68°C for 5 min and finally cooled to 4°C. Assessment of DNA fragment length was 
performed by electrophoretic separation in a 0.4% agarose gel with DNA ladder (Promega, WI, 
USA) being used as a size standard. 
Table 3.2: The cycle numbers used to detect MTf, NDRG1, c-Myc and β-actin. 
Primer MTf NDRG1 c-Myc β-actin 
Cycles 25 22 27 24 
 
3.2.8 Tissue Microarrays and Tissue Sections 
 
Tissue microarrays (TMAs) constructed from formalin-fixed paraffin-embedded (FFPE) 
lesions, ranging from compound naevus to distant melanoma metastases, and normal skin 
tissues were retrieved from the Department of Tissue Pathology and Diagnostic Oncology at 
the Royal Prince Alfred Hospital, Australia. Studies using human tissues were approved by the 
Human Research Ethics Committees of the University of Newcastle and Royal Prince Alfred 
Hospital, Australia. 
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3.2.9 Quantitative Multiplex Immunohistochemistry (mIHC) 
 
All immunofluorescence staining was carried out on TMAs and normal skin tissue sections using 
an Autostainer Plus (Dako, Agilent Technologies) with appropriate positive and negative controls. 
Opal Multiplex IHC Assay kit (PerkinElmer, USA) was used as per the manufacturer's protocol. 
Briefly, FFPE tissue sections were first deparaffinised and rehydrated using xylene and ethanol. 
Heat-induced antigen retrieval (AR) was performed in a Decloaking Chamber (Biocare) in pH 6 
AR buffer at 95˚C/20 min. Endogenous peroxidase activity was quenched with 3% hydrogen 
peroxide for 5 min. Individual primary antibodies targeting MTf (1:100; HPA004880, Sigma), 
NDRG1 (1:800; D8G9 XP, Cell Signaling Technology), and SOX10 (1:1500; ab212843, Abcam) 
were incubated for 30 min. Primary antibodies were detected using Opal Polymer HRP (Perkin 
Elmer) and visualised using Tyramide Signal Amplification for 10 min (Opal 7-Colour IHC, 
Perkin Elmer). Sections were stained with DAPI for 5 min and mounted using ProLong® 
Diamond. Imaging was performed using the Vectra 3 multispectral slide scanner in conjunction 
with Vectra 3.3 and Phenochart 1.0.4 software (PerkinElmer). Images were unmixed in inForm 
2.2.0 and a selection of 15 representative original multi-spectral images was used to train the 
single-cell separation algorithm in HALO™ Image Analysis software (Indica Labs, melanocytic 
cells identified based on SOX10 expression). All the settings applied to the training images were 
saved within an algorithm to allow batch analysis of multiple original multispectral images of the 
individual TMA cores. 
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3.2.10 Statistical Analysis 
 
Data were compared using Student’s t-test. Gene Expression Omnibus (GEO) and mIHC data were 
compared using one-way ANOVA and the Mann-Whitney U test, respectively. Data were 
considered statistically significant when p < 0.05. Results are expressed as mean ± SD or mean ± 
SEM. 
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3.3 Results 
3.3.1 The Inverse Relationship Between MTf and NDRG1 Protein Expression 
in Multiple Melanoma Cell Models  
 
Considering the potential opposing roles of MTf and NDRG1 on WNT signalling and their 
possible interaction in melanoma biology, Chapter 3 initially examined the effect of modulating 
MTf levels using melanoma cell transfected with either over-expression or silencing vectors 
(Figure 3.1A-G). Two different MTf over-expressing clones in SK-MEL-28 cells, namely hIF and 
hIE (195), were utilised and compared to their vector control transfected SK-MEL-28 counterparts 
(VA).  Both the hIF and hIE clones expressed significantly (p<0.001) higher MTf levels at 90 kDa 
when compared to VA cells and also a marked and significant (p<0.001) decrease in the major 
NDRG1 bands at 47 kDa, but not 41 kDa (Figure 3.1A).  This observation of two major NDRG1 
bands is in good agreement with previous studies (208,209) and indicates the presence of NDRG1 
isoforms, with the top NDRG1 band representing a post-translational modification (208). This 
upper NDRG1 band has been suggested be the active form of the protein for metastasis 
suppression, as it is potently up-regulated by drugs that inhibit tumour growth and block metastasis 
(174,176,208). Moreover, silencing of the top NDRG1 band prevents the ability of NDRG1 to act 
on downstream effectors (e.g., E-cadherin and β-catenin) involved in preventing the EMT and 
metastasis (72). The down-regulation of the top NDRG1 band is important to achieve in terms of 
preventing its downstream anti-oncogenic functions. 
 
Similar inverse regulation of MTf and NDRG1 was also observed using a stable MTf silencing 
clone of SK-MEL-28 cells (i.e., B1) relative to the corresponding scrambled (SCR) control (105) 
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(Figure 3.1B), with an additional stable MTf silencing clone (i.e., B2) showing the same regulation 
of NDRG1 (Appendix Figure 1A). This up-regulation of NDRG1 was also demonstrated by 
transient silencing of MTf relative to the negative control (NC) transfected counterpart (Figure 
3.1C). Using both these MTf silencing models, marked and significant (p<0.001) down-regulation 
of MTf was achieved and also resulted in a significant (p<0.001-0.01) up-regulation of NDRG1 
relative to the SCR or NC control (Figure 3.1B, C). Similarly, stable silencing of MTf in another 
melanoma cell-type, SK-MEL-2 (termed clone A3), led to a significant (p<0.01) decrease in MTf 
levels relative to the SCR control, and also resulted in significant (p<0.01) increase in NDRG1 
expression (Figure 3.1D). Collectively, these studies using 4 models of MTf expression in two 
different melanoma cell-types demonstrate for the first time that MTf expression has a negative 
effect on the expression of the metastasis suppressor, NDRG1. As such, this negative effect on 
NDRG1 may play a role in the pro-oncogenic activity of MTf in melanoma cells (105,113,195).  
 
 
3.3.2 MTf and NDRG1 are Localised in the Nucleus and Cytoplasm 
 
MTf is known to exist in several isoforms, including a membrane-bound form that is attached by 
a glycosylphosphatidylinositol (GPI)-anchor as well as a soluble variant (201,210). In the current 
study, a major single band at 90 kDa was observed together with a minor lower band that appeared 
as a shadow to the 90 kDa band and was not consistently found (Figure 3.1A-D). Previous studies 
have commonly reported MTf expression in the plasma membrane (199), but the nuclear 
expression of MTf has not been reported. Furthermore, considering our results showing that MTf 
down-regulates NDRG1 in multiple models (Figure 3.1A-D), further studies were conducted to 
determine the intracellular localisation of both NDRG1 and MTf, as this may play a role in their 
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activity (211,212). It has been demonstrated that NDRG1 can be localised to the nucleus and the 
cytosol (185,194,208,211,212). Considering this, the cytoplasmic- (C) and nuclear (N)-
fractionation of SK-MEL-28 MTf over-expressing cells (hIF, hIE) relative to the VA control were 
examined in terms of MTf and NDRG1 expression (Figure 3.1E). Appropriate 
compartmentalisation into C- and N-fractions was demonstrated using glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and histone deacetylase (HDAC) expression, respectively. 
MTf expression in VA cells was ~2-fold greater in the N- than the C-fractions (Figure 3.1E). For 
the hIF and hIE clones, MTf expression was significantly (p<0.001-0.01) greater than the VA 
control in both the C- and N-fractions, with again, the N-levels of MTf being 2-fold greater than 
the C-fraction. However, examining NDRG1 levels after MTf over-expression in the hIE and hIE 
clones, it was markedly and significantly (p < 0.001-0.01) lower in the N- and C-fractions relative 
to VA cells, with a markedly greater decrease being observed for the 47-kDa band relative to the 
41-kDa band (Figure 3.1E).  
 
Both MTf and NDRG1 expression/localisation was also determined using SK-MEL-28 MTf over-
expressing (hIF, hIE) and siMTf-treated cells, compared with their relevant controls, VA and NC, 
respectively, via immunofluorescence using confocal microscopy (Figures 3.1F, G). To enable 
examination of the proportion of MTf and NDRG1 inside and outside of the nucleus in Figure 
3.1F, G, the software, ImageJ, and its analytical tool, Co-Masking Analysis, were used. This 
analysis creates a “mask” over the DAPI channel to enable quantification of the nuclear 
fluorescence intensity of MTf or NDRG1, which was then subtracted from the total to derive the 
cytoplasmic estimate (Figure 3.1F, G). 
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Examining SK-MEL-28 cells, MTf (red fluorescence) was expressed in both the C- and N-
fractions. The nuclear localisation of this protein was further evident upon co-localising MTf with 
the nuclear stain, DAPI (blue fluorescence), leading to purple fluorescence (Figure 3.1F). For 
MTf, its total, C- and N- expression was significantly (p<0.001-0.05) higher in the over-expressing 
hIF and hIE clones than in VA (Figure 3.1F). There was markedly and significantly (p<0.01) 
decreased total, C- and N-MTf expression after siMTf relative to the NC (Figure 3.1F).  
 
Examining NDRG1 expression, it was distributed in the C- and N-compartments of SK-MEL-28 
cells (Figure 3.1G), as demonstrated previously in other cell-types (194,208). Compared to the 
VA control, total, C- and N-NDRG1 was markedly and significantly (p<0.001-0.05) decreased in 
the MTf over-expressing hIF and hIE cells (Figure 3.1G). On the other hand, total, C- and N-
NDRG1 expression was robustly and significantly (p<0.01) increased in siMTf-treated cells 
compared to its NC (Figure 3.1G).  
 
In summary, as demonstrated by the earlier western blot studies (Figure 3.1A-E), there was little 
NDRG1 expression in the hIF and hIF MTf over-expressing cells, while NDRG1 was highly 
expressed in siMTf-treated cells. Importantly, MTf was also detected in the nuclei of these cells, 
which was confirmed via fractionation and confocal immunofluorescence, and may indicate a 
novel function for MTf that has not been described previously.  
 
  
 
 
 
 
 
 
 
Figure 3.1: Over-Expression of MTf in Two SK-MEL-28 Melanoma Cell Clones (hIF and 
hIE) Down-Regulates NDRG1, while MTf Silencing Using Two Different Melanoma Cell-
Types (SK-MEL-28 and SK-MEL-2) Leads to NDRG1 Up-Regulation. Western blot analysis 
of: (A) MTf and NDRG1 expression in VA control and MTf over-expressing, hIF and hIE clones;  
(B) MTf and NDRG1 expression in a stable siMTf clone (B1) of SK-MEL-28 cells vs. the 
scrambled (SCR) control; (C) MTf and NDRG1 expression after transient  transfection with siMTf  
in SK-MEL-28 cells vs. the negative control (NC); (D) MTf and NDRG1 expression in a stable 
siMTf clone (A3) of SK-MEL-2 cells relative to SCR control; (E) Nuclear (N) and cytoplasmic 
(C) fractions of the MTf over-expressing, hIF and hIE clones, relative to the VA control examining 
MTf and NDRG1 in these fractions relative to the N and C markers, histone deacetylase (HDAC) 
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), respectively. β-actin is used as a 
loading control in (A-D) and the results were normalised to the protein expression of the respective 
control (VA, Scr, NC), while HDAC and GAPDH were used for assessing relative expression in 
the nuclear (N) and cytosolic (C) fractions, respectively (E). Results in (A-E) are representative 
blots and the densitometry is presented as mean ± SD (3 experiments). *p<0.05 **p<0.01 
***p<0.001 relative to control lysate. (F, G) Confocal immunofluorescence microscopy of the 
VA, hIF and hIE MTf over-expression model as well as NC and siMTf cell models examining: (F) 
MTf and (G) NDRG1 expression and subcellular localisation. The software ImageJ and its 
analytical tool, Co-Masking Analysis, were used to examine total, cytosolic and nuclear MTf and 
NDRG1 levels. Results are mean + SD (3 experiments). Image J analysis utilised a total of 14-31 
cells over 3 experiments. All images were taken using an 63x objective and the scale bar in the 
bottom left hand corner of the first image in (F) and (G) represents 30 μm and is the same across 
all images. 
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3.3.3 An Inverse Relationship Exists Between MTf Expression and NDRG1 
Phosphorylation 
 
Phosphorylation of NDRG1 (p-NDRG1) at Ser330 and Thr346 by serum- and glucocorticoid-
regulated kinase 1 (SGK1) was demonstrated necessary for NDRG1 to inhibit the downstream 
signalling in pancreatic tumour cells (193). Further, p-NDRG1 at Ser330 and Thr346 are potently 
up-regulated by pharmacological agents that show marked anti-tumour and anti-metastatic activity 
(174,208). As such, pNDRG1 levels were critical to investigate in terms of the effect of MTf on 
its anti-oncogenic activity. 
 
Both p-NDRG1 at Ser330 and Thr346 consisted of minor and major bands at 41- and 47-kDa 
respectively, with the minor band not being consistently observed, or observed as a shadow, 
throughout all blots. Over-expression of MTf (hIF and hIE clones) resulted in a marked and 
significant (p<0.001) decrease in p-NDRG1 Ser330 and Thr346 relative to the VA control (Figure 
3.2A). Conversely, the marked and significant (p<0.001) silencing of MTf in SK-MEL-28 cells 
resulted in a significant (p<0.001-0.05) increase in p-NDRG1 at Ser330 and Thr346 relative to the 
NC (Figure 3.2B). The C- and N-fractions of SK-MEL-28 MTf over-expressing cells relative to 
the VA control were also examined in terms of p-NDRG1 Ser330 and Thr346 levels (Figure 
3.2C). Again, similarly to total NDRG1 (Figure 3.1E), p-NDRG1 at Ser330 and Thr346 were 
higher in the C- than the N-fraction and were markedly and significantly (p<0.001-0.01) reduced 
in the MTf over-expression clones versus the VA control (Figure 3.2C). In an analogous way to 
the fractionation, confocal immunofluorescence images examined using the Co-Masking Analysis 
Tool of ImageJ demonstrated a pronounced and significant (p<0.001-0.05) decrease in the total, 
C- and N-levels of p-NDRG1 Ser330 and Thr346 in the MTf over-expression clones relative to 
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VA (Figure 3.2D, E). In contrast, siMTf in SK-MEL-28 cells resulted in a significant (p<0.05) 
increase in the total, C- and N-levels of p-NDRG1 Ser330 and Thr346 (Figure 3.2D, E). 
 
Overall, the studies in Figure 3.2 demonstrate MTf regulates pNDRG1 at Ser330 and Thr346 that 
are important for its anti-oncogenic activity (174,193,208). In particular, MTf over-expression 
decreased p-NDRG1 at Ser330 and Thr346, suggesting pro-oncogenic activity, while MTf 
silencing had an opposite effect. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 3.2: MTf Expression Down-Regulates the Phosphorylation of NDRG1 (p-NDRG1) at 
Ser330 and Thr346 in SK-MEL-28 Cells. (A) Relative to the empty vector-transfected control 
SK-MEL-28 cells (VA) the MTf over-expressing vector-transfected cells (hIF and hIE) down-
regulate p-NDRG1 at Ser330 and Thr346, as demonstrated by western blotting. (B) Cells 
transiently transfected with either MTf siRNA or the negative control siRNA (NC). (C) 
Cytoplasmic (C) and nuclear (N) fractions of VA, hIF and hIE cells demonstrate decreased p-
NDRG1 at Ser330 and Thr346 levels, with fraction purity being monitored by probing for histone 
deacetylase (HDAC; nucleus) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 
cytosol). Results in (A-C) are representative blots and the densitometry is presented as mean ± SD 
(3 experiments). *p<0.05 **p<0.01 ***p<0.001 relative to the respective control. (D, E) Confocal 
immunofluorescence microscopy of the VA, hIF and hIE MTf over-expression model as well as 
NC and siMTf cell models examining: (D) p-NDRG1 Ser330 and (E) p-NDRG1 Thr346 intensity 
and their subcellular localisation. The software ImageJ and its analytical tool, Co-Masking 
Analysis, were used to examine p-NDRG1 Ser330 and Thr346 levels (total, cytoplasmic and 
nuclear). Results are mean + SD (3 experiments). *p<0.05, **p<0.01, ***p<0.001 relative to the 
respective control. Image J analysis utilised a total of 12-22 cells over 3 experiments. All images 
were taken using an 63x objective and the scale bar in the bottom left hand corner of the first image 
in (D) and (E) represents 30 μm and is the same across all images. 
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3.3.4 NDRG1 Silencing and Over-Expression Down- and Up-Regulates MTf 
Levels, Respectively 
 
To further examine whether a Yin-Yang relationship between MTf and NDRG1 expression existed 
in melanoma cells, additional investigation was performed (Figure 3.3). To achieve this, SK-
MEL-28 cells and SK-MEL-2 were transfected with NDRG1 siRNA or with a NC siRNA. 
Silencing of NDRG1 resulted in a significant (p<0.001) increase in MTf levels, while there was 
significant (p<0.001) decrease in the 47-kDa NDRG1 band when compared to the NC siRNA 
(Figure 3.3A). In contrast, the NDRG1 band at 41-kDa was not silenced, as shown using other 
cell-types (162,208,209). Both pNDRG1 at Ser330 and Thr346 were also significantly (p<0.001-
0.01) decreased by siNDRG1 relative to the NC (Figure 3.3A). Similar results were also obtained 
with another NDRG1 siRNA (i.e., siNDRG1 II; Appendix Figure 1B).  
 
Immunofluorescence using confocal microscopy was performed after incubation of SK-MEL-28 
cells with siNDRG1 and NC to visualise the cell membrane and nucleus (Figure 3.3B) and 
examine the localisation of MTf using ImageJ and its analytical tool, Plot Profile Analysis (213) 
(Figure 3.3Ci,ii). This latter analysis displays intensities of different channels (i.e., blue for 
nuclear DAPI and red for MTf) across the white line that crosses the cell body in the merged image 
in Figure 3.3B. This analysis in the plot for the NC (Figure 3.3Ci) demonstrates MTf expression 
in the cytoplasm (red arrows) and nucleus (black asterisk), with some MTf at the plasma membrane 
(see green arrows). In contrast, siNDRG1 markedly increased MTf expression in the nuclear (black 
asterisk) and cytoplasmic (red arrow) compartments (Figure 3.3Cii).  
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Examining MTf in confocal immunofluorescence images (Figure 3.3B) using Co-Masking 
Analysis demonstrated a significant (p<0.01-0.05) increase in total, C- and N-levels of MTf in 
siNDRG1 treated SK-MEL-28 cells relative to the NC (Figure 3.3D). In contrast, Plot Profile 
(Figure 3.3F) and Co-Masking Analysis (Figure 3.3G) investigating NDRG1 expression and 
distribution in Figure 3.3E showed a decrease in total, C- and N-levels of NDRG1 in siNDRG1 
treated SK-MEL-28 cells versus the NC. 
 
To confirm these results in SK-MEL-28 cells, NDRG1 silencing in SK-MEL-2 cells resulted in 
significant (p<0.001) up-regulation of MTf and significantly (p<0.001) reduced NDRG1 
expression relative to the NC (Figure 3.3H). Collectively, these data in Figures 3.1, 3.2, 3.3A-H 
clearly demonstrate a novel regulatory link and Yin-Yang relationship between NDRG1 and MTf 
expression in melanoma cells, which may be crucial to their effects on melanoma progression and 
metastasis. 
 
Considering our results showing that MTf negatively regulates NDRG1, it was necessary to 
examine whether modulating NDRG1 expression in other cancer cell-types had any effect on MTf 
expression (Figure 3.3I) and localisation (Appendix 1Ci, ii). Expression of NDRG1 was 
demonstrated to modulate a number of oncogenic pathways and inhibit tumour progression of 
PANC-1 pancreatic cancer cells (162). Hence, these cells were examined to determine whether 
NDRG1 had any effect on MTf expression. To investigate this, two PANC-1 clones stably 
transfected with NDRG1 (N1 and N2) were compared to the VC (Figure 3.3I). To be noted, the 
NDRG1 top band of N1 and N2 was observed at 48 kDa, due to its FLAG-tag (191). Expression 
of MTf was significantly (p<0.001) decreased when NDRG1 was significantly (p<0.001-0.01) 
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over-expressed in both the N1 and N2 clones (Figure 3.3D) with a similar effect being 
demonstrated using immunofluorescence (Appendix Figure 1Ci, ii).  Hence, these data further 
demonstrate a link between NDRG1 and MTf expression also in a non-melanoma cancer cell-type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Silencing NDRG1 Expression in Two Different Melanoma Cell-Types (SK-MEL-
28 and SK-MEL-2) Up-Regulates MTf, while Over-Expression of NDRG1 in Two Pancreatic 
Cancer Cell Clones (PANC-1) Down-Regulates MTf Levels. (A) Transient silencing of NDRG1 
(siNDRG1) relative to the negative control, up-regulates MTf and decreases p-NDRG1 Ser330 
and Thr346, as demonstrated by western blotting. (B-D) Immunofluorescence using confocal 
microscopy was performed (B) and MTf intensity and localisation in the cell examined using 
ImageJ and its analytical tools, Plot Profile Analysis (Ci, ii) and Co-Masking Analysis via Image 
J (D). (E-G) Immunofluorescence using confocal microscopy was performed (E) and NDRG1 
intensity and localisation examined by Plot Profile Analysis (Fi, ii) and Co-Masking Analysis (G). 
(H) siNDRG1 also increases MTf and decrease NDRG1 expression in SK-MEL-2 cells vs. the NC. 
(I) NDRG1 over-expression in Panc-1 N1 and N2 clones markedly decreases MTf expression vs. 
vector control (VC). Results are mean + SD (3 experiments). *p<0.05, **p<0.01, ***p<0.001 
relative to the respective control. Image J analysis utilised a total of 8 cells over 3 experiments. All 
images were taken using an 63x objective and the scale bar in the bottom left hand corner of the 
first image in (B) and (E) represents 30 μm and is the same across all images. The white line that 
crosses the cell body in the merged image displays intensities of different channels in the Plot 
Profile Analysis. 
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3.3.5 MTf Over-Expression Increases β-Catenin and its Translocation to the 
Nucleus with Up-Regulation of its Downstream Targets, c-Myc and yclin D1 
 
The EMT is the initial key step in tumour cell metastasis (166). There are various molecular 
pathways which are involved in EMT in melanocytes/melanoma cells, including WNT 
(42,125,214,215). Recent investigations confirmed that NDRG1 inhibits the EMT in prostate and 
colon cancer cells, causing reduced cell migration and invasion (72,181,184). This effect was 
mediated by the ability of NDRG1 to: (1) stabilise the adherens junction, which is composed of 
the adhesion proteins, E-cadherin and β-catenin at the cell membrane (72,194); and (2) prevent β-
catenin oncogenic nuclear translocation (72,194). In fact, once β-catenin translocates to the nucleus 
it can transcribe pro-oncogenic genes, such c-Myc and cyclin D1 (39-41). To determine whether 
NDRG1 modulates the WNT signalling pathway in melanoma cells, β-catenin levels were 
examined by western blotting of the whole-cell lysates of SK-MEL-28 melanoma cells (Figure 
3.4A). Total β-catenin expression was found to be markedly and significantly (p<0.001) increased 
upon MTf over-expression in SK-MEL-28 cells. Furthermore, MTf expression also resulted in a 
pronounced and significant (p<0.001) increase in the levels of phosphorylated β-catenin at serine 
552 (p-β-catenin S552), which is known to increase its transcriptional activity once in the nucleus 
(216). The ratio of p-β-catenin (Ser552)/β-catenin significantly (p<0.01) decreased upon MTf 
over-expression, suggesting MTf could be involved preferentially in up-regulation of total β-
catenin protein levels relative to its phosphorylation at serine 552 (Figure 3.4A). Consistent with 
the increased nuclear translocation of β-catenin after MTf over-expression, there was also a 
marked and significant (p<0.001) increase the levels of its downstream effectors, namely c-Myc 
and cyclin D1, relative to the VA control cell-type. Confocal immunofluorescence microscopy and 
Co-Masking Analysis also demonstrated that MTf over-expression resulted in a significant 
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(p<0.001-0.01) increase in total, cytoplasmic and nuclear cyclin D1 expression, while siMTf 
resulted in a significant (p<0.001-0.01) decrease of cyclin D1 in these compartments (Appendix 
Figure 2A). 
 
In contrast, upon transient MTf silencing in SK-MEL-28 cells, which significantly (p<0.001) 
decreased MTf relative to the NC, there was a significant increase (p<0.001-0.05) of total β-catenin 
and p-β-catenin (Ser552), while c-Myc and cyclin D1 levels significantly (p<0.01) decreased 
(Figure 3.4B). Similar results were obtained with the additional stable MTf silencing clones B1 
and B2, where total β-catenin was up-regulated (Appendix Figure 2B), and c-Myc and cyclin D1 
were down-regulated (Appendix Figure 2B, C).  
 
Regarding the increase in total β-catenin and p-β-catenin (Ser552) (Figure 3.4B), it is notable that 
its cellular localisation in melanoma cells is crucial for its function (216-218). Therefore, 
immunofluorescence using confocal microscopy was performed with MTf over-expressing and 
transient silenced SK-MEL-28 cells, to visualise the cell membrane and nucleus (Figure 3.4C) 
and examine the localisation of β-catenin using ImageJ and Plot Profile Analysis (213) (Figure 
3.4Di-v). This analysis in the plots for vector control VA (Figure 3.4Di) and NC cells (Figure 
3.4Div) demonstrates β-catenin expression being highly expressed on the plasma membrane (see 
green arrows at outer most edges of plot) with correspondingly less cytoplasmic (red arrows) and 
also nuclear (DAPI) staining (black asterisk; Figure 3.4Di, iv). In contrast, MTf over-expression 
in hIF and hIE cells increased the nuclear (black asterisk) and cytoplasmic (red arrow) expression 
of β-catenin, as shown in the Plot Profile Analysis (Figure 3.4Dii, iii). Examining the expression 
of β-catenin in the MTf silenced cells (Figure 3.4C), its levels were prominently increased in the 
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plasma membrane (green arrows; Figure 3.4Dv) relative to the NC (Figure 3.4Div). Furthermore, 
MTf silencing resulted in decreased nuclear β-catenin (black asterisk; Figure 3.4Dv) relative to 
the NC (Figure 3.4Div). 
 
Next, to enable examination of the proportion of β-catenin inside and outside of the nucleus in 
Figure 3.4C, the Co-Masking Analysis tool was implemented (Figure 3.4E). Using this analysis, 
total, cytoplasmic and nuclear β-catenin was significantly (p<0.01-0.05) increased upon MTf over-
expression relative to the VA Control (Figure 3.4Ei-iii). In contrast, after MTf silencing, the total 
and cytoplasmic β-catenin was significantly (p<0.01) increased, while nuclear β-catenin was 
slightly decreased relative to the NC (Figure 3.4Ei-iii)  
 
The cellular localisation of p-β-catenin (Ser552) in melanoma cells (Figure 3.4F), was then 
examined by Plot Profile Analysis (Figure 3.4G). The plots for VA (Figure 3.4Gi) and NC cells 
(Figure 3.4Giv) demonstrate that p-β-catenin (Ser552) levels were, in part, nuclear (black asterisk; 
Figure 3.4Gi, iv). In contrast, MTf over-expression in hIF and hIE cells markedly increased the 
proportion of nuclear (black asterisk) and cytoplasmic (red arrow) expression of p-β-catenin 
(Ser552) (Figure 3.4Gii, iii). Examining levels of p-β-catenin (Ser552) in the MTf silenced cells 
(Figure 3.4F), its levels were increased in the cytoplasm (red arrows; Figure 3.4Gv) relative to 
the NC (Figure 3.4Giv). Furthermore, MTf silencing resulted in a decrease in the nuclear p-β-
catenin (Ser552) (black asterisk; Figure 3.4Gv) relative to the NC (Figure 3.4Giv). 
 
To examine the proportion of p-β-catenin (Ser552) inside and outside of the nucleus in Figure 
3.4F, Co-Masking Analysis was implemented (Figure 3.4H). Using this assessment, total, 
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cytoplasmic and nuclear p-β-catenin (Ser552) was significantly (p<0.001-0.05) increased upon 
MTf over-expression relative to the VA Control (Figure 3.4Hi-iii). In contrast, after MTf silencing, 
the total and nuclear p-β-catenin (Ser552) were significantly (p<0.001-0.01) decreased, while 
cytoplasmic p-β-catenin (Ser552) was significantly (p<0.01) increased relative to the NC (Figure 
3.4Hi-iii). 
 
Overall, MTf over-expression results in a translocation of both β-catenin and p-β-catenin (Ser552), 
from the plasma membrane to the nucleus and cytoplasm that could be responsible for the 
transcriptional activation of oncogenic WNT downstream proteins, such as c-Myc and cyclin D1, 
while MTf silencing has an opposite effect. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Over-Expression of MTf in SK-MEL-28 Melanoma Cells, Increased Total and 
Nuclear β-catenin, p-β-Catenin (Ser552), and the Downstream Effectors of WNT Signalling 
Including, c-Myc and cyclin D1, While Silencing MTf Has the Opposite Effect. (A) Relative 
to the empty vector-transfected control of SK-MEL-28 cells (VA), the MTf over-expressing 
vector-transfected clones (hIF and hIE) increased total β-catenin, p-β-catenin S552, c-Myc and 
cyclin D1 expression, as demonstrated by western blotting. (B) Silencing MTf (siMTf) in SK-
MEL-28 cells increased total β-catenin, p-β-catenin S552 and decreased c-Myc and cyclin D1 vs. 
the negative control (NC). (C-E) Immunofluorescence using confocal microscopy was performed 
in VA relative to hIE and hIF MTf over-expressing cells and in siMTf vs. the NC (C). The 
subcellular localisation of β-catenin was examined using ImageJ, Plot Profile Analysis (Di-v) and 
Co-Masking Analysis (E). (F) Immunofluorescence using confocal microscopy was performed in 
VA relative to hIE and hIF MTf over-expressing clones and in siMTf vs. the NC with p-β-catenin 
S552 localisation examined using ImageJ, Plot Profile Analysis (Gi-v) and Co-Masking Analysis 
(H). Results are mean + SD (3 experiments). *p<0.05, **p<0.01, ***p<0.001 relative to the 
respective control. Image J analysis utilised a total of 27-55 cells over 3 experiments. All images 
were taken using an 63x objective and the scale bar in the bottom left hand corner of the first image 
in (B) and (E) represents 30 μm and is the same across all images. The white line that crosses the 
cell body in the merged image displays intensities of different channels in the Plot Profile Analysis. 
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3.3.6 NDRG1 Silencing Increases β-Catenin and its Translocation to the 
Nucleus in Melanoma Cells 
 
Considering, the results in Figure 3.1 demonstrated an inhibitory effect of MTf on NDRG1 levels, 
the next studies examined whether NDRG1 could modulate β-catenin expression and localisation 
in SK-MEL-28 melanoma cells (Figure 3.5). Silencing NDRG1 significantly (p<0.001) increased 
MTf expression as previously shown (Figure 3.3A), with also a significant (p<0.001-0.01) 
increase in β-catenin, p-β-catenin (Ser552), c-Myc and cyclin D1 (Figure 3.5A). Examining the 
effect of NDRG1 silencing on cellular localisation of β-catenin using confocal microscopy (Figure 
3.5B) and Plot Profile analysis (Figure 3.5C), demonstrated a marked translocation of β-catenin 
from the plasma membrane (green arrows) to the cytoplasm (red arrows) and nucleus (asterisk; cf. 
Figure 3.5Ci to 3.5Cii). Further analysis of Figure 3.5B using Co-Masking Analysis 
demonstrated a significant (p<0.001-0.05) increase of β-catenin in the total, cytoplasm and nucleus 
of siNDRG1 cells relative to the NC (Figure 3.5D). Similarly, examining the cellular localisation 
of p-β-catenin (Ser552) after siNDRG1 treatment (Figure 3.5E), demonstrated translocation 
predominantly from the cytoplasm to the nucleus, leading to a significant (p<0.01) increase in 
nuclear p-β-catenin (Ser552) in siNDRG1 cells versus the NC (Figure 3.5F, G) 
 
In summary, NDRG1 silencing in melanoma cells results in oncogenic alterations, resulting in the 
up-regulation of MTf and the increased translocation of β-catenin from the plasma membrane to 
the nucleus. Similarly, p-β-catenin (Ser552) translocated from the cytoplasm to the nucleus after 
silencing NDRG1. Together, these results suggest MTf promotes the WNT signalling pathway, 
while NDRG1 counters these effects. 
  
 
 
 
 
 
Figure 3.5: Silencing NDRG1 in SK-MEL-28 Melanoma Cells Increases MTf Expression and 
Results in Translocation of β-Catenin and p-β-Catenin S552 into the Nucleus, as well as Up-
Regulation of the Downstream WNT Targets, c-Myc and cyclin D1. (A) Transient silencing of 
NDRG1 (siNDRG1) relative to the negative control (NC), up-regulates MTf, total β-catenin, p-β-
catenin S552, c-Myc and cyclin D1, as shown by western blotting. (B-D) Immunofluorescence 
using confocal microscopy was performed examining siNDRG1 relative to the NC, with β-catenin 
localisation examined using ImageJ, Plot Profile Analysis (Ci, ii) and Co-Masking Analysis (Di-
iii). (E-G) Immunofluorescence using confocal microscopy was performed examining siNDRG1 
relative to the NC, with p-β-catenin S552 localisation being assessed using ImageJ, Plot Profile 
Analysis (Fi, ii) and Co-Masking Analysis (Gi-iii). Results are mean + SD (3 experiments). 
*p<0.05, **p<0.01, ***p<0.001 relative to the respective control. Image J analysis utilised a total 
of 25-27 cells over 3 experiments. All images were taken using an 63x objective and the scale bar 
in the bottom left hand corner of the first image in (B) and (E) represents 30 μm and is the same 
across all images. The white line that crosses the cell body in the merged image displays intensities 
of different channels in the Plot Profile Analysis. 
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3.3.7 The Novel Thiosemicarbazone, DpC, Up-Regulates NDRG1 and Down-
Regulates MTf and cyclin D1 in Melanoma Cells 
 
As shown herein, MTf silencing results in an increase of NDRG1 levels in SK-MEL-28 cells 
(Figure 3.1B-D) and also decreased expression of oncogenic WNT downstream targets, such as 
c-Myc and cyclin D1 (Figure 3.4B). Moreover, NDRG1 over-expression in PANC-1 cells led to 
a decrease in MTf levels (Figure 3.3I). Indeed, the ability of NDRG1 to suppress metastasis and 
inhibit MTf and WNT signalling makes it a viable therapeutic target for cancer therapy (192). As 
demonstrated previously, NDRG1 is effectively up-regulated by the novel di-2-pyridylketone 
thiosemicarbazone (DpT) class of anti-cancer agents, such as DpC (174,192), that entered clinical 
trials (153). Moreover, this class of thiosemicarbazones have also been demonstrated to markedly 
inhibit melanoma xenograft growth in nude mice (171). 
 
To pharmacologically up-regulate NDRG1 expression, SK-MEL-28 melanoma cells (VA) were 
incubated with media alone (Control) or media containing increasing concentrations of DpC (1-, 
5- and 10-μM) for 24 h/37°C. The expression of MTf, NDRG1 and cyclin D1 was then examined 
by western blotting (Figure 3.6A-D). In good agreement with previous studies (174,191,192), 
DpC was able to markedly and significantly (p<0.001-0.01) up-regulate NDRG1 with increasing 
DpC concentration in SK-MEL-28 cells (Figure 3.6C). In addition, DpC significantly (p<0.001-
0.01) decreased MTf and cyclin D1 expression at concentrations of 5-10 μM (Figure 3.6B, D). 
 
In conclusion, these results indicate that pharmacological targeting of NDRG1 expression has the 
same anti-oncogenic effect on decreasing MTf and cyclin D1 levels, as genetic up-regulation of 
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NDRG1. Hence, the identification of the novel NDRG1-MTf axis of regulation enables a potential 
therapeutic intervention against melanoma using DpC. 
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Figure 3.6: The Thiosemicarbazone DpC Up-Regulates NDRG1, while Down-Regulating 
MTf and cyclin D1 in VA SK-MEL-28 Melanoma Cells. Western blot analysis of: (A) MTf, 
NDRG1 and cyclin D1 expression after treatment with DpC (1 μM, 5 μM, 10 μM) after an 
incubation of 24 h/37°C and compared to their control in VA. Results in (B-D) are representative 
blots and the densitometry is presented as mean ± SD (3 experiments). *p<0.05 **p<0.01 
***p<0.001 relative to the control lysate.  
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3.3.8 MTf Over-Expression or NDRG1 Silencing Up-Regulates PI3K, AKT and 
mTOR Activation 
 
Translocation of β-catenin localisation from the cell membrane and cytoplasm to the nucleus 
promotes the oncogenic EMT and melanoma metastasis (219). This outcome could be due to 
activation of PI3K/AKT signalling (85), which inhibits glycogen synthase kinase-3β (GSK3β) and 
allows β-catenin to accumulate and translocate to the nucleus (219). Furthermore, p-AKT activates 
mTOR, which then increases c-Myc expression (62). On the other hand, NDRG1 is known to 
suppress PI3K/AKT and mTOR signalling and also decreases c-Myc expression (162,220). 
 
To examine the involvement of MTf and NDRG1 in modulating the PI3K/AKT pathway, the effect 
of MTf over-expression and silencing on MTf and NDRG1 levels was then investigated (Figure 
3.7A-F).  Class IA PI3Ks are composed of regulatory subunits (p85α, p85β, and p55γ) and a p110 
catalytic subunit (with various isoforms; α, β, δ, γ) and can be activated to promote proliferation 
(221). 
  
In this study, representative detectable isoforms of both the catalytic and regulatory subunits of 
PI3K were examined. The effect of MTf over-expression on PI3K isoform subunits resulted in a 
significant (p<0.001-0.01) increase in total PI3K p85α and 110β relative to the VA control (Figure 
3.7A). Furthermore, MTf over-expression resulted in a significant (p<0.001) increase in phospho-
p85α (p-p85α) relative to VA, while the levels of the PI3K p-p85β were not detectable in this cell-
type (Figure 3.7A). In contrast, transient MTf silencing resulted in a significant (p<0.001) decrease 
in total PI3K p85α and 110β, as well as p-p85α relative to the NC (Figure 3.7B). Thus, MTf 
regulates PI3K activity, and considering the effect of Yin-Yang relationship between MTf and 
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NDRG1, the effects of siNDRG1 on PI3K were assessed. Again, siNDRG1 up-regulated MTf, and 
as found for MTf over-expression, there was a significant (p<0.001-0.01) increase of total PI3K 
p85α and 110β, as well as p-p85α to NC (Figure 3.7C). 
 
Considering the regulation of PI3K by MTf, its downstream targets, AKT, p-AKT, mTOR, p-
mTOR, and c-Myc were then examined (Figure 3.7D-F). The over-expression of MTf in hIF and 
hIE resulted in a significant (p<0.001-0.05) increase in AKT, p-AKT, mTOR, p-mTOR and c-Myc 
relative to VA (Figure 3.7D). On the other hand, transient MTf silencing resulted in a significant 
(p<0.05) increase in total AKT, but a significant (p<0.001-0.05) decrease in p-AKT, mTOR, p-
mTOR and c-Myc relative to NC (Figure 3.7E). Hence, MTf also is regulating downstream PI3K 
targets and considering the effect of the inverse relationship between MTf and NDRG1, the effects 
of siNDRG1 on PI3K downstream targets were assessed. Incubation of SK-MEL-28 cells with 
siNDRG1 significantly (p<0.001-0.05) increased AKT, p-AKT, mTOR, p-mTOR and c-Myc 
relative to NC (Figure 3.7F). 
 
In summary, MTf regulates PI3K activity and its critical downstream oncogenic targets, which is 
counteracted by NDRG1 and elucidates a mechanism of how MTf promote tumourigenesis. 
Further, these studies provide a mechanism of how MTf expression leads to β-catenin nuclear 
translocation. This is particularly relevant, as p-AKT phosphorylates β-catenin Ser552 leading to 
its nuclear translocation and the promotion of WNT signalling (216) (Figures 3.4F-H; 3.5). 
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3.3.9 The Effect of MTf and NDRG1 on Proliferation of Melanoma Cells 
 
Previous studies have indicated that MTf expression is pro-proliferative in vitro and in vivo 
(105,195), but in different models and under different conditions. These studies indicate MTf 
expression results in a pro-oncogenic phenotype, with silencing having the opposite effect. 
Considering these data collectively, the effect of MTf expression on proliferation in the models 
used in the current investigation was then assessed using MTT assays (Figure 3.7G-H). Both MTf 
over-expression clones (hIF and hIE) significantly (p<0.001) enhanced proliferation after 3-4 days 
of incubation, while the stable MTf silencing clones, B1 and B2, resulted in significantly (p<0.001) 
decreased proliferation after 3-4 days of incubation (Figure 3.7G-H). Thus, MTf played a pro-
proliferative role which agrees with previous data (105,195) and also the results in the current 
investigation (Figure 3.7G-H). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 3.7: Over-Expression of MTf in SK-MEL-28 Cells Up-Regulates Pro-Oncogenic PI3K 
p85, p-PI3K p85, AKT, p-AKT, mTOR, p-mTOR and c-Myc, while Silencing MTf has the 
Opposite Effect, and Silencing NDRG1 has a Similar Effect as MTf Over-Expression. (A) 
Relative to the empty vector-transfected control SK-MEL-28 cells (VA), the MTf over-expressing 
vector-transfected clones (hIF and hIE) increased PI3K p85, p-PI3K p85 and PI3K 110β levels, as 
demonstrated by western blotting. (B) Silencing MTf in SK-MEL-28 cells decreased PI3K p85, p-
PI3K p85 and PI3K 110β levels vs. the negative control (NC), as shown by western blotting. (C) 
Silencing NDRG1 in SK-MEL-28 cells increased PI3K p85, p-PI3K p85 and PI3K 110β vs. the 
negative control (NC), as shown by western blotting. (D) Relative to VA cells the MTf over-
expressing clones increased AKT, p-AKT, p-AKT/AKT ratio, mTOR, p-mTOR, p-mTOR/mTOR 
ratio, and c-Myc, as demonstrated by western blotting. (E) Silencing MTf in SK-MEL-28 cells 
decreased p-AKT, mTOR, p-mTOR vs. the negative control (NC), as shown by western blotting. 
(F) Silencing NDRG1 in SK-MEL-28 cells increased AKT, p-AKT, mTOR, p-mTOR and c-Myc 
vs. the negative control (NC), as shown by western blotting. (G) Relative to VA cells the MTf 
over-expressing cells increased proliferation, as judged by MTT assays and validated by viable 
cell counts using Trypan blue. (H) Stable silencing of MTf in SK-MEL-28 cells (clones B1 and 
B2) decreases proliferation, as judged by MTT assays and validated by viable cell counts. Results 
are mean + SD (3 experiments). *p<0.05, **p<0.01, ***p<0.001 relative to the respective control. 
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3.3.10 MTf Over-Expression Increases c-Myc mRNA and Protein and its 
Nuclear Translocation, while Silencing of c-Myc Partially Negates the Ability of 
MTf to Down-Regulate NDRG1 
 
Considering that MTf over-expression in both hIF and hIE clones up-regulates c-Myc protein 
levels (Figure 3.4A), the studies herein further assessed the effect of MTf over-expression and 
silencing on MTf, NDRG1 and c-Myc mRNA levels (Figure 3.8A). Upon MTf over-expression, 
the mRNA levels of both MTf and c-Myc mRNA were increased, while NDRG1 mRNA levels 
were decreased. The MTf stable silencing clone, B1, showed the opposite effect found for MTf 
over-expression, resulting in decreased levels of c-Myc and increased NDRG1 expression relative 
to the SCR control (Figure 3.8A). Hence, MTf expression regulates both NDRG1 and c-Myc at 
the mRNA and protein levels. 
 
Since, NDRG1 mRNA levels were shown to be decreased in MTf over-expressing cells and c-Myc 
is a known NDRG1 repressor (205) and was up-regulated under these conditions (Figures 3.4A 
and 3.8A), the next step was to investigate if c-Myc became translocated to the nucleus where it 
is transcriptionally active (205). Upon fractionation of cells into the C- and N-fractions, the hIF 
and hIE MTf over-expression clones demonstrated that c-Myc levels were markedly and 
significantly (p<0.001) increased in the N-fraction relative to the VA control (Figure 3.8B). In 
contrast, little c-Myc expression was observed in the C-fraction under all conditions. 
 
In an analogous way to the fractionation, confocal immunofluorescence microscopy was utilised 
to examine the intracellular distribution of c-Myc (Figure 3.8C). In these studies, processing of 
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the images using the Co-Masking Analysis Tool demonstrated that there was a prominent and 
significant (p<0.001-0.05) increase in the total, C- and N-levels of c-Myc in the MTf over-
expression clones relative to VA (Figure 3.8Di-iii). In these same imaging studies, treatment of 
SK-MEL-28 cells with siMTf resulted in significant (p<0.01-0.05) down-regulation of the total, 
C- and N-levels of c-Myc (Figure 3.8Ei-iii).  
 
Plot Profile analysis of the images in Figure 3.8C, demonstrated a marked increase of c-Myc in 
the C (red arrows) and N (asterisk) after MTf over-expression in both clones (cf. Figure 3.8Ei to 
3.8Eii & iii). Interestingly, peri-nuclear localisation (red arrows) of c-Myc was observed when 
MTf was over-expressed compared to VA (Figure 3.8Fi-iii). In contrast, c-Myc expression 
decreased in the N-compartment when MTf was silenced (Figure 3.8Fiv-v). 
 
To investigate the relationship between MTf, NDRG1 and c-Myc, we next silenced c-Myc in the 
VA, hIF and hIE clones and probed for their expression using western blotting (Figure 3.8F-I). 
Both, MTf and NDRG1 were markedly and significantly (p<0.001-0.01) increased in both MTf 
over-expression clones and also VA cells when c-Myc was silenced and compared to their 
respective NC (Figure 3.8F-I). It is notable that after c-Myc silencing that both NDRG1 and MTf 
increase in expression (Figure 3.8F). Moreover, upon treatment of the MTf over-expression clones 
with c-Myc silencing, NDRG1 and MTf again both increase. This observation is in direct contrast 
to when examining the NC treatments, where MTf over-expression led to a decrease in NDRG1 
levels (Figure 3.8F), as demonstrated previously (Figure 3.1). Hence, these observations indicate 
that the Yin-Yang relationship, which is observed under control conditions, is broken after c-Myc 
silencing, suggesting that c-Myc plays a role in the inter-relating regulation of MTf and NDRG1. 
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Overall, the studies in Figure 3.8 demonstrate upon MTf over-expression that: (i) mRNA levels 
reflect the protein levels of MTf, NDRG1 and c-Myc; (ii) c-Myc mainly localises to the nucleus 
and cytoplasm, while silencing MTf had an opposite effect; and (iii) importantly, after silencing 
c-Myc, the Yin-Yang relationship between MTf and NDRG1 was broken. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3.8: Over-Expression of MTf in SK-MEL-28 Melanoma Cell Clones (hIF and hIE) 
Up-Regulates MTf, NDRG1, and c-Myc mRNA, as well as inducing c-Myc Nuclear 
Translocation. In Contrast, Silencing c-Myc in VA, hIF and hIE cells Partially Negates the 
Ability of MTf to Down-Regulate NDRG1. (A) The MTf, NDRG1, c-Myc mRNA levels in 
various cancer cell-types were examined using RT-PCR. Results in (A) are representative blots (1 
experiment). (B) Nuclear (N) and cytoplasmic (C) fractions of the MTf over-expressing, hIF and 
hIE clones, relative to the VA control examining MTf and c-Myc in these fractions relative to the 
N and C markers, histone deacetylase (HDAC) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), respectively. HDAC and GAPDH were used for assessing relative expression in the N 
and C fractions, respectively. (C) Confocal immunofluorescence microscopy of the VA, hIF and 
hIE MTf over-expression model as well as NC and siMTf cell models examining c-Myc expression 
and subcellular localisation using Co-Masking Analysis (Di-iii) and ImageJ, Plot Profile Analysis 
(Ei-v)). (F) Transient silencing of c-Myc (si-c-Myc) relative to NC, up-regulates MTf and NDRG1 
expression, as shown by western blotting. Results in (B-D, F-I) are mean + SD (3 experiments). 
*p<0.05, **p<0.01, ***p<0.001 relative to the respective control. Image J analysis utilised a total 
of 15-39 cells over 3 experiments. All images were taken using an 63x objective and the scale bar 
in the bottom left hand corner of the first image in (C) represents 30 μm and is the same across all 
images. The white line that crosses the cell body in the merged image displays intensities of 
different channels in the Plot Profile Analysis. 
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3.3.11 The Inverse Relationship between MTf and NDRG1 Expression is 
Demonstrated in Patient Melanoma Samples 
 
To evaluate the clinical relevance of our in vitro data, the studies herein first assessed the impact 
of MTf and NDRG1 expression on clinical outcomes of melanoma patients. Analysis of the 
treatment naïve samples from TCGA-SKCM dataset revealed that both up-regulated MTf mRNA 
expression and downregulated NDRG1 mRNA expression tend to be linked with poor overall 
survival in melanoma patients, although not significantly (p>0.05) (Figure 3.9Ai, ii). However, a 
low ratio of NDRG1 to MTf mRNA expression significantly (p<0.01) predicts poor survival in 
melanoma patients (Figure 3.9Aiii), which suggests that the balance between MTf and NDRG1 
expression is an important factor in melanoma progression. 
 
As the in vitro data suggested that MTf promotes melanoma tumourigenesis, MTf and NDRG1 
mRNA expression was further examined using GEO dataset (GSE46517; Figure 3.9Bi-iii). This 
comprises samples ranging from normal skin (n = 8) to various stages of melanoma progression, 
including dysplastic nevi (n = 9), primary (n = 31), and metastatic melanoma (n = 52). Compared 
to normal skin, MTf mRNA expression was significantly up-regulated in dysplastic nevi (p<0.05) 
and also both primary and metastatic melanoma (p<0.001) (Figure 3.9Bi), which suggests early 
involvement of MTf in melanoma tumourigenesis. Conversely, NDRG1 mRNA levels were 
markedly (p<0.001) decreased in metastatic melanoma (Figure 3.9Bii), corroborating the role of 
NDRG1 as a metastasis suppressor as found in other tumour-types (187-189). There was a slight, 
but not significant decrease in NDRG1 in both dysplastic nevi and primary melanoma (Figure 
3.9Bii). 
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Strikingly, NDRG1/MTf expression ratios in individual samples were the most indicative of the 
progression towards a more aggressive state (Figure 3.9Biii). While higher NDRG1 mRNA levels 
were associated with low MTf mRNA levels in normal skin, this ratio was reversed in metastatic 
melanoma, which exhibited the highest MTf mRNA levels and lowest NDRG1 expression. The 
NDRG1/MTf mRNA ratios changed gradually exhibiting a significant decrease between normal 
skin and both dysplastic nevi and primary melanoma (p<0.05 and p<0.01, respectively), and 
further markedly and significantly (p<0.0001) decreased between primary and metastatic 
melanoma (Figure 3.9B). Further, a pronounced and significant (p<0.0001) difference was evident 
between normal skin and metastatic melanoma. Together, these results support a strong negative 
relationship between MTf and NDRG1 expression and confirm the importance of the 
MTf/NDRG1 regulatory axis in melanoma progression in patient samples. 
 
To validate these in silico data at the protein level, mIHC was performed using a range of human 
tissue samples, comprising normal skin whole tissue sections (n = 9), dysplastic nevi TMAs (n = 
27), and treatment naïve (not treated by any systemic therapy) primary (n = 31), and metastatic 
melanoma TMAs (n = 57) (Figure 3.9C, D). First, normal skin melanocytes were detected using 
the well-characterised melanocytic marker, SOX10 (222,223) (cyan fluorescence; Figure 3.9Ci). 
However, upon the merge with MTf (green fluorescence; Figure 3.9Cii) or NDRG1 (magenta 
fluorescence; Figure 3.9Ciii) very low levels were observed in melanocytes at the level of the 
stratum basale (Figure 3.9Civ, Cv). On the other hand, MTf expression was observed in the highly 
proliferative basal layer of epidermis (Figure 3.9Cii, Ciii; arrowheads) and decreased towards 
the outer layer in good agreement with the decreased proliferation, which is known to occur as the 
keratinocytes move from the stratum basale to the outermost stratum corneum (224). In contrast, 
NDRG1 was lower in the basal layer and increased towards the outermost corneum (Figure 3.9Cii, 
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Ciii; asterisk; as demonstrated by quantitation of signal intensity across the white line in 
Appendix Figure 3). Hence, an inverse relationship was observed between NDRG1 and MTf in 
the epidermis as found for the cultured tumour cells (Figures 3.1-3.3, 3.5). 
 
In melanoma tumours, where NDRG1 was detected, the pattern of NDRG1 distribution again 
clearly demonstrated the negative relationship with MTf (Figure 3.9D). In fact, melanoma cells 
expressing high levels of MTf (Figure 7Dii) were negative for NDRG1 (Figure 3.9Diii) and vice 
versa (also see Merge Figure 3.9Div and Close-Up Figure 3.9Dv). Moreover, areas with 
intermediate states exhibiting a moderate expression of both MTf and NDRG1 were observed in 
such melanoma samples (Figure 3.9Cii, asterisk). Examining the histoscores, compared with 
normal skin melanocytes (SOX10+), most of the primary and metastatic melanoma samples were 
characterised by the significantly (p<0.05 and p<0.01, respectively) increased MTf expression 
(Figure 3.9Ei), whereas NDRG1 protein levels (Figure 3.9Eii) were markedly and significantly 
(p<0.05 and p<0.01, respectively) decreased.  
 
The protein expression of both MTf and NDRG1 remarkably reflected the trends of gene 
expression at mRNA levels (Figure 3.9Bi, 3.9Bii). Indeed, the MTf histoscore gradually increased 
from lowest values detected in normal skin melanocytes to metastatic melanoma samples 
exhibiting the highest expression of MTf protein (Figure 3.9Ei). In contrast, histoscore for 
NDRG1 revealed a gradual decrease in protein expression, with 7 out of 31 primary, and 12 out of 
57 metastatic tumours exhibiting completely negative NDRG1 expression (Figure 3.9Eii). Most 
importantly, the ratio of NDRG1/MTf from the histoscores significantly (p<0.0001-0.01) 
correlated with melanoma progression (Figure 3.9Eiii), which demonstrates the clinical 
significance of the MTf/NDRG1 axis in human melanoma patients. 
  
 
 
 
 
Figure 3.9: Analysis of Melanoma Patient Tumour Samples Examining MTf and NDRG1 
Expression. (A) Overall survival analysis of melanoma patients based on the mRNA levels of MTf 
or NDRG1 using treatment naïve samples from TCGA-SKCM dataset (B) Analysis of MTf and 
NDRG1 mRNA expression in normal skin samples (n = 8), dysplastic naevi (n =9), primary 
melanoma (n = 31), and metastatic melanoma (n = 52) from data provided in the GEO GSE46517 
dataset. (C, D) Representative images of mIHC analysis of MTf and NDRG1 expression in normal 
skin (C) and primary melanoma (D). The SOX10 melanocytic marker was used to identify 
melanocytes and melanoma cells. (C) Only weak expression of MTf was observed in normal skin 
melanocytes. Note the high expression of MTf and low levels of NDRG1 in SOX10-negative cells 
in basal layer of epidermis (stratum basale; arrowhead) compared with the high levels of NDRG1 
and low expression of MTf in the uppermost layers of epidermis (stratum corneum asterisk). (D) 
Melanoma tissue samples revealed a clear negative relationship between MTf and NDRG1. Areas 
with moderate expression of both proteins (asterisk) suggest a Yin-Yang relationship between MTf 
and NDRG1 expression. (E) MTf and NDRG1 histoscores calculated based on a single-cell 
analysis of SOX10-positive cells in individual normal skin samples (n = 9), dysplastic naevi (n = 
27), primary melanoma (n = 31) and metastatic melanoma tissues (n = 57). *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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3.4 Discussion 
MTf was one of the first melanoma tumour antigens that was well-characterised (199), yet its 
functional role has remained a mystery (106). The high homology of MTf to the iron-binding 
protein, transferrin, and its ability to bind iron at one specific, high affinity site, initially suggested 
a role in iron metabolism (199). However, multiple studies, including those using melanoma cell 
models and also MTf knockout and transgenic mice, indicate that MTf did not play a significant 
role in iron trafficking or homeostasis (105,195,200,203,204). In contrast, MTf was demonstrated 
to play a role in the proliferation and oncogenic capacity of melanoma cells in vitro and in vivo, 
although the precise molecular mechanism involved remained unknown (105,113,195).  
 
For the first time, the current study has demonstrated using 7 different models of MTf and NDRG1 
expression and 3 different cell-types, that MTf regulates the expression of the potent metastasis 
suppressor, NDRG1, and vice versa in a Yin-Yang inter-relationship (Figure 3.10). The 
intertwined functional association between these molecules was also clearly evident in melanoma 
patient samples at both the mRNA and protein levels. In fact, the ratio of NDRG1 to MTf decreased 
in correlation with the progression from dysplastic nevi to metastatic melanoma at both the mRNA 
(Figure 3.9B) and protein levels (Figure 3.9D). Not only did MTf down-regulate total NDRG1 in 
vitro, but also its phosphorylation of NDRG1 at Ser330 and Thr346 that has been implicated in its 
anti-metastatic activity (174,193,208) was decreased (Figure 3.10). These findings are significant, 
as NDRG1 is a bona fide metastasis suppressor that is down-regulated in multiple tumour-types 
(187,188). NDRG1 is commonly deleted in prostate cancer patients with high Gleason grade 
(225,226), particularly in patients with loco-regional or distant metastasis (187). Previous studies 
have also indicated poor patient prognosis with decreased NDRG1 levels in non-melanoma 
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tumours (227). However, nothing is currently known regarding the role of NDRG1 in melanoma 
pathogenesis or metastasis.   
 
MTf has been reported to be a well-characterised glycosylphosphatidylinositol (GPI)-linked, 
plasma membrane protein (228). Surprisingly in the current investigation, MTf was also 
demonstrated by both fractionation analysis and confocal microscopy to be also expressed in the 
cytosol and nucleus. Furthermore, NDRG1 silencing increased nuclear, as well as cytoplasmic 
MTf expression, suggesting a pro-oncogenic role, as nuclear translocation is often observed in 
relation to oncogenic events (39-41,194,229,230). It is known that other membrane proteins can 
translocate from the plasma membrane to the nucleus by a process of internalisation via 
endocytosis, followed by fusion with the endoplasmic reticulum and its subsequent transport to 
the nucleus via this system (231-233). It has been previously demonstrated that MTf can be 
internalised into cells by mechanisms consistent with both endocytosis and caveolae formation 
(108,228,234). However, there have been no previous reports of MTf expression in the nucleus. It 
has been demonstrated that other GPI-linked proteins, such as the folate receptor-alpha, can 
translocate to the nucleus and can act as a transcription factor (235). Considering this, the 
transferrin homologue, lactoferrin, which shares high sequence homology to MTf (203), also has 
been reported in the nucleus, where it may act as a transcription factor (229,230). Hence, the 
nuclear localisation of MTf reported in this investigation can be speculated to be involved in gene 
transcription, and potentially, the expression of the genetic program in melanoma cells where MTf 
is identified at the greatest levels (116,117,198,200,201).  
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Considering the molecular mechanism of action of MTf, it was important to note that it markedly 
down-regulated NDRG1 (Figure 3.10). NDRG1 is a key signalling protein that has been 
demonstrated to inhibit the WNT pathway via its effect on β-catenin expression and intracellular 
distribution (72,176,194). In fact, NDRG1 promotes plasma membrane β-catenin localisation and 
inhibits the epithelial mesenchymal transition, while NDRG1 silencing induces β-catenin nuclear 
translocation followed by activation of oncogenic targets e.g., cyclin D1 (194). Considering this, 
it was demonstrated that up-regulation of MTf, which decreases NDRG1 expression, resulted in 
increased nuclear β-catenin expression (Figure 3.10). In contrast, MTf silencing led to a marked 
and distinct increase in plasma membrane β-catenin localisation. In addition, the nuclear levels of 
p-β-catenin (Ser552), which is known to activate WNT signalling (216), was also increased by 
MTf over-expression (Figure 3.10), with silencing having an opposite effect. The activation of 
WNT signalling by MTf expression was further confirmed by the up-regulation of the downstream 
WNT signalling molecules, c-Myc and cyclin D1 (Figure 3.4A; Figure 3.10).  Furthermore, 
NDRG1 silencing in melanoma cells resulted in MTf entering the nucleus. Hence, the mechanism 
responsible for the ability of MTf expression to increase proliferation and tumourigenesis in vivo 
(105,203,204), could be related to its ability to down-regulate NDRG1, leading to a subsequent 
increase in WNT signalling (Figure 3.10). 
 
Apart from WNT signalling, NDRG1 is also known to suppress PI3K and AKT signalling in 
pancreatic and prostate cancer cells (162,163). The up-regulation of MTf in melanoma cells 
(leading to down-regulation of NDRG1; Figure 3.1A; Figure 3.10) was also demonstrated to 
increase the regulatory and catalytic subunits of PI3K and also AKT, mTOR and their respective 
phosphorylated forms (Figure 3.10). This probably occurred due to the Yin-Yang relationship 
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between MTf and NDRG1. In fact, NDRG1 silencing which up-regulated MTf, also led to an 
increase in the expression and activation of PI3K, AKT, and mTOR. This inter-relationship of 
NDRG1 and MTf was further confirmed by MTf silencing, which up-regulated NDRG1 and led to 
decreased expression and phosphorylation of PI3K, AKT and mTOR.  Finally, it is notable that 
the activation of AKT upon MTf over-expression also resulted in the phosphorylation of p-β-
catenin at Ser552, resulting in nuclear translocation of this protein that then is active in transcribing 
pro-oncogenic targets, such as c-Myc and cyclin D1 (39-41) (Figure 3.10). As such, the up-
regulation of c-Myc would be expected to maintain the down-regulation of the metastasis 
suppressor, NDRG1, to promote metastasis (Figure 3.10). 
 
 
Importantly, c-Myc is a well-known transcription factor that activates target genes that are 
involved in cell proliferation and differentiation (236-240). In addition, as part of its regulatory 
ability, c-Myc transcriptionally represses certain target genes (241). One of these targets is 
NDRG1, and studies have previously demonstrated that c-Myc represses NDRG1 at its core 
promoter region (185,205). Herein, the studies demonstrated that upon MTf over-expression, c-
Myc mRNA increased, while NDRG1 mRNA decreased, while an opposite effect was observed 
after stable MTf silencing. This finding suggested that an increase in c-Myc upon MTf over-
expression acted as a possible repressor on NDRG1 transcription and that MTf potentially plays a 
vital role in facilitating c-Myc up-regulation (Figure 3.10). Moreover, upon treatment of the MTf 
over-expression clones with c-Myc silencing both NDRG1 and MTf expression increased. This 
observation is in direct contrast to the results observed upon examining the control treatments, 
where MTf over-expression typically led to a decrease in NDRG1 levels, as demonstrated 
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previously (Figure 3.1). These observations indicate that the Yin-Yang mechanism between 
NDRG1 and MTf is broken after c-Myc silencing, suggesting that c-Myc plays a role in the inter-
related regulation of MTf and NDRG1 (Figure 3.10). 
   
Significantly, this investigation demonstrated that there was an inverse relationship between MTf 
and NDRG1 in multiple melanoma cell models in vitro, but also at the mRNA and protein levels 
in normal human skin and a range of human melanoma patient samples. This is critical not only 
for understanding melanoma biology and generating a potential prognostic marker, but also is 
crucial for the development of potential treatments. As such, the potent NDRG1-inducing 
thiosemicarbazone, DpC, that has entered clinical trials for the treatment of advanced cancer (153), 
was demonstrated to potently up-regulate NDRG1 and down-regulate MTf expression in 
melanoma cells. Previous studies using thiosemicarbazones of this class have demonstrated 
marked activity against SK-MEL-28 melanoma tumours in vivo (171), suggesting that the anti-
tumour activity of these drugs may, in part, be due to targeting of the NDRG1-MTf axis.    
 
In conclusion, this is the first study demonstrating that MTf has a pro-oncogenic role mediated 
through cellular signalling and its ability to down-regulate the levels and phosphorylation of the 
potent metastasis suppressor, NDRG1. In fact, a distinct Yin-Yang relationship existed between 
MTf and NDRG1 expression and this link could be disrupted after c-Myc silencing, suggesting a 
critical role of c-Myc in this inter-relationship. The expression of MTf resulted in pro-oncogenic 
alterations including increased nuclear β-catenin, p-β-catenin (Ser552), PI3K p85α, p-PI3K p85 α, 
p-AKT, AKT, p-mTOR and mTOR, cyclin D1 and c-Myc. In conclusion, for the first time, this 
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investigation demonstrates that MTf plays a key role in pro-oncogenic cellular signalling, which 
can be therapeutically targeted via potent NDRG1-inducing agents. 
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Figure 3.10: Schematic Diagram Demonstrating the Differential Effect of MTf Over-
Expression on its Molecular Targets, Namely, NDRG1, p-NDRG1 S330, p-NDRG1 Thr346, 
β-Catenin, p-β-Catenin S552, c-Myc, cyclin-D1, PI3K p85, p-PI3K p85, PI3K 110β, AKT, p-
AKT, mTOR, and p-mTOR. Over-expression of MTf (highlighted in red) leads to activation of 
the PI3K downstream cascade, including up-regulation of PI3K p85, p-PI3K p85, PI3K 110β, 
AKT, p-AKT, mTOR, p-mTOR which then results in up-regulated c-Myc expression. MTf also 
up-regulates β-catenin expression, which results in its accumulation in the cytoplasm. p-AKT then 
phosphorylates β-catenin to its activated form, namely p-β-catenin S552 (216), which then results 
in its nuclear translocation and transcriptional activation of WNT downstream effectors, such as 
c-Myc and cyclin D1.  Up-regulated c-Myc expression leads to decreased NDRG1, p-NDRG1 
S330 and p-NDRG1 Thr346 levels (205), explaining the herein observed Yin-Yang relationship 
between MTf and NDRG1. Moreover, MTf was demonstrated to be also expressed in the cytosol 
and nucleus suggesting a pro-oncogenic role, as nuclear translocation is often observed in relation 
to oncogenic events (39-41,194,229,230). 
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CHAPTER 4 
 
 
The Search for a Function: Pro-Proliferative Signalling 
Protein, MTf, Promotes Increased Expression of Pro-
Oncogenic Tyrosine Kinases, c-Met, VEGFR2 and the WNT 
Co-Receptor, LRP6  
 
 
 
 
 
 
 
 
 
 
 
This chapter contains work prepared in the manuscript: 
 
Paluncic, J., Lane, D.J., Skoda, J., Bae, D.H., Scolyer, R., Wilmott, J., Kovacevic, Z., Huang 
M.L., Jansson P.J and Richardson, D.R. (2019) In Preparation 
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4.1 Introduction 
A persistent mystery in the melanoma field has been ascribing a function to the enigmatic protein, 
melanotransferrin (MTf). MTf, which is tethered to the outer leaflet of the plasma membrane by a 
glycosylphosphatidylinositol (GPI)-anchor (106) and is a founding melanoma tumour antigen that 
is expressed at high levels in melanoma cells and low levels in other tissues (242). Although MTf 
can bind iron (108,201,243), it is not involved in cellular iron uptake, metabolism or homeostasis 
(201,234,244,245). While some studies suggest MTf plays a role in endothelial migration, 
angiogenesis (111,112)  and differentiation (246), our laboratory was the first to show that MTf 
stimulates melanoma cell proliferation, DNA synthesis, migration and melanoma tumour growth 
in vivo (105). These findings were subsequently confirmed by others in terms of 
migration/invasion of melanoma cells in vivo (113), but a plausible model for the mechanisms 
involved has been absent until now (247). 
 
On the contrary, N-myc downstream regulated gene 1 (NDRG1) was verified to function as a 
powerful metastasis suppressor in a variety of cancers, including prostate, pancreatic cancer, colon 
cancer, etc. (187-189). However, a role in malignant melanoma has yet to be investigated. The 
expression of NDRG1 is widespread in normal tissues and has often been found to be down-
regulated in cancer cells (187,188). Moreover, it has been demonstrated that the level of NDRG1 
is inversely related with the Gleason grade of the prostate cancer, with higher grade and poorly 
differentiated tumours expressing less NDRG1 (187). The molecular mechanisms behind the anti-
metastatic function of NDRG1 were found to involve a number of crucial signalling pathways that 
control cell proliferation, invasion, motility and adhesion (186). Specifically, NDRG1 was 
observed to inhibit the oncogenic PI3K, Ras and NF-κB pathways in prostate and pancreatic 
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cancers (162,186), as well as oncogenic TGFβ- (72), EGFR family member- and WNT-signalling 
(72,176,194), all of which play vital roles in inducing EMT and metastasis (166). Each of these 
pathways are involved in the progression and development in cancer, including pancreatic cancer 
and are negatively regulated by NDRG1 (162). Therefore, NDRG1 is a promising therapeutic 
target for the treatment of cancer (72,162). 
 
Most notably, Chapter 3 has successfully demonstrated that MTf was found to down-regulate the 
expression of NDRG1 in vitro, as well as the well-characterised phosphorylation of NDRG1 at 
Ser330 and Thr346  (Figure 3.1A; Figure 3.2A; C-E) that has been implicated in its anti-
metastatic activity (174,193,208). On the other hand, over-expression of NDRG1 decreased MTf 
levels in PANC-1 (Figure 3.3I). In addition, these studies have demonstrated that down-regulation 
of MTf by siRNA as well as stable transfection in B1 (A3; SK-MEL-2) cells, leads to increased 
expression of total NDRG1 (Figure 3.3B-D) and p-NDRG1 Ser330 and Thr346 levels (Figure 
3.3B). Treatment with NDRG1 siRNA resulted into up-regulation of MTf levels in both, SK-MEL-
28 and SK-MEL-2 cells compared to their control (Figure 3.3A-H). This indicates that a potential 
feedback loop exists between MTf and NDRG1 as an integral part of the Ying-Yang inter-
relationship between these molecules. 
 
Importantly, the canonical WNT pathway plays an important regulatory role in proliferation, 
migration and invasion in melanoma cells that express the mutant MAPK kinase, BRAF (e.g., 
BRAFV600E). Thus, to investigate the hypothesis that MTf acts to enhance these key 
melanomagenic processes via WNT signalling, the role of MTf in regulating key aspects in 
canonical WNT signalling was first examined in BRAFV600E melanoma cells (e.g., SK-Mel-28). 
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Indeed, using these cells, Chapter 3 demonstrated that MTf positively regulates the levels and 
nuclear translocation of the key intracellular signal transducer for the canonical WNT pathway, β-
catenin, as well the levels of β-catenin phosphorylated at S552 that is known to activate 
transcription of downstream oncogenic targets e.g., c-Myc and cyclin D1 (Figure 3.4A-E). 
Additionally, when examining another crucial signalling mechanism that plays a key role in 
melanoma pathogenesis, namely PI3K signalling (58),  MTf increased the total and activated forms 
of key proteins involved in the PI3K pathway, namely PI3K p85α and 110β, PI3K p-p85α, AKT, 
p-AKT, mTOR, p-mTOR and c-Myc (Figure 3.6A-F). This is particularly relevant, as p-AKT 
phosphorylates β-catenin Ser552 leading to its nuclear translocation and the promotion of WNT 
signalling (216). 
 
While WNT signalling in melanoma is complex, activation of traditional WNT signalling requires 
the binding of secreted WNT ligands to key receptors [e.g., the WNT receptor, Frizzled (FZ) and 
the WNT co-receptors (LRP5/6)] at the cell surface, leading to proliferation, metabolic 
reprogramming and metastasis (198,217). Importantly, our laboratory and others have shown that 
the inhibition of WNT-signalling pathway via NDRG1 involves binding and inhibition of WNT 
co-receptor, LRP6 (176), as well as the inhibition of β-catenin translocation to the nucleus (194). 
 
The studies further assessed another group of receptors receptor tyrosine kinases (RTKs), such as 
c-Met, vascular endothelial growth factor receptor (VEGFR2) and fibroblast growth factor 
receptor 1 (FGFR1) that are known to induce e.g. EMT and PI3K pathways. This was crucial as 
their dysregulation was linked to development and progression of several cancer types (131-133) 
including melanoma (134-137). Interestingly, recent studies have demonstrated that NDRG1 not 
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only inhibits WNT and PI3K pathways, but also negatively regulates several RTKs that play key 
roles in the pathogenesis of other tumours (190,191). Considering this in conjunction with the 
common localisation of  c-Met, LRP6, VEGFR2, FGFR1 and MTf at the plasma membrane and 
also the previously reported interaction of glycosylphosphatidylinositol-anchored proteins with 
PTKs (138), studies were then conducted investigate their potential relationship.  
 
Herein, the studies examine upstream target proteins of the WNT signalling pathway, such as the 
WNT co-receptor LRP6 and its active form p-LRP6 (Ser1490) and demonstrate that MTf 
increased: (i) total and active forms of the WNT co-receptor, LRP6; (ii) stimulated translocation 
of total and active LRP6 forms from the plasma membrane into the cytoplasm and nucleus; (iii) 
and potentiated the interaction between MTf and LRP6. Furthermore, MTf increased the total and 
active forms of c-Met and also VEGFR2 and their translocation to the nucleus.  For the first time, 
these studies demonstrated that MTf interacts with c-Met, β-catenin, and VEGFR2, potentially 
forming an oncogenic signalling complex. Hence, due to its promiscuous pro-oncogenic signalling 
interactions, MTf may be a promising new molecular target for novel and existing anti-melanoma 
therapeutics, including thiosemicarbazones that target the metastasis suppressor, NDRG1. 
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4.2 Material and Methods 
4.2.1 Cell Culture  
 
Over-expression of MTf was accomplished by stably transfecting SK-MEL-28 cells with human 
MTf cDNA or with the empty pCMV-Script® (Stratagene, CA, USA) vector alone (195). The over-
expressing clones are termed, hIF and hIE, and their vector control as VA, maintained in the media 
above in G418 (1000 μg/ml; Alexis Biochemicals, Switzerland) (195) and cultured as described in 
Section 2.1. In terms of stable MTf down-regulation model, SK-MEL-28 cells were stably 
transfected with the expression vector, pSilencer 3.1-H1 neo (Ambion, Texas) (105). These clones 
were referred to as the B1 clones, and as a control, the cells were transfected with the same vector 
(SCR) containing a scrambled, non-specific siRNA insert (pS-scrambled; Ambion) (105). The B1 
clone demonstrated superior silencing of MTf and was used in preference in most experiments. 
These stably transfected cells were selected and maintained in G418 (1000 μg/ml; Alexis 
Biochemicals, Lausen, Switzerland) (195).  
 
4.2.2 Reagents and Treatments   
 
DpC was synthesized and characterised, as previously described [236-238] and cells were treated 
as described in Section 2.3.  
 
4.2.3 Protein Extractions, Western Blot and Antibodies  
 
Total protein was extracted, and Western analysis were performed as described previously in 
Section 2.6. The following primary antibodies were used in this study: MTf (Sigma Aldrich Cat#: 
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HPA004880; 1:1000, 1:300 for IF), NDRG1 (Abcam, Cambridge, MA, USA; ab37897, 1:2000), 
LRP6 (Cell Signaling Technology, Danvers, MA, USA; Cat#: 2560S; 1:1000; 1:250 for IF), p-
LRP6 (Ser1490) (Cell Signaling Technology, Danvers, MA, USA Cat#: 2568S; 1:500; 1:100 for 
IF), c-Met (Cell Signaling Technology, Danvers, MA, USA; Cat#: 8198S; 1:3000, 1:300 for IF), 
p-C-Met (Cell Signaling Technology, Danvers, MA, USA; Cat#:  3121S; 1:200, 1:50 for IF), 
VEGFR2 (Cell Signaling Technology, Danvers, MA, USA; Cat#: 9698S; 1:1000), FGFR1 (Cell 
Signaling Technology, Danvers, MA, USA; Cat#: ab63601; 1:1000), HDAC (Cell Signaling 
Technology, Danvers, MA, USA; Cat#: 2062S; 1:1000) GAPDH (Cell Signaling Technology, 
Danvers, MA, USA; Cat#: 5174S; 1:10,000), LRP6 (Abcam, Cambridge, MA, USA; Cat#: 
ab75358; 1:250), c-Met (Cell Signaling Technology, Danvers, MA, USA; Cat#: 8741S; 1:300), 
MIG6 (Cell Signaling Technology, Danvers, MA, USA; Cat#: 2440S; 1:200), NDRG1 XP (Cell 
Signaling Technology, Danvers, MA, USA; Cat#: 9485S; 1:150), β-catenin (Abcam, Cambridge, 
MA, USA; ab32572, 1:10,000), β-catenin (Abcam, Cambridge, MA, USA; ab22656, 1:250), c-
Myc (Cell Signaling Technology, Danvers, MA, USA; Cat#: 5605S; 1:1000), cyclin D1 (Cell 
Signaling Technology, Danvers, MA, USA; Cat#: 2922S; 1:1000), and β-actin (Sigma Aldrich; 
1:10,000), which was used as a protein-loading control, was from Sigma-Aldrich. The secondary 
antibodies implemented were anti-goat, anti-rabbit and anti-mouse (Sigma-Aldrich, St. Louis, 
MO; 1:10,000). 
 
4.2.4 Fractionation 
 
Cytosolic and nuclear fractions were prepared from cultured cells using NE-PER nuclear and 
cytosolic extraction reagents (Thermo Fisher Scientific, Waltham, MA). Fractionation was 
performed according to the kit instructions and as described in Section 2.5.2. 
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4.2.5 Gene Silencing by Small Interfering RNA (siRNA)  
 
Two specific siRNAs for NDRG1, were used, namely, siNDRG1 (Cat.#: s20336; Life 
Technologies), and these were compared to non-targeting negative control siRNA (siControl; Life 
Technologies). The siRNA was reverse transiently transfected into SK-MEL-28 cells using 
Lipofectamine RNAiMAX® (Life Technologies) following the manufacturer's instructions and 
incubated for 72 h/37oC, respectively. siRNAs specific for MTf (siMTf; Life Technologies) and 
MIG6 (siMIG6, Cat.#: AM16706; Thermofisher) were compared to non-targeting negative control 
siRNA (siControl; Life Technologies). The siRNAs were reverse transiently transfected into SK-
MEL-28 cells using Lipofectamine RNAiMAX® (Life Technologies) following the manufacturer's 
instructions and incubated for 72 h/37oC, respectively.  Western blotting was then performed, as 
described in Section 2.6.  
 
4.2.6 Co-immunoprecipitation   
 
Co-immunoprecipitation was performed using Dynabeads Protein G (Life Technologies, Inc.) 
following the manufacturer's instructions and described in Section 2.7. Proteins were detected 
using standard western Blot protocols described in Section 2.6. 
  
4.2.7 Immunofluorescence and Confocal Microscopy 
 
Immunofluorescence was performed as described (72) as described in Section 2.9. Images were 
captured using a Zeiss LSM 510 Meta Spectral confocal microscope and also a ZEISS LSM 800 
plus Airyscan Spectral confocal microscope using a 63×objective (Zeiss, Jena, Germany). Raw 
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images were analysed using AxioVision (Carl Zeiss, Australia) and ImageJ software (National 
Institutes of Health). Confocal images analysed using the Plot Profile and Co-Masking Analysis 
functions in ImageJ.  
 
4.2.8 Tissue Microarrays and Tissue Sections 
 
Tissue microarrays (TMAs) constructed from formalin-fixed paraffin-embedded (FFPE) 
lesions, ranging from compound naevus to distant melanoma metastases, and normal skin 
tissues were retrieved from the Department of Tissue Pathology and Diagnostic Oncology at 
the Royal Prince Alfred Hospital, Australia. Studies using human tissues were approved by the 
Human Research Ethics Committees of the University of Newcastle and Royal Prince Alfred 
Hospital, Australia. 
 
4.2.9 Quantitative Multiplex Immunohistochemistry (mIHC) 
 
All immunofluorescence staining was carried out on TMAs and normal skin tissue sections using 
an Autostainer Plus (Dako, Agilent Technologies) with appropriate positive and negative controls. 
Opal Multiplex IHC Assay kit (PerkinElmer, USA) was used as per the manufacturer's protocol. 
Briefly, FFPE tissue sections were first deparaffinised and rehydrated using xylene and ethanol. 
Heat-induced antigen retrieval (AR) was performed in a Decloaking Chamber (Biocare) in pH 6 
AR buffer at 95˚C/20 min. Endogenous peroxidase activity was quenched with 3% hydrogen 
peroxide for 5 min. Individual primary antibodies targeting MTf (1:100; HPA004880, Sigma), 
NDRG1 (1:800; D8G9 XP, Cell Signaling Technology), c-Met (1:300; D1C2 XP, Cell Signaling 
Technology) and SOX10 (1:1500; ab212843, Abcam) were incubated for 30 min. Primary 
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antibodies were detected using Opal Polymer HRP (Perkin Elmer) and visualised using Tyramide 
Signal Amplification for 10 min (Opal 7-Colour IHC, Perkin Elmer).  
 
Sections were stained with DAPI for 5 min and mounted using ProLong® Diamond. Imaging was 
performed using the Vectra 3 multispectral slide scanner in conjunction with Vectra 3.3 and 
Phenochart 1.0.4 software (PerkinElmer). Images were unmixed in inForm 2.2.0 and a selection 
of 15 representative original multi-spectral images was used to train the single-cell separation 
algorithm in HALO™ Image Analysis software (Indica Labs, melanocytic cells identified based 
on SOX10 expression). All the settings applied to the training images were saved within an 
algorithm to allow batch analysis of multiple original multispectral images of the individual TMA 
cores. 
 
4.2.10 Statistical Analysis 
 
Densitometry was performed using Quantity One software (Bio-Rad) and normalised using the 
relative β-actin loading control. Experimental data were compared using Student’s paired t-test, 
and presented as mean ± standard deviation. Data was considered statistically significant when p 
< 0.05. Gene Expression Omnibus (GEO) and mIHC data were compared using one-way ANOVA 
and the Mann-Whitney U test, respectively. 
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4.3 Results 
4.3.1 MTf Over-Expression or NDRG1 Silencing Up-Regulates LRP6 and its 
Activation 
 
The WNT pathway plays key roles in development and differentiation and has recently been 
discovered to play a key regulatory role in metastatic melanoma (217).  WNT signalling originates 
from the binding of so-called WNT ligands to key receptors, in particular the WNT receptor, 
Frizzled (FZ), and the WNT co-receptor LRP6, at the cell surface (35). This triggers a signalling 
cascade that promotes proliferation, metabolic reprogramming and metastasis (39-41). 
  
Previously, Chapter 3, has demonstrated that the expression of WNT-Pathway downstream 
protein β-catenin was up-regulated in MTf over-expressing cells (Figure 3.4). Furthermore, MTf 
expression also resulted in a pronounced increase in the levels of phosphorylated β-catenin at 
serine 552 (p-β-catenin (Ser552); Figure 3.4), which is known to increase its transcriptional 
activity once in the nucleus (216). Overall, MTf over-expression results in a translocation of both 
β-catenin and p-β-catenin (Ser552), from the plasma membrane to the nucleus and cytoplasm that 
could be responsible for the up-regulation of downstream WNT effectors, such as c-Myc and 
cyclin D1, while MTf silencing had an opposite effect (Figure 3.4A, B; Figure 3.8; Appendix 
Figure 2). 
 
Importantly, MTf is tethered to the cell surface by a GPI anchor and no transmembrane domains 
to “communicate” with the cytosol (198). Thus, it can be hypothesised that MTf, like many other 
GPI-anchored proteins (138), may functions as a ligand for other transmembrane signalling 
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molecules (e.g., WNT signalling). This is particularly the case considering previous reports 
indicating that PTKs associate with other GPI-anchored proteins (138). Considering the previous 
results demonstrating an activating effect of MTf on the WNT downstream proteins and also its 
high levels on the cell surface, the studies further examined whether MTf could also modulate 
expression and localisation of WNT upstream proteins, such as the WNT co-receptor LRP6 in SK-
MEL-28 melanoma cells. 
 
To assess whether MTf modulates the WNT signalling pathway in melanoma cells, total LRP6 
levels were examined by western blotting of the whole-cell lysates of SK-MEL-28 melanoma cells 
(Figure 4.1A). First, as demonstrated in Chapter 3, MTf expression in both hIF and hIE clones 
resulted in a pronounced and significant (p<0.001) decrease in NDRG1 levels. Interestingly, both 
the total expression of LRP6 and its activating phosphorylation at Serine 1490 (p-LRP6 
(Ser1490)), which is known to recruit axin to the membrane to activating β-catenin signalling (248-
250), was found to be markedly and significantly (p<0.001) increased upon MTf over-expression 
(Figure 4.1A). In contrast, the stable MTf silencing clone B1 of SK-MEL-28 cells, demonstrated 
a significant (p<0.001) increase of NDRG1 as well as a significant decrease (p<0.001) of total 
LRP6 and p-LRP6 (Ser1490) (Figure 4.1B). Similar results were obtained with additional 
transient MTf silencing using SK-MEL-28, where total LRP6 and p-LRP6 were significantly 
(p<0.001-0.01) down-regulated (Figure 4.1C).  
 
Hence, MTf is additionally regulating upstream WNT co-receptors and considering the previously 
shown effect of the inverse relationship between MTf and NDRG1, the effects of siNDRG1 on 
WNT upstream co-receptors were assessed (Figure 4.1C). Incubation of SK-MEL-28 cells with 
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siNDRG1 significantly (p<0.001) up-regulated MTf and down-regulated NDRG1 and also 
significantly (p<0.01) increased both LRP6 and p-LRP6 (Ser1490) relative to the NC siRNA 
(Figure 4.1D). 
 
In summary, these data suggest that MTf increases WNT signalling by increasing levels of total 
and active forms of the WNT co-receptor LRP6, which is counteracted by NDRG1 and elucidates 
a mechanism of how MTf promotes tumourigenesis. Further, these studies provide a mechanism 
of how MTf expression leads to the activation of β-catenin signalling demonstrated in Chapter 3, 
including activation of its nuclear translocation (Figures 3.4C, F). 
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Figure 4.1: Over-Expression of MTf in SK-MEL-28 Cells Up-Regulates the WNT co-
Receptor LRP6 and its Active Form p-LRP6 (Ser1490), while Silencing MTf Has the 
Opposite Effect, and Silencing NDRG1 Has a Similar Effect as MTf Over-Expression. 
Western blot analysis of: (A) MTf, NDRG1, LRP6 and p-LRP6 (Ser1490) levels in VA control 
and MTf over-expressing, hIF and hIE clones;  (B) MTf, NDRG1, LRP6 and p-LRP6 (Ser1490) 
levels in a stable siMTf clone (B1) of SK-MEL-28 cells vs. the scrambled (Scr) control; (C) MTf, 
NDRG1, LRP6 and p-LRP6 (Ser1490) levels after transient transfection with siMTf in SK-MEL-
28 cells vs. the negative control (NC); (D) MTf, NDRG1, LRP6 and p-LRP6 (Ser1490) levels after 
silencing NDRG1 in SK-MEL-28 melanoma cells. Results in (A-D) are representative blots and 
the densitometry is presented as mean ± SD (3 experiments). **p<0.01 ***p<0.001 relative to 
control lysate. 
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4.3.2 LRP6, p-LRP6 (Ser1490) and their Downstream Target, β-Catenin are 
Localised in the Nucleus and Cytoplasm 
 
As demonstrated by the earlier studies in Chapter 3, MTf was detected in the nuclei and cytoplasm 
in the hIF and hIF MTf over-expressing cells, as demonstrated via both fractionation and confocal 
immunofluorescence (Figure 3.1E, F, 3.8B).  Since MTf expression was able to up-regulate total 
LRP6 and its active form p-LRP6 (Ser1490), the studies further investigated if MTf is capable of 
regulating their intracellular localisation, especially their translocation to the nucleus. Therefore, 
the C- and N-fractions of SK-MEL-28 MTf over-expressing cells relative to the VA control were 
examined in terms of LRP6 and p-LRP6 (Ser1490) levels (Figure 4.2A). Again, similarly to total 
MTf expression (Figure 3.1E, 4.2A), LRP6 and p-LRP6 (Ser1490) were markedly and 
significantly (p<0.001-0.05) increased in the C- and N-fractions of MTf over-expression clones 
versus the VA control (Figure 4.2A). In addition, MTf expression also significantly (p<0.01-0.05) 
increased the nuclear translocation of β-catenin as well as its cytoplasmic levels (Figure 4.2A). 
In contrast, when MTf was stably silenced, a significant (p<0.001-0.01) decrease in nuclear MTf, 
LRP6 and p-LRP6 (Ser1490) levels were observed, while either a slight decrease or no alteration 
of LRP6 expression, respectively, was observed in the C-fraction (Figure 4.2B). On the other 
hand, MTf stable silenced B1 cells showed a pronounced and significant (p<0.001) decrease of β-
catenin in the N-fraction, while the C-fraction was significantly (p<0.01) increased compared to 
the SCR control (Figure 4.2B). Notably, as demonstrated in Figure 3.4Div, v the increase in β-
catenin levels in the C-fraction is predominantly due to the increase of β-catenin at the plasma 
membrane.  
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Overall, MTf over-expression results in an increased translocation of both LRP6 and p-LRP6 
(Ser1490) from the plasma membrane to the N- and C-fractions. Based on the known role of 
activated LRP6 in WNT signalling (35), this latter effect could be responsible for increased 
activation and nuclear translocation of the WNT downstream target β-catenin, which leads to up-
regulation of the downstream oncogenic effectors, c-Myc and cyclin D1 (Figure 3.4A). In 
conclusion, these data suggest MTf enhances canonical WNT signalling. 
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Figure 4.2: Over-Expression of MTf in SK-MEL-28 Increases the Nuclear Translocation of 
LRP6, p-LRP6 (Ser1490) and β-catenin, while Silencing MTf has the Opposite Effect. 
Western blot analysis of nuclear (N) and cytoplasmic (C) fractions of: (A) the MTf over-
expressing, hIF and hIE clones, relative to the VA control; and (B) the stable MTf silenced B1 
clones relative to the SCR control, examining MTf, LRP6, p-LRP6 (Ser1490) and β-catenin in 
these fractions relative to the N- and C-markers, histone deacetylase (HDAC) and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), respectively. HDAC and GAPDH were used for assessing 
relative expression in the N- and C-fractions, respectively. Results in (A-B) are representative blots 
and the densitometry is presented as mean ± SD (3 experiments). *p<0.05 **p<0.01 ***p<0.001 
relative to the control lysate. 
 
 
M
r
 M
r
 
123 
 
4.3.3 MTf Associates with LRP6, p-LRP6 (Ser1490), β-catenin and p-β-catenin 
(Ser552), as Demonstrated by Co-immunoprecipitation in Melanoma Cells 
 
Given the effect of MTf in up-regulating the total and activated levels of LRP6, β-catenin and their 
nuclear translocation, it was crucial to understand by which mechanism MTf regulates these 
proteins. In this study, MTf over-expressing and MTf stable silenced SK-MEL-28 lysates were 
immunoprecipitated with the MTf antibody, and then MTf, LRP6, p-LRP6 (Ser1490), β-catenin 
or p-β-catenin (Ser552) levels examined in the immunoprecipitate using western blot (Figure 
4.3A, B). 
 
When MTf was first co-IP and then tested for MTf expression by western blot as a positive control, 
a markedly and significant (p<0.001) increase of MTf levels was observed in MTf over-expressing 
cells relative to their VA control (Figure 4.3A). Notably, the co-IP from MTf over-expressing 
cells also contain significantly (p<0.001-0.01) increased levels of LRP6, p-LRP6 (Ser1490), β-
catenin and p-β-catenin (Ser552), versus VA cells (Figure 4.3A). Interestingly, relative to the 
western analysis (Input) where β-catenin migrated as a single band at 90 kDa, in the 
immunoprecipitate it migrated as two bands at 85- and 90-kDa, with the 85-kDa band being 
predominant in hIF and hIE clones (Figure 4.3A). These studies suggest a potential association 
between MTf and these WNT proteins. 
 
When performing the same co-immunoprecipitated (co-IP) studies with stable silenced MTf 
B1cells, a significant decrease (p<0.001-0.01) of MTf, LRP6, p-LRP6 (Ser1490), β-catenin and p-
β-catenin (Ser552) was observed in the co-IP samples in B1 cells versus the SCR control (Figure 
4.3B). It is notable that even though there is a significant increase (p<0.001) of total β-catenin and 
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p-β-catenin (Ser552) in the B1 western input, a significant decrease (p<0.001-0.01) was 
nevertheless observed in the immunoprecipitate of MTf silenced B1 cells compared to SCR 
(Figure 4.3B). 
 
Generally, these studies indicate that MTf and LRP6, p-LRP6 (Ser1490), β-catenin and p-β-catenin 
(Ser552) associate to form a possible complex. To further confirm these observations, MTf over-
expressing and MTf stable silenced SK-MEL-28 lysates were co-immunoprecipitated this time 
with LRP6 antibody, and then LRP6 or MTf levels examined in the co-IP using western blot 
(Figure 4.3A, B). When LRP6 was co-immunoprecipitated and assessed for LRP6 expression by 
western analysis in the co-IP, a substantial increase of LRP6 levels was observed in MTf over-
expressing cells relative to their VA control (Figure 4.3C), while using the stable B1 MTf silenced 
cells, LRP6 was markedly decreased in the co-IP (Figure 4.3D). Moreover, the LRP6 co-IP MTf 
over-expressing lysates were also found to contain substantial levels of MTf in the co-IP, which 
was increased compared to VA cells (Figure 4.3C). In contrast, a decrease in MTf was observed 
in the LRP6 immunoprecipitate, relative to SCR cells (Figure 4.3D). 
 
When the β-catenin antibody was used to co-immunoprecipitate β-catenin in the MTf over-
expression clones, it was demonstrated that both MTf and β-catenin levels were higher in the co-
IP (Fig. 4.3E). An opposite effect was demonstrated examining the MTf silencing B1 clone, where 
upon co-IP with the β-catenin antibody, MTf and β-catenin levels were lower in the 
immunoprecipitate (Figure 4.3F).  
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Collectively, these co-IP studies in Figure 4.3 demonstrated an association between MTf and the 
WNT upstream and downstream effectors, namely LRP6 and β-catenin and their activated forms 
that also increased upon MTf over-expression.  
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 4.3: MTf Associates with LRP6, p-LRP6 (Ser1490), β-Catenin and p-β-Catenin S552 
and Over-Expression of MTf Increases their Association in SK-MEL-28, while Silencing MTf 
has the Opposite Effect. (A-B) MTf was co-immunoprecipitated and western blotting performed 
in: (A) MTf over-expressing hIF and hIE clones, relative to the VA control; and (B) the stable MTf 
silenced B1 clones relative to the SCR control, examining MTf, LRP6, p-LRP6 (Ser1490), β-
catenin and p-β-catenin S552. (C-D) LRP6 was co-immunoprecipitated and western blotting 
performed in (C) MTf over-expressing hIF and hIE clones, relative to the VA control and (D) the 
stable MTf silenced B1 clones relative to the SCR control, examining LRP6 and MTf. (E-F) β-
catenin was co-immunoprecipitated and western blotting performed in (E) MTf over-expressing 
hIF and hIE clones, relative to the VA control; and (F) the stable MTf silenced B1 clones relative 
to the SCR control, examining β-catenin and MTf. Results in (A-B) are representative blots and 
the densitometry is presented as mean ± SD (3 experiments). **p<0.01 ***p<0.001 relative to 
control lysate. Results in (C-F) are representative blots of 2 experiments. 
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4.3.4 MTf Over-Expression Increases LRP6 and its Translocation to the 
Nucleus in Melanoma Cells 
 
To further investigate the association of MTf with either LRP6 or β-catenin and its activated forms, 
confocal microscopy was used. This technique images cells on a single lateral focal plane, which 
results in molecules in the same location being co-localised (251). In addition, as a negative 
control, cells were stained with secondary antibodies only (same dilution) and no signal was 
detected (Appendix Figure 2D). First, the studies assessed the intracellular distribution of LRP6 
within MTf over-expressing and stable silenced B1 clones of SK-MEL-28 (Figure 4.4A). To 
enable examination of the proportion of LRP6 inside and outside of the nucleus in Figure 4.4A 
the software, ImageJ, and its analytical tool, Co-Masking Analysis, were used (as discussed in 
Chapter 3; Section 2.9). This analysis creates a “mask” over the DAPI channel to enable 
quantification of the nuclear fluorescence intensity of LRP6, which was then subtracted from the 
total to derive the cytoplasmic estimate (Figure 4.4B). 
 
Examining SK-MEL-28 cells, MTf (red fluorescence) and LRP6 (green fluorescence) were 
distributed as minute puncta in both the C- and N-fractions. The nuclear localisation of these 
proteins were further evident upon co-localising MTf, LRP6 with the nuclear stain, DAPI (blue 
fluorescence), leading to white fluorescence in the merged image (Figure 4.4A). For LRP6, its 
total and N-expression was significantly (p<0.001-0.01) higher in the over-expressing hIF and hIE 
clones versus VA (Figure 4.4B). The C-expression of LRP6 was also increased in hIF and 
significantly (p<0.01) increased in hIE (Figure 4.4B). In contrast, there was a significant (p<0.01-
0.05) decrease in total, C- and N-LRP6 expression after MTf silencing compared to the SCR 
(Figure 4.4B). 
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To further investigate the possible association between MTf with LRP6, co-localisation was 
assessed using the Co-localisation Analysis tool of ImageJ. Again, to enable examination of the 
co-localisation proportion inside and outside of the nucleus in Figure 4.4A, the “mask” over the 
DAPI channel was used to enable quantification of the nuclear fluorescence intensity of the co-
localisation, which was then subtracted from the total co-localisation to derive the cytoplasmic 
estimate (Figure 4.4C). Examining MTf over-expression in hIF and hIE cells, the total, C- and N- 
co-localisation between MTf and LRP6 markedly and significantly (p<0.001-0.05) increased 
relative to the VA resulting in intense yellow vesicular-like staining in the cytoplasm and white 
granular staining in the nucleus (Figure 4.4A, C). Comparing the co-localisation of LRP6 and 
MTf in the MTf stable silenced B1 relative to their control SCR clone, there was a prominent and 
significant decrease (p<0.001-0.05) observed in the total, cytoplasm and nuclear co-localisation 
(Figure 4.4C). 
 
In conclusion, these results in Figure 4.4 in terms of MTf and LRP6 expression are in agreement 
with the previous western blot data (Figure 4.1A-C), while the co-localisation study is consistent 
with the co-immunoprecipitation results (Figure 4.3). Additionally, the localisation of LRP6 in 
cytoplasm, as well as in the nucleus particularly after MTf over-expression, is concordant with the 
previous fractionation results (Figure 4.2). Finally, these data in Figure 4.4A-C suggest not only 
an association between MTf and the WNT co-receptor LRP6, but also demonstrate for the first 
time, that these proteins co-localise in the nucleus upon MTf over-expression. 
 
 
  
 
 
 
 
 
Figure 4.4: Over-Expression of MTf in SK-MEL-28 Melanoma Cells Results in Increased 
Total and Nuclear LRP6 and its Co-Localisation with MTf, while Silencing MTf has the 
Opposite Effect. (A) Immunofluorescence using confocal microscopy was performed in VA 
relative to hIE and hIF MTf over-expressing cells and MTf silenced B1 cells vs. SCR control. (B) 
LRP6 localisation was examined using ImageJ, Co-Masking Analysis; and (C) co-localisation 
between MTf and LRP6 was examined using ImageJ Co-localisation Analysis tool. Results are 
mean + SD (3 experiments). *p<0.05, **p<0.01, ***p<0.001 relative to the respective control. 
Image J analysis utilised a total of 11-52 cells over 3 experiments. All images were taken using an 
63x objective and the scale bar in the bottom left hand corner of the first image in (A) represents 
30 μm and is the same across all images, except the magnified panel, where the scale bar is 3.8 
µm. 
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4.3.5 MTf Over-Expression Increases p-LRP6 (Ser1490) Levels and its 
Translocation to the Nucleus  
 
In good agreement with the western analysis, fractionation results and co-immunoprecipitation 
(Figures 4.1, 4.2, 4.3A, B), confocal immunofluorescence microscopy and Co-Masking Analysis 
demonstrated that MTf over-expression resulted in a significant (p<0.001-0.05) increase in total, 
C- and N-LRP6 expression, while stable silenced MTf cells resulted in a significant (p<0.001) 
decrease of LRP6 in the nucleus (Figure 4.3A-B; Figure 4.4). 
 
Considering, that the active form of LRP6, p-LRP6 (Ser1490) recruits axin to the membrane which 
then activates β-catenin signalling (248-250), it was crucial to assess its localisation within cells, 
when MTf was over-expressed and stably silenced. Therefore, immunofluorescence using 
confocal microscopy was performed with MTf over-expressing and stable silenced B1 clones of 
SK-MEL-28 cells, to visualise the cytoplasm and nucleus (Figure 4.5A) to examine the 
localisation of p-LRP6 (Ser1490) using ImageJ and Plot Profile Analysis (213) (Figure 4.5Bi-v). 
Analysis of the plots for VA (Figure 4.5Bi) and SCR control cells (Figure 4.5Biv), demonstrated 
that p-LRP6 (Ser1490) was mainly expressed in the DAPI-stained nucleus (black asterisk) with 
correspondingly less on the plasma membrane (see green arrows at outer edges of the plot) and 
cytoplasm (red arrows; Figure 4.5Bi, iv). MTf over-expression in hIF and hIE cells increased the 
nuclear p-LRP6 (Ser1490) (black asterisk) and decreased the cytoplasmic (red arrow) levels of p-
LRP6 (Ser1490), as shown in the Plot Profile Analysis (Figure 4.5Bii, iii). Examining the 
expression of p-LRP6 (Ser1490) in the MTf stable silenced cells (Figure 4.5A), its levels were 
decreased in all compartments (Figure 4.5Bv) relative to the SCR control (Figure 4.5Biv).  
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Next, to enable examination of the proportion of p-LRP6 (Ser1490) inside and outside of the 
nucleus in Figure 4.5A, the Co-Masking Analysis tool was implemented (Figure 4.5C). Using 
this analysis, total, cytoplasmic and nuclear p-LRP6 (Ser1490) was significantly (p<0.001-0.05) 
increased upon MTf over-expression relative to the VA control (Figure 4.5C). In contrast, after 
MTf silencing, the total and nuclear p-LRP6 (Ser1490) was significantly (p<0.001-0.01) decreased, 
while cytoplasmic p-LRP6 (Ser1490) was slightly decreased relative to the SCR (Figure 4.5C).  
 
In summary, MTf over-expression resulted in increased nuclear translocation of the activated 
LRP6 (p-LRP6 (Ser1490)) WNT co-receptor that is involved in WNT oncogenic signalling (35). 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 4.5: Over-Expression of MTf in SK-MEL-28 Melanoma Cells, Increased Total and 
Nuclear p-LRP6 (Ser1490), while Silencing MTf has the Opposite Effect. (A) 
Immunofluorescence using confocal microscopy was performed in VA relative to hIE and hIF 
MTf over-expressing cells and MTf silenced B1 cells vs. SCR with p-LRP6 (Ser1490) localisation 
examined using ImageJ, Plot Profile Analysis (Bi-v) and Co-Masking Analysis (C). Results are 
mean + SD (3 experiments). *p<0.05, **p<0.01, ***p<0.001 relative to the respective control. 
Image J analysis utilised a total of 15-41 cells over 3 experiments. All images were taken using an 
63x objective and the scale bar in the bottom left hand corner of the first image in (A) represents 
30 μm and is the same across all images. The white line that crosses the cell body in the merged 
image displays intensities of different channels in the Plot Profile Analysis. 
 
132 
 
 
 
 
 
 
133 
 
4.3.6 The Co-localisation between MTf and β-Catenin Increases in MTf Over-
expressing Melanoma Cells 
 
Chapter 3 has demonstrated that upon MTf over-expression, β-catenin translocates from the 
plasma membrane to the cytoplasm and nucleus (Figure 3.4C-E), providing a potential 
explanation for the transcriptional activation of the oncogenic WNT downstream proteins, c-Myc 
and cyclin D1 (Figure 3.4A-E). Considering this together with the fact that MTf was associated 
with β-catenin (Figure 4.3A, B, E, F) and also that MTf and β-catenin were translocated to the 
nucleus upon MTf over-expression (Figures 3.1E, F; 3.4C-E; 3.4F-H; 3.8B; 4.2A) the next 
hypothesis was that MTf could be directly involved in the translocation of β-catenin from the 
plasma membrane into the nucleus.  
 
Hence, to further assess this relationship, our next step was to determine where exactly MTf and 
β-catenin associate in cells using confocal microscopy (Figure 4.6A). Using the Co-localisation 
Analysis tool of ImageJ, the studies demonstrated that the total co-localisation between MTf (red) 
and β-catenin (green) markedly and significantly increased (p<0.01) with MTf over-expression in 
hIF and hIE cells (Figure 4.6C), resulting in intense yellow vesicular-like fluorescence in the 
cytoplasm (Figure 4.6A). In addition, white granular-like nuclear staining was observed in MTf 
over-expressing cells, indicating co-localisation between DAPI (blue), MTf and β-catenin (Figure 
4.6A). Furthermore, co-localisation between MTf and β-catenin in hIF and hIE cells was also 
substantially and significantly (p<0.01-0.05) increased in C- and N-fractions (Figure 4.6B). After 
MTf silencing in the B1 clone, the co-localisation of MTf and β-catenin in the total, C- and N-
compartments of B1 cells was significantly (p<0.01-0.05) decreased versus the SCR control 
(Figure 4.6B). 
134 
 
In conclusion, these results in Figure 4.6 not only confirm our previous findings of MTf 
association with β-catenin, but moreover, demonstrated the exact localisation of this association. 
This has uncovered a novel function of MTf, that is, its involvement in WNT pathway via 
enhancing the translocation of β-catenin into the nucleus of melanoma.  
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Figure 4.6: Over-Expression of MTf in SK-MEL-28 Melanoma Cells, Increased Total and 
Nuclear β-catenin and its Co-Localisation with MTf, While Silencing MTf Has the Opposite 
Effect. (A) Immunofluorescence using confocal microscopy was performed in VA relative to hIE 
and hIF MTf over-expressing cells and MTf silenced B1 cells vs. SCR with (B) co-localisation 
between β-catenin and MTf examined using ImageJ Co-localisation Analysis tool. Results are 
mean + SD (3 experiments). *p<0.05, **p<0.01 relative to the respective control. Image J analysis 
utilised a total of 13-37 cells over 3 experiments. All images were taken using an 63x objective 
and the scale bar in the bottom left hand corner of the first image in (A) represents 30 μm and is 
the same across all images, except the magnified panel, where the scale bar is 11.6 µm. 
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4.3.7 MTf Over-Expression or NDRG1 Silencing Up-Regulates C-Met and 
VEGFR2 and its Activation and Down-regulates FGFR1 
 
The preceding data in Chapters 3 and 4, have provided new insights into the novel functional 
roles of MTf in crucial signalling pathways that are known to be involved in melanoma 
pathogenesis, such as the WNT- and PI3K pathways. Chapter 3 has also demonstrated that MTf 
expression suppresses the expression of the metastasis suppressor NDRG1, which is known to 
inhibit the spread of prostate, pancreatic cancer, colon cancer etc. (187-189) and also plays a vital 
role in regulating a plethora of signalling pathways (72,162,163,190,194). Furthermore, the studies 
in Figure 4.3 have discovered that MTf associates in a potential complex with LRP6, β-catenin 
and their activated forms. Interestingly, another group of receptors, namely receptor tyrosine 
kinases (RTKs), are known to play a role in a key role in metastasis, namely the EMT, and NDRG1 
has recently been demonstrated to down-regulate the expression of a number of these proteins 
(190,191). RTKs consist of 20 subfamilies, such as hepatocyte growth factor receptor (c-Met), 
vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) 
and fibroblast growth factor receptor (FGFR) etc. and play major roles in physiological and 
pathological processes (134). Indeed, their dysregulation is known to be involved in the 
development and progression of several cancer-types (252). Notably, these receptors can crosstalk 
between each other (253,254) and are also crucial components of signal transduction pathways 
that mediate cell-to-cell communication (255,256). The following investigation focused on c-Met, 
VEGFR2 and FGFR1, due to their known roles in melanoma pathogenesis (134-137). 
 
The c-Met receptor and its ligand, HGF, have often been demonstrated to be over-expressed in 
melanoma (257) and is associated with tumour formation and progression to metastasis (258), 
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making c-Met a major target for cancer therapy (259). Especially, HGF/c-Met pathway is known 
to regulate major melanoma drivers, such as the PI3K- and MAPK pathway, leading to increased 
cell survival, motility and proliferation (260). 
 
VEGFR2 is crucial for vascular endothelial cell development and is the principal receptor 
transmitting vascular endothelial growth factor (VEGF) signals in the vascular endothelium (261). 
The VEGF family is a major member involved in vasculogenesis and angiogenesis and have high 
binding affinity to the VEGFRs on the cell surface, leading to their activation via 
transphosphorylation and cellular response stimulation (261). These include proliferation, survival 
and migration via MAPK and PI3K-Pathway activation (261). Interestingly, recent studies have 
shown that the downstream effector of c-Met, namely Gab 1 adaptor protein, links VEGFR2 
activation to PI3K and cellular migration, as it contains a binding side for the p85 subunit of PI3K 
and further binds to VEGFR2 (262,263). Indeed, VEGFR2 overexpression is associated with 
invasion and metastasis in several malignancies (264).  
 
Considering, their common localisation at the cell surface of MTf, c-Met, VEGFR2 and FGFR1, 
studies progressed to investigate the relationship between MTf and the latter receptors (Figure 
4.7). The 170-kDa band represents the single-chain c-Met precursor, while the ~140-kDa band 
corresponds to the β-subunit of the mature 190-kDa c-Met protein (265,266). Over-expression of 
MTf resulted in a significant (p<0.001) increase in the mature c-Met β-subunit (140 kDa), p-c-Met 
(Tyr 1439) (140 kDa) and mature VEGFR2 (230 kDa) relative to the VA control (Figure 4.7A). 
The quantification of these bands are represented in the densitometry (Figure 4.7A). In addition, 
an increase in c-Met (170 kDa), p-c-Met (Tyr 1439) (170 kDa) and VEGFR2 (150-, 170-, 210 
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kDa) was observed with MTf over-expression, relative to the VA control (Figure 4.7A). In 
contrast MTf silencing had the opposite effect significantly (p<0.001) decreasing the levels of all 
these RTKs (Figure 4.7B). Notably, VEGFR2 appeared as multiple isoforms probably because it 
is initially synthesised as a 150 kDa protein in the endoplasmic reticulum (ER) and is rapidly 
glycosylated to a 200 kDa intermediate form, which then is glycosylated to a mature 230 kDa form 
(267).  
 
As NDRG1 is known to be involved in the Yin-Yang relationship with MTf and also has been 
shown to down-regulate other RTKs (190,191), it was important to also understand the potential 
role of this metastasis suppressor. Again, silencing NDRG1 up-regulated MTf, and as 
demonstrated for MTf over-expression (Figure 4.7A), there was a significant (p<0.001-0.01) 
increase of total c-Met and VEGFR2, as well as p-c-Met (Tyr1349) to NC (Figure 4.7C). 
 
Another class of RTKs namely, the FGFR family, are also involved in cell proliferation, survival, 
migration, differentiation and apoptosis (268). In contrast, to c-Met and VEGFR2, a marked and 
significant (p<0.001) decrease in FGFR1 was demonstrated in hIF and hIE cells compared to the 
VA control (Figure 4.7D). As found for the other RTKs, multiple bands of FGFR1 were observed 
at 120- and 145-kDa as described previously (269). 
 
In summary, pro-oncogenic MTf up-regulates c-Met and VEGFR2 expression, while down-
regulating FGFR1. This indicates that MTf over-expression differentially regulates RTK 
expression, demonstrating its complex interaction with multiple oncogenic effectors. It can be 
hypothesised that these effects of MTf on RTKs may be indirectly mediated by NDRG1. 
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Figure 4.7: Over-Expression of MTf in SK-MEL-28 Cells Up-Regulates the RTKs c-Met, 
VEGFR2 and the Active Form p-c-Met (Tyr1349), while Silencing MTf has the Opposite 
Effect, and Silencing NDRG1 has a Similar Effect as MTf Over-Expression. Western blot 
analysis of: (A) MTf, c-Met and p-c-Met (Tyr1349) and VEGFR2 expression in VA control and 
MTf over-expressing, hIF and hIE clones; (B) MTf, c-Met and p-c-Met (Tyr1349) and VEGFR2 
expression in a stable siMTf clone (B1) of SK-MEL-28 cells vs. the scrambled (Scr) control; (C) 
MTf, NDRG1, LRP6 and p-LRP6 (Ser1490) levels after silencing NDRG1 in SK-MEL-28. (D) 
MTf and FGFR1 expression in VA control and MTf over-expressing, hIF and hIE clones. Results 
in (A-D) are representative blots and the densitometry is presented as mean ± SD (3 experiments). 
The quantification of the mature bands of these proteins are represented in the densitometry. 
**p<0.01 ***p<0.001 relative to the control lysate. 
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4.3.8 Localisation of c-Met, p-c-Met (Tyr1349) and VEGFR2 in the Nucleus and 
Cytoplasm is Increased after MTf Over-Expression 
 
Considering the earlier observed nuclear translocation of LRP6 and β-catenin upon MTf over-
expression (Figures 4.2A, 4.4, 4.5, 4.6), the next step was to assess if a similar effect occurred 
with c-Met and VEGFR2. First, cellular fractionation demonstrated using the MTf over-expression 
clones that similarly to total MTf, LRP6 and p-LRP6 (Ser1490), all isoforms of c-Met, p-c-Met 
(Tyr1349) and VEGFR2 were markedly and significantly (p<0.001-0.05) increased in C- and N-
fractions versus the VA control (Figure 4.8A). However, relative to the SCR control, when MTf 
was silenced, a significant (p<0.001-0.01) decrease in c-Met and p-c-Met Tyr1349 was observed 
in the C- and N-fractions, while a significant (p<0.001) decrease of VEGFR2 occurred in the N-
fraction (Figure 4.8B). Overall, these data demonstrated increased nuclear translocation of c-Met, 
p-c-Met (Tyr1349) and VEGFR2 upon MTf over-expression that was similar to that previously 
observed with LRP6 and β-catenin (Figure 4.2A). These studies indicating a novel mechanism of 
how MTf could regulate RTKs and other oncogenic signalling proteins by increased intracellular 
trafficking to the nucleus. 
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Figure 4.8: Over-Expression of MTf in SK-MEL-28 Increases the Nuclear Translocation of 
c-Met and p-c-Met (Tyr1349) and VEGFR2, while Silencing MTf has the Opposite Effect. 
Western blot analysis of nuclear (N) and cytoplasmic (C) fractions of: (A) the MTf over-
expressing, hIF and hIE clones, relative to the VA control; and (B) the stable silenced MTf B1 
clones relative to the SCR control, examining MTf, c-Met and p-c-Met (Tyr1349) and VEGFR2 
levels in these fractions relative to the N and C markers, histone deacetylase (HDAC) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), respectively. HDAC and GAPDH were 
used for assessing relative expression in the N- and C-fractions, respectively. Results in (A-B) are 
representative blots and the densitometry is presented as mean ± SD (3 experiments). *p<0.05 
**p<0.01 ***p<0.001 relative to control lysates. 
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4.3.9 MTf Associates with c-Met, p-c-Met (Tyr1349) and VEGFR2 in 
Melanoma Cells as Demonstrated by Co-IP 
 
Considering that MTf associates with LRP, p-LRP6 (Ser1490), β-catenin and β-catenin (Ser552) 
(Figures 4.3, 4.4, 4.6), a potential direct interaction could occur between the RTKs and MTf.  
Moreover, previously studies established a positive association between MTf and LRP6, p-LRP6 
(Ser1490), β-catenin and β-catenin (Ser552) and therefore, the next step was to asses if there is 
also a potential association between MTf and c-Met, p-c-Met (Tyr1349) and VEGFR2, 
respectively.  This was also deemed important as interactions between protein-tyrosine kinases 
(PTKs) and GPI-anchored proteins have been identified previously (138).  In these studies, SK-
Mel-28 cells with MTf over-expression and stable silencing were co-immunoprecipitated with 
MTf antibody, and then MTf, c-Met, p-c-Met (Tyr1349), or VEGFR2 levels were then examined 
in the immunoprecipitate by western analysis (Figure 4.9A, B). A pronounced and significant 
(p<0.001-0.01) increase of MTf, c-Met, p-c-Met (Tyr1349) and VEGFR2 was observed in MTf 
over-expressing cells relative to their VA control (Figure 4.9A). Interestingly, MTf became 
associated mainly with the mature forms of c-Met (140 kDa), p-c-Met (Tyr1349) (140 kDa) and 
VEGFR2 (230 kDa) (Figure 4.9A). Examining MTf silenced B1 cells, a significant (p<0.001-0.01) 
decrease of the mature forms of c-Met (140 kDa), p-c-Met (Tyr1349) (140 kDa) and VEGFR2 
(230 kDa) was observed in the immunoprecipitated versus the SCR control (Figure 4.9B). 
Together, these data suggest a potential association between MTf and the latter RTKs. 
 
To further investigate these observations, MTf over-expressing and stably silenced SK-MEL-28 
lysates were then subjected to co-IP using a c-Met antibody, with c-Met and MTf levels then being 
examined in the immunoprecipitate using western blot (Figure 4.9C, D). In these studies, an 
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increase of c-Met and MTf expression was detected in the immunoprecipitate of cells over-
expressing MTf relative to their VA control (Figure 4.9C), while there was a decrease of c-Met 
and MTf in the immunoprecipitate of MTf stable silenced cells (Figure 4.9D).  
 
When MTf over-expression and silencing clones were subjected to co-IP using a VEGFR2 
antibody, both VEGFR2 and MTf levels were increased in the immunoprecipitate of MTf over-
expressing cells, while there was decrease in VEGFR2 and MTf in the MTf stable silenced cells 
(Figure 4.9E, F). Comparing the co-IP where anti-MTf and anti-VEGFR2 were used in the pull-
down and then the immunoprecipitated probed for VEGFR2, it is notable that all 4 VEGFR2 
isoforms were observed in the samples treated with anti-VEGFR2 (Figure 4.9E), while samples 
treated with anti-MTf demonstrated mainly 2 bands, of which 230 kDa is the mature form and 210 
kDa the intermediate (267) (Figure 4.9A). Hence, these results may suggest the anti-MTf antibody 
is detecting the differential association of MTf with VEGFR2 isoforms. 
 
In summary, co-IP demonstrates an association between MTf and c-Met and VEGFR2 that may 
be biologically significant. 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.9: MTf Associates with c-Met and p-c-Met (Tyr1349) and VEGFR2 and Over-
Expression of MTf Increases their Association in SK-MEL-28, while Silencing MTf has the 
Opposite Effect. (A-B) MTf was co-immunoprecipitated and western blotting performed in (A) 
MTf over-expressing hIF and hIE clones, relative to the VA control; and (B) the stable MTf 
silenced B1 clones relative to the SCR control, examining MTf, c-Met and p-c-Met (Tyr1349) and 
VEGFR2. (C-D) c-Met was co-immunoprecipitated and western blotting performed in (C) MTf 
over-expressing hIF and hIE clones, relative to the VA control; and (D) the stable MTf silenced 
B1 clones relative to the SCR control, and then examined for c-Met and MTf. (E-F) VEGFR2 was 
co-immunoprecipitated and western blotting performed in (E) MTf over-expressing hIF and hIE 
clones, relative to the VA control; and (F) the stable MTf silenced B1 clones relative to the SCR 
control, and then examined VEGFR2 and MTf. Results in (A-B) are representative blots and the 
densitometry is presented as mean ± SD (3 experiments). *p<0.05 **p<0.01 ***p<0.001 relative 
to control lysate. Results in (C) are representative blots of 2 experiments and (D) are representative 
blots of 1 experiment. 
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4.3.10 MTf Over-Expression Increases c-Met and its Translocation to the 
Nucleus in Melanoma Cells 
 
A number of studies have reported that the RTKs are only expressed and active in terms of 
signalling on the plasma membrane, but continue to be active and deliver signals after endocytosed 
(270). Endosomes containing activated receptors are referred as signalling endosomes and are 
traditionally sorted to either the lysosomes for degradation, or recycled back to the cell surface 
(132). However, recent studies have indicated a potential third route of RTKs trafficking that it is 
directed to the nucleus, to regulate gene expression and cell function, e.g. calcium signalling 
(132,270,271). More importantly, it is possible that RTKs transport other associated molecules 
into the nucleus, which on the other hand are then functional in the nucleus (270). However, the 
exact mechanism by which these receptors are translocated from the plasma membrane to the 
nucleus is not yet fully understood. Considering these facts, the cellular localisation of c-Met in 
MTf over-expressing or stable silenced cells was investigated using confocal immunofluorescence 
microscopy and the co-localisation between c-Met (green) and MTf (red) examined (Figure 
4.10A). To enable examination of the proportion of c-Met inside and outside of the nucleus in 
Figure 4.10A, the Co-Masking Analysis tool was implemented (Figure 4.10B). There was 
significant (p<0.001-0.05) increase in all compartment (total, cytoplasmic and nucleus) upon MTf 
over-expression relative to the VA control (Figure 4.10B). However, quantitatively the greatest 
increase in c-Met after MTf over-expression was observed in the cytosol. In contrast, when MTf 
was stably silenced, c-Met was significantly (p<0.01) decreased in all compartments (Figure 
4.10B).  
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Co-localisation between c-Met and MTf was determined using confocal microscopy to further 
investigate their possible association within the cell. The co-localisation between MTf and c-Met 
markedly and significantly (p<0.001-0.05) increased in all compartments upon MTf over-
expression (Figure 4.10C). Of note, the co-localisation was pronounced in intense perinuclear 
accumulations of yellow vesicular-like structures in the cytosol (Figure 4.10A). On the other hand, 
c-Met and MTf co-localisation in MTf silenced cells demonstrated a prominent and significant 
(p<0.001-0.01) decrease in co-localisation in all compartments (Figure 4.10C). 
 
In conclusion, these results are in good agreement with the previous fraction and co-IP findings 
(Figure 4.8; Figure 4.9A-D), regarding c-Met localisation and association with MTf. Moreover, 
these findings indicate a novel trafficking/signalling mechanism after MTf over-expression 
leading to internalisation of both c-Met and MTf, which are appear complexed together. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Over-Expression of MTf in SK-MEL-28 Melanoma Cells, Increases Total and 
Nuclear c-Met and its Co-Localisation with MTf, while Silencing MTf has the Opposite 
Effect. (A) Immunofluorescence using confocal microscopy was performed in VA relative to hIE 
and hIF MTf over-expressing cells and MTf silenced B1 cells vs. the SCR control. (B) c-Met 
localisation examined using ImageJ, Co-Masking Analysis. (C) Co-localisation between MTf and 
c-Met was examined using the ImageJ Co-localisation Analysis tool. Results are mean + SD (3 
experiments). *p<0.05, **p<0.01, ***p<0.001 relative to the respective control. Image J analysis 
utilised a total of 13-22 cells over 3 experiments. All images were taken using an 63x objective 
and the scale bar in the bottom left hand corner of the first image in (A) represents 30 μm and is 
the same across all images, except the magnified panel, where the scale bar is 11.6 µm. 
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4.3.11 MTf Over-Expression Increases the Total Levels of c-Met and its 
Activated Form (p-c-Met (Tyr1349)) and also its Nuclear Translocation   
 
The studies above have demonstrated that c-Met was mainly localised in the cytoplasm and partly 
in the nucleus. Moreover, cytosolic c-Met accumulated in a perinuclear manner and may suggest 
an endosomal associated localisation (Figure 4.10A). On the other hand, p-c-Met (Tyr1349) is 
known to be the active form of c-Met and regulates PI3K signalling through an interaction of PI3K 
with Gab1 (272). Hence, it is crucial to assess the localisation of p-c-Met (Tyr1349) with altering 
MTf expression. 
 
Immunofluorescence using confocal microscopy was performed with MTf over-expressing and 
stably silenced SK-MEL-28 cells, to visualise the sub-cellular localisation of p-c-Met (Tyr1349) 
using ImageJ and Plot Profile Analysis (213) (Figure 4.11). The Plot Profile Analysis of VA 
control (Figure 4.11Bi) and SCR cells (Figure 4.11Biv) demonstrated that p-c-Met (Tyr1349) 
was  evenly expressed within the cell, including the plasma membrane (green arrows), cytoplasm 
(red arrows) and nuclear (DAPI) staining (black asterisk; Figure 4.11Bi, iv). Upon MTf over-
expression, nuclear and cytoplasmic p-c-Met (Tyr1349) levels increased relative to the VA control 
(Figure 4.11Bi-iii). In particular, the perinuclear localisation (red arrows) increased in MTf over-
expressing cells compared to the VA control (Figure 4.11Bii, iii).  In contrast, the p-c-Met 
(Tyr1349) levels in the MTf silenced cells were decreased in all compartments (Figure 4.11A) 
relative to SCR control (Figure 4.11Bv-iv).  
 
To examine the proportion of p-c-Met (Tyr1349) levels inside and outside of the nucleus in Figure 
4.11A, the Co-Masking Analysis tool was implemented (Figure 4.11B). The total, C- and N-
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compartment of p-c-Met (Tyr1349) was significantly (p<0.01-0.05) increased upon MTf over-
expression relative to the VA control (Figure 4.11B). In contrast, upon MTf silencing, there was a 
significant (p<0.01-0.05) decrease of p-c-Met (Tyr1349) levels in all compartment (total, 
cytoplasmic and nucleus) (Figure 4.11B). In summary, these results in Figure 4.11 suggest that 
MTf is involved in the activation and nuclear translocation of p-c-Met (Tyr1349) upon MTf over-
expression. 
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Figure 4.11: Over-Expression of MTf in SK-MEL-28 Melanoma Cells, Increases Total and 
Nuclear p-c-Met (Tyr1349), while Silencing MTf has the Opposite Effect. (A) 
Immunofluorescence using confocal microscopy was performed in VA relative to hIE and hIF 
MTf over-expressing cells and MTf silenced B1 cells vs. SCR control. The localisation of p-c-Met 
(Tyr1349) was examined using ImageJ, Plot Profile Analysis (Bi-v) and Co-Masking Analysis 
(C). Results are mean + SD (3 experiments). *p<0.05, **p<0.01 relative to the respective control. 
Image J analysis utilised a total of 9-55 cells over 3 experiments. All images were taken using an 
63x objective and the scale bar in the bottom left hand corner of the first image in (A) represents 
30 μm and is the same across all images. The white line that crosses the cell body in the merged 
image displays intensities of different channels in the Plot Profile Analysis. 
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4.3.12 Silencing MIG6 in VA Cells Increases c-Met and cyclin D1 and decreases 
LRP6 together with its downstream targets 
 
NDRG1 has been demonstrated to down-regulate a wide range of signalling pathways potentially 
by decreasing the expression of a key regulator of these pathways, namely the RTKs EGFR, HER2 
and HER3 (190,273). In addition, a recent investigation has reported that NDRG1 promotes EGFR 
down-regulation through up-regulation of the tumour suppressor, mitogen-inducible gene 6 
(MIG6), leading to late endosomal/lysosomal processing of EGFR (191).  Thus, MIG6 is a EGFR 
inhibitor that binds to NDRG1 resulting in its stabilisation and its increased inhibitory activity 
(191). Moreover, MIG6 has been also demonstrated to regulate the activity of other RTKs, namely 
c-Met (274). Considering this together with the role of MTf -NDRG1 axis in regulating RTKs and 
the WNT pathway, studies then examined the relationship between MIG6 and MTf, NDRG1, 
LRP6, c-Met, VEGFR2 and the WNT downstream targets, β-catenin, c-Myc and cyclin D1 
(Figure 4.12). Silencing of MIG6 in VA melanoma cells resulted in a significant (p<0.001) 
increase of MTf compared to the NC (Figure 4.12A), while NDRG1 expression significantly 
(p<0.01) decreased and a third NDRG1 band at 45 kDa appeared (Figure 4.12A). As NDRG1 and 
MIG6 form a complex that leads to the increased half-life of MIG6 (191), it can be speculated that 
MIG6 silencing decreases the formation of the stabilising complex enabling the degradation of 
NDRG1 that is known to result in progressive processing that then leads to the increased 
appearance of a middle band (275). 
 
Both LRP6 and p-LRP6 (Ser1490) levels were significantly (p<0.001-0.01) decreased in siMIG6 
cells (Figure 4.12A). Silencing of MIG6 resulted in a pronounced and significant (p<0.001) up-
regulation of c-Met and p-c-Met (Tyr1349) compared to NC, while there was no significant change 
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observed in VEGFR2 (Figure 4.12B). The expression of the WNT downstream targets, β-catenin 
and c-Myc were significantly (p<0.001-0.01) down-regulated in siMIG6 VA cells, while cyclin 
D1 expression was significantly (p<0.01) up-regulated versus the NC (Figure 4.12F). Of interest, 
we observed that EGFR levels were decreased with siMIG6 compared to NC (data not shown). 
This may be due to the fact that EGFR is mutated in SK-MEL-28 cells within the region of the 
domain often affected by in-frame deletions (276),  
 
In summary, MIG6 silencing in melanoma cells demonstrated surprising results regarding the 
down-regulation of the WNT receptor LRP6 and its downstream key targets β-catenin and c-Myc. 
In contrast, MTf, c-Met and cyclin D1 were up-regulated when MIG6 was silenced, suggesting a 
regulatory involvement of MIG6 in their expression.  
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Figure 4.12: Silencing MIG6 Up-Regulates MTf, c-Met, p-c-Met (Tyr1349), β-catenin and 
cyclin D1, while Down-Regulating NDRG1, LRP6, p-LRP6 (Ser1490), c-Myc. The VA SK-
MEL-28 cells were transiently transfected with siMIG6 or the NC and western analysis 
performed examining: (A) MTf, MIG6, NDRG1, LRP6 and p-LRP6 (Ser1490) levels; (B) c-Met, 
p-c-Met (Tyr1349) and VEGFR2 levels; or (C) β-catenin, c-Myc, and cyclin D1 expression. 
Results in (A-C) are representative blots and the densitometry is presented as mean ± SD (3 
experiments). **p<0.01 ***p<0.001 relative to control lysate. 
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4.3.13 The Novel Thiosemicarbazone, DpC, Up-Regulates NDRG1 and Down-
Regulates MTf and cyclin D1 in Melanoma Cells 
 
Chapter 3 demonstrated that the novel thiosemicarbazone, namely DpC (174,192), markedly up-
regulated NDRG1 and decreased expression of MTf and the WNT downstream target, cyclin D1. 
Importantly, this class of agents has also been demonstrated to potently inhibit melanoma 
xenograft growth in nude mice (171) and has entered clinical trials (153). Hence, a potential effect 
of DpC on the WNT co-receptor LRP6 and MIG6 was examined next (Figure 4.13A, E-G). With 
increasing DpC concentration, LRP6 and p-LRP6 (Ser1490) levels were significantly (p<0.001-
0.05) down-regulated, whereas MIG6 expression was prominently and significantly (p<0.001-
0.01) up-regulated in SK-MEL-28 cells compared to the NC (Figure 4.13E-G).  
 
In conclusion, these results are in good agreement with the previously demonstrated DpC 
regulation of NDRG1, MTf and cyclin D1, indicating that pharmacological NDRG1 targeting has 
the same anti-oncogenic effect as genetic up-regulation of NDRG1 regarding the LRP6, p-LRP6 
(Ser1490) and MIG6 levels. Hence, the identification of the novel NDRG1-MTf axis of regulation 
enables a potential therapeutic intervention against melanoma using a DpC treatment strategy. 
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Figure 4.13: The Thiosemicarbazone DpC Up-Regulates MIG6, while Down-Regulating the 
WNT co-receptor LRP6 and its Active Form p-LRP6 (Ser1490) in VA SK-MEL-28 
Melanoma Cells. Western blot analysis of: (A) MTf, NDRG1, cyclin D1, LRP6, p-LRP6 
(Ser1490) and MIG6 expression after treatment with DpC (1-, 5-, 10-μM) and these treatments 
then compared to the VA control. Results in (B-D) are representative blots and the densitometry 
is presented as mean ± SD (3 experiments). *p<0.05 **p<0.01 ***p<0.001 relative to the control 
lysate.  
M
r
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4.3.14 c-Met Expression is Associated with Progression to Metastatic Disease in 
Patient Melanoma Samples 
 
Considering the comprehensive in vitro results that indicated a link between MTf and c-Met 
expression levels (Figures 4.7-4.11), the expression analysis of c-Met was performed in human 
melanoma samples to evaluate the clinical significance of our findings. Similar to the MTf 
expression analysis (Figure 3.9Ai,iii), the analysis of TCGA-SKCM transcriptomics data revealed 
that high expression of c-Met mRNA alone is not a significant (p>0.05) predictor of survival, 
although a trend to worse survival was observed in human melanoma expression data with 
increasing c-Met mRNA levels (Figure 4.14Ai).  However, when evaluated against NDRG1 
expression, a high c-Met/NDRG1 mRNA ratio was significantly (p<0.05) associated with poor 
prognosis of melanoma patients (Figure 4.14Aiii). 
 
To further investigate the changes in expression of c-Met during different stages of melanoma 
progression, mRNA expression was examined using GEO dataset comprising samples from human 
normal skin, dysplastic nevi, primary and metastatic melanoma (GSE46517; Figure 4.14Ai-iii). 
This analysis revealed that c-Met mRNA was significantly (p<0.05) up-regulated in metastatic 
melanoma compared with primary tumours (Figure 4.14Bi), which supports our in vitro data and 
suggest an important role of c-Met in melanoma progression towards the metastatic state. In fact 
the, c-Met/NDRG1 mRNA expression ratio was significantly (p<0.0001) increased in metastatic 
melanoma relative to primary tumours (Figure 4.14Biii), which indicates that c-Met is up-
regulated in melanoma with low NDRG1 levels.  
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Importantly, the up-regulation of c-Met expression during melanoma progression was also 
detected at the protein level in human melanoma tissues (Figure 4.14C, D). Whereas the c-Met 
expression in primary tumours was weak, its levels dramatically increased in metastatic melanoma 
samples (Figure 4.14Cii). Interestingly, although a decrease in c-Met histoscore was identified in 
dysplastic nevi compared with normal skin (Figure 4.14Di), c-Met histoscore values for metastatic 
melanoma samples were significantly (p<0.05) increased compared to both dysplastic nevi and 
primary melanoma. Taken together, these results suggest the importance of c-Met expression in 
the pathobiology of aggressive melanoma. 
 
  
 
 
 
 
 
 
 
Figure 4.14: Analysis of Melanoma Patient Tumour Samples Examining MTf, NDRG1 and 
c-Met Expression. (A) Overall survival of melanoma patients based on the mRNA levels of c-
Met alone and c-Met/MTf or c-Met/NDRG1 ratios using treatment naïve samples from TCGA-
SKCM dataset. (B) Analysis of c-Met mRNA expression and its correlation to MTf or NDRG1 
expression in normal skin samples (n = 8), dysplastic naevi (n = 9), primary melanoma (n = 31), 
and metastatic melanoma (n = 52) using the GEO GSE46517 dataset. (C) Representative images 
of mIHC analysis of c-Met, MTf and NDRG1 expression in primary vs. metastatic melanoma 
tissue. The melanocytic marker, SOX10 (orange), was used to identify melanocytes and melanoma 
cells. When compared with expression in primary melanoma (upper panel), an increase in c-Met 
levels was observed in metastatic melanoma cells (lower panel). (E) c-Met histoscore and the ratio 
of MTf to NDRG1 histoscores calculated based on single-cell analysis of SOX10-positive cells in 
individual normal skin samples (n = 9), dysplastic naevi (n = 27), primary melanoma (n = 31) and 
metastatic melanoma samples (n = 57). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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4.4 Discussion 
Prelude 
 
Several signalling pathways involved in proliferation and development are crucial for the 
pathogenesis of melanoma, such as the MAPK-, PI3K- and WNT pathways (198).  Chapter 3 
demonstrated a regulating role of MTf in key intracellular signal transducers of the canonical WNT 
signalling, such as β-catenin and p-β-catenin (Ser552) in BRAFV600E SK-MEL-28 melanoma cells. 
This modulatory activity of MTf could be mediated through its ability to down-regulate expression 
of the metastasis suppressor, NDRG1. Indeed, MTf expression positively regulated the levels and 
nuclear translocation of β-catenin and p-β-catenin (Ser552) and its downstream effectors, c-Myc 
and cyclin D1 (Figure 3.4A-E). The current study has expanded the understanding of this 
mechanisms via demonstrating an up-regulatory effect of MTf on the WNT upstream co-receptor 
LRP6 and the RTKs, c-Met and VEGFR2.  These findings are supported by several studies 
demonstrating MTf capability of interacting with, and being internalised by, an LRP family 
member, although the specific LRP isoform was never determined (112,115). 
 
4.4.1 MTf Up-Regulates Expression of LRP6, c-Met and VEGFR2 and the 
Activation of LRP6 and c-Met 
 
For the first time, the current study has demonstrated using 5 different models of MTf and NDRG1 
expression in SK-Mel-28 cells, that MTf regulates total LRP6, p-LRP6 (Ser1490), c-Met, p-c-Met 
(Tyr1349) and VEGFR2 levels. Of note, MTf expression had a positive effect on up-regulating all 
on the forms of these receptors. Silencing NDRG1, which up-regulates MTf, had the same 
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stimulatory effect on these receptors, indicating an involvement of NDRG1 expression in their 
regulation. This is critical, considering our studies demonstrating that the potent metastasis 
suppressor, NDRG1, is down-regulated during melanoma progression and correlated with poor 
patient prognosis (Figure 3.9). It has also been demonstrated that NDRG1 was involved in the 
inhibition of WNT signalling via binding and suppressing LRP6 (176) and increasing β-catenin 
expression on the plasma membrane (72,194). Hence, the decrease in LRP6, c-Met and VEGFR2 
expression after MTf silencing, may be due to the resultant increase in NDRG1 expression (Figure 
4.1B-C). 
 
Considering their common localisation on the plasma membrane, the studies herein investigated 
the existence of a potential relationship between MTf and other RTKs, such as c-MET, VEGFR2 
and FGFR1 that are known to be dysregulated in melanoma, inducing EMT and are linked to 
development and progression of melanoma (134-137). Moreover, these receptors have been 
demonstrated to regulate the PI3K signalling pathway in melanoma cells (134,277,278). Since the 
studies Chapter 3 demonstrated a regulatory connection between MTf and PI3K upstream and 
downstream effectors, the next hypothesis was whether MTf regulates PI3K signalling via the 
upstream receptors c-Met, VEGFR2 and FGFR1. In particular, c-Met has often been found to be 
over-expressed and is associated with melanoma formation and progression to metastasis 
(257,279) and additionally is linked with melanoma growth (258). VEGFR2 over-expression is 
also associated with invasion and metastasis of melanoma (135) and activated VEGFR2 leads to 
proliferation, survival and migration via MAPK- and PI3K-pathway activation (261).  
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Moreover, c-Met synergistically induces angiogenesis and tumour progression by up-regulating 
VEGF expression in various cancers (280). The increase in VEGF could then potentially increase 
VEGFR2 signalling. The link between c-Met, VEGFR2 and PI3K signalling via the c-Met 
downstream target Gab1 (262,263), links these pathways, and made c-Met and VEGFR2 
interesting target molecules for this study. Importantly, melanoma patient samples demonstrated a 
significant increase in c-Met levels from primary tumour to metastatic melanoma at both the 
mRNA (Figure 4.14B) and protein levels (Figure 4.14D). In addition, c-Met/NDRG1 mRNA 
expression was significantly increased in metastatic melanoma (Figure 4.14Biii), indicating that 
c-Met is up-regulated in melanoma with low NDRG1 levels, which is achieved by MTf over-
expression.  
 
In contrast to c-Met and VEGFR2 that were up-regulated by MTf expression, FGFR1 levels were 
decreased under these conditions in SK-MEL-28 cells. However, the mechanism of how FGFR1 
is attenuated was not investigated herein, but it has been demonstrated to vary depending on the 
cell-type used (281). The down-regulation of FGFR1 is thought to involve a negative feedback 
mechanism, including receptor internalisation through ubiquitination (282,283) and the interaction 
of FGFR1 with negative regulator proteins (133,284). Auto-inhibition is another potential 
mechanism (283,285) and potentially MTf could be involved in this process. This negative 
regulation of MTf on FGFR1, while positively increasing c-Met and VEGFR2, demonstrates that 
MTf activates only particular receptors and signalling pathways, while attenuating others. In order 
to understand this special relationship between MTf and FGFR1, additional investigations are 
required. 
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4.4.2 MTf Expression Increases the Internalisation and Nuclear Translocation 
of LRP6, c-Met, VEGFR2 and the Activated Forms of LRP6 and c-Met 
 
Classically, it is widely known that endocytosis of cell surface receptors is crucial for the regulation 
of signal transduction involved in the WNT, c-Met and VEGFR2 pathways (259,270,286-288). 
Indeed, several studies have demonstrated that LRP6 is internalised via a clathrin-mediated 
pathway, which plays a crucial role in down-regulating this transmembrane signalling receptor, 
and thus, terminating its cell signalling function (286). More recently, recent studies another 
process of receptor internalisation has been discovered, namely that mediated through caveolae 
formation that is clathrin-independent (289).  
 
Herein, the studies demonstrated via fractionation and confocal immunofluorescence that total 
LRP6, p-LRP6 (Ser1490) and β-catenin are internalised within the cell. Moreover, the nuclear 
translocation of these proteins increases with MTf over-expression, while MTf silencing 
counteracted this process. Chapter 3 demonstrated that MTf over-expression and NDRG1 
silencing that results in increased MTf, leads to MTf internalisation into puncta distributed in the 
cytoplasm, the peri-nuclear region and nucleus. This finding is supported by studies demonstrating 
that GPI-anchored proteins are internalised similar to LRP6 via caveolae and lipid rafts (290). This 
is critical, as the novel findings in Chapter 4 have demonstrated using co-IP and confocal 
microscopy that MTf associates with LRP6, p-LRP6 (Ser1490), β-catenin and p-β-catenin 
(Ser552) and as such, this mechanism may explain, at least in part, the pro-oncogenic activity of 
MTf in patients (Figure 3.9). Considering this association, MTf may bind with these proteins at 
the cell surface and is involved in the internalisation leading to intracellular vesicle formation that 
are consistent with endosomes. Further co-localisation studies with MTf, LRP6, p-LRP6 
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(Ser1490), β-catenin, p-β-catenin (Ser552) and caveolin and clathrin or endosomal markers (e.g., 
early endosomal antigen) need to confirm this hypothesis.  
 
An increase in the translocation of c-Met and VEGFR2 into the cytoplasm and nucleus upon MTf 
expression was demonstrated using fractionation and confocal microscopy suggesting that MTf 
may have a vital role in the internalisation of these receptors. Moreover, the fact that MTf remained 
associated with both c-Met upon internalisation, as shown by confocal microscopy, suggested the 
formation of a stable complex that potentially is functionally significant (Figure 4.15). This is 
particularly important considering that p-c-Met was also detected in the nucleus suggesting a pro-
oncogenic role. In fact, nuclear translocation of c-Met has been demonstrated to be involved in the 
regulation of calcium signalling (271). Additionally, MTf expression resulted in increased peri-
nuclear co-localisation between MTf and c-Met (Figure 4.15). These findings indicate a novel 
function of MTf and c-Met, as they co-localise intracellularly in vesicles that appear similar to 
endosomes or lysosomes (Figure 4.15). This hypothesis is supported by a previously reported 
model, in which RTKs, such as c-Met and VEGFR2 can potentially translocate to the nucleus 
through the ER-associated degradation system (ERAD) (270). In general, the ERAD system 
detects misfolded proteins in the ER and extracts intact transmembrane proteins into the 
cytoplasm, where they get ubiquitinated and degraded (291). A model by Carpenter suggests 
retrograde-transportation of receptor-bearing endosomes from the Golgi to the ER, in which the 
receptors are degraded, but are transported to the nucleus (270).   
 
There are two mechanisms reported for the ER-to-nucleus transport of RTKs, namely integrative 
nuclear FGFR1 signalling (INFS) and integral trafficking from the ER to the nuclear envelope 
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transport (INTERNET) (231-233). Within the INFS route, FGFR1 has been shown to enter the 
cytosol after being pumped out of the ER and translocates to the nucleus through the nuclear pore 
complex (233,292). In contrast, considering the INTERNET pathway, EGFR on the plasma 
membrane remains membrane-bound upon internalisation into an endosome and is trafficked to 
the Golgi and then through retrograde transport to the ER (231,232). From the ER, EGFR is 
transferred from the ER membrane connecting the outer nuclear membrane into the inner nuclear 
membrane via the nuclear pore complex (231,293).  
 
Once in the nucleus, RTKs have been reported to have non-canonical functions in transcriptional 
regulation, DNA repair regulation and DNA replication (232,294). Chen et al. have shown that 
full length c-Met uses the INTERNET route to enter the nucleus through the retrograde vesicle 
trafficking upon H2O2 stimulation (294). Hence, the INTERNET mechanism could be involved in 
the internalisation and nuclear translocation observed with c-Met and VEGFR2. VEGFR2 has been 
found to translocate into the nucleus after VEGF stimulation (295). Interestingly, Domingues et 
al. have demonstrated that after internalisation, VEGFR2 binds to its own promoter and activates 
it in vivo in endothelial cells, suggesting that nuclear VEGFR2 regulates its own transcription and 
thus, amplifies the angiogenic response (131). It is also possible that RTKs act as chaperones to 
transport other associated molecules into the nucleus, that are then functional (270). As such, the 
demonstrated association between MTf and c-Met or MTf and VEGFR2 using co-IP and co-
localisation (MTf/c-Met) by confocal microscopy, indicates that MTf may interact with RTK 
chaperones, which then results in their transport to the nucleus for potential pro-oncogenic roles 
(Figure 4.15). On the other hand, MTf could be a nuclear-targeting chaperone for RTKs and also 
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LRP6 and β-catenin (Figure 4.15). As such, this model may explain the potential mechanism of 
how MTf promotes melanoma tumourigenesis and proliferation. 
 
4.4.3 MIG6 Silencing Up-Regulates MTf, c-Met, p-c-Met (Tyr1349), while 
Down-Regulating NDRG1, LRP6, p-LRP6 (Ser1490), β-Catenin and c-Myc 
 
Recently, Menezes et al. have demonstrated an association between NDRG1 and MIG6, which 
stabilises MIG6 to promote EGFR processing and down-regulation (191). Considering this in 
conjunction with the role of NDRG1 in regulating WNT signalling and the RTKs, studies were 
performed to assess whether a similar relationship existed between MIG6 and MTf and the 
receptors of interest. Upon silencing MIG6, there was increased expression of proteins such as 
MTf, c-Met and cyclin D1, while there was down-regulation of key proteins in the WNT pathway, 
as well as, NDRG1. These findings suggest a crucial role of MIG6 in regulating these proteins 
(Figure 4.15). In particular, the up-regulation of MTf, c-Met and cyclin D1 after silencing the 
tumour suppressor MIG6 could suggest that it is acting via its well characterised tumour 
suppressive function (Figure 4.15). This could occur by the direct binding of MIG6 to MTf, c-
Met and cyclin D1 to induce their internalisation and degradation, as observed with EGFR (296). 
Alternatively, this tumour suppressive effect of MIG6 could be mediated indirectly through its 
interactions with other molecules. This is probable, as c-Met lacks the sequence identified in the 
EGFR as the MIG6-binding site (297) and appears not to be able to bind MIG6 directly (274). 
Indeed, MIG6 has been demonstrated to attenuate c-Met signalling, distally from c-Met, as part of 
a potential negative feedback loop (274).  
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Upon silencing MIG6, there was also down-regulation of key proteins in the WNT pathway, as 
well as, NDRG1. The silencing of MIG6 decreased NDRG1 levels which can be explained by the 
decrease in the formation of the MIG6-NDRG1 complex that stabilises MIG6 (191), but may also 
increase the stability and half-life of NDRG1 in melanoma cells. Considering the decrease in 
LRP6, p-LRP6 (Ser1490), β-catenin and c-Myc after MIG6 silencing it can be hypothesised that 
this may occur through the down-regulation of c-Myc upon MIG6 loss. In fact, recently, a new 
positive c-Myc-WNT-feedback mechanism has been identified in which c-Myc is capable of 
stimulating WNT signalling by repressing the WNT pathway inhibitor, Dickkopf-related protein 
1 (DKK1), in breast cancer cells (298). Indeed, in normal mammary epithelial cells, DKK1 is an 
extracellular WNT inhibitor that targets LRP5/6 for degradation, which results in decreased c-Myc 
gene expression and maintained normal proliferative cycles (299-301). However, oncogenic 
lesions that increase c-Myc expression, then leads to the repression of DKK1, which activates the 
WNT signalling pathway (301). Due to the fact, that c-Myc is a downstream of the WNT pathway, 
this activation will lead to further activation of c-Myc expression, maintaining a positive feedback 
loop (301). In this study, the decrease of LRP6, p-LRP6 (Ser1490) and β-catenin suggests an 
inhibition of WNT-signalling, potentially due to increased levels of DKK1 upon MIG6 silencing. 
The observed inhibition of WNT signalling upon loss of MIG6, can potentially be explained as a 
result of compensatory activation of cell survival pathways, such as c-Met signalling. Furthermore, 
cells potentially adapt to this situation by selecting specific signalling pathways, while switching 
others off, e.g. WNT signalling.  
 
 
167 
 
4.4.4 Therapeutic Targeting of the MTf-NDRG1 Axis 
 
One of the major findings in Chapter 3 was the effect of the novel pharmacological agent DpC 
on up-regulating NDRG1 expression in a similar manner to the observed findings upon genetic 
NDRG1 over-expressing or up-regulation, demonstrating a decrease in MTf and cyclin D1 
expression after incubation of melanoma cells with DpC (Figure 3.6). Chapter 4 additionally 
demonstrated that DpC treatment up-regulated the tumour suppressor, MIG6, as well as decreasing 
the levels of the WNT upstream co-receptor, LRP6 and its activating phosphorylation (p-LRP6 
(Ser1490)). This is significant as the targeting of MIG6 via therapeutic agents has not been 
assessed to date (191), and moreover, MIG6 has been reported to inhibit tumour formation (302). 
In conclusion, DpC effectively down-regulated MTf and the oncogenic WNT signalling pathway 
potentially through its ability to potently up-regulate the metastasis suppressor, NDRG1, and 
tumour suppressor, MIG6, in melanoma cells. As such, thiosemicarbazones such as DpC, provide 
an innovative strategy for the treatment of melanoma and potentially other tumours, by inhibiting 
a plethora of oncogenic signalling pathways (72,162,163,194,303), including the WNT pathway, 
that then inhibits cancer growth and metastasis in vivo (171,172,174-176). 
 
In conclusion, this is the first study demonstrating that the pro-oncogenic role MTf, which includes 
oncogenic cellular signalling mediation, is a consequence of its ability to increase the 
internalisation and nuclear translocation of the WNT co-receptor LRP6 and its downstream 
effectors, and also the RTKs, namely c-Met and VEGFR2 (Figure 4.15). Moreover, the fact that 
MTf remained associated with LRP6, β-catenin and c-Met upon internalisation, suggested the 
formation of a stable complex that potentially is functionally significant (Figure 4.15). In fact, 
MTf may interact with the RTK with or both acting as co-chaperones, which then facilitates their 
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transport to the cytoplasm and nucleus for potential pro-oncogenic roles (Figure 4.15). This model 
may explain the potential mechanism of how MTf promotes melanoma tumourigenesis and 
proliferation, which can be therapeutical targeted via potent NDRG1- and MIG6-inducing agents. 
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Figure 4.15: Schematic Diagram Illustrating the Ability of MTf to Increase the Levels, 
Internalisation and Nuclear Translocation of LRP6, p-LRP6 (Ser1490), c-Met, p-c-Met 
(Tyr1349) and VEGFR2 in Intracellular Vesicles. Over-expression of MTf increases the levels, 
association, internalisation and nuclear translocation of the LRP6, p-LRP6 (Ser1490), c-Met, p-c-
Met (Tyr1349) and VEGFR2 in intracellular vesicles that are consistent with endosomes. MTf 
remains associated with LRP6, β-catenin and c-Met upon internalisation, suggesting the formation 
of a stable complex that potentially is functionally significant. The  endosomal vesicle complex, 
consisting of MTf, LRP6, c-Met and VEGFR2 potentially fuses with the endoplasmic reticulum 
(ER) and potentially translocates to the nucleus through the ER-associated degradation system 
(ERAD), as it has been hypothesised for RTKs, such as c-Met and VEGFR2 (270). From the ER, 
the complex potentially translocate to the nucleus via a mechanism mediated by the integral 
trafficking from the ER to the nuclear envelope transport (INTERNET), in which they are 
transferred from the ER into the nucleus via the nuclear pore complex, as reported for EGFR 
(231,232,293).  In fact, MTf could be a nuclear-targeting co-chaperone for c-Met, VEGFR2, LRP6 
and β-catenin. As such, this model may potentially explain the mechanism of how MTf promotes 
melanoma tumourigenesis. The loss of tumour suppression of MIG6 could be responsible for the 
increased MTf, c-Met and VEGFR2 levels when MIG6 is silenced. This hypothesis is suggested 
as it is already known that binding of MIG6 to another RTK, namely EGFR, leads to EGFR 
lysosomal processing and down-regulation (191). 
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CHAPTER 5 
 
 
 
Silencing of c-Myc in Melanoma Cells Breaks the MTf-
NDRG1 Yin-Yang Relationship and also Inhibits WNT 
Signalling by the Up-Regulation of NDRG1 
 
 
 
 
 
 
 
 
This chapter contains work prepared in the manuscript: 
 
Paluncic, J., Skoda, J., Jansson P.J., Richardson, D.R.  In Preparation 
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5.1 Introduction 
 
Chapter 3 has demonstrated a negative feedback loop between MTf and NDRG1, a Yin-Yang 
relationship. Furthermore, Chapter 4 demonstrated a pro-oncogenic positive regulatory 
mechanism between MTf and the upstream receptors of major signalling pathways, including the 
WNT-, PI3K-, c-Met-, VEGFR2- pathways, as well as signalling downstream key targets, that are 
involved in melanoma progression. In detail, these findings indicate that MTf is a novel enhancer 
of WNT/β-catenin signalling in melanoma cells, which acts at the level of the WNT co-receptor, 
LRP6. Additionally, MTf up-regulated other pro-oncogenic RTKs, such as c-Met and VEGFR2, 
that provide an additional relationship between MTf, WNT, and the PI3K-pathway. In addition, 
since Chapter 4 demonstrated an association between these receptors with MTf in the cytoplasm 
and nucleus, a new model facilitating cytosolic and nuclear translocation via MTf binding to LRP6, 
β-catenin and the RTKs. Therefore, MTf may be a promising new molecular target for novel and 
existing anti-melanoma therapeutics. 
 
Findings in Chapter 3 demonstrated that upon MTf over-expression both protein and mRNA 
levels of NDRG1 were down-regulated, while silencing MTf had an opposite effect. This is 
important since NDRG1 was demonstrated in other cancer-types to inhibit the oncogenic PI3K, 
Ras, NF-κB, TGF-β, EGFR, HER2, HER3 and WNT-signalling (72,162,176,186,194). These 
pathways play crucial roles in promoting the EMT and metastasis (166) and are involved in the 
progression and development in cancer (162). In addition, Chapter 3 and 4 demonstrated that 
upon DpC treatment, NDRG1 and the tumour suppressor, MIG6, were up-regulated, whereas MTf, 
cyclin D1, LRP6 and p-LRP6 (Ser1490) were decreased with increasing DpC concentration 
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(Figure 4.13), indicating that pharmacological targeting of NDRG1 expression has a similar anti-
oncogenic effect on these proteins, as genetic up-regulation of NDRG1. Therefore, NDRG1 is a 
promising therapeutic target for the treatment of cancer using DpC (72,162), especially metastatic 
melanoma.  
 
Interestingly, these data in Chapter 3 establish c-Myc as a potential regulatory link between MTf 
and NDRG1. These findings demonstrated that c-Myc is mainly localised in the nucleus in SK-
MEL-28 cells and that nuclear expression increases upon MTf over-expression. Furthermore, its 
notable that: (i) c-Myc mRNA and protein were up-regulated after MTf over-expression; (ii) c-
Myc is a known NDRG1 repressor (205); (iii) NDRG1 mRNA levels were decreased in MTf over-
expressing cells; and (iv) the Yin-Yang relationship between MTf and NDRG1, which is observed 
under control conditions, was broken after c-Myc silencing (Figures 3.4A, 3.8A, 3.8F-I). These 
results suggest a crucial role of c-Myc in the inter-relationship of MTf and NDRG1. 
 
Hence, the aim of Chapter 5 was to further examine whether silencing c-Myc had an effect on 
modulating LRP6, p-LRP6 (Ser1490), c-Met, p-c-Met (Tyr1349) and VEGFR2, as well as the 
WNT downstream targets β-catenin, cyclin D1 and the tumour suppressor, MIG6. In addition, as 
demonstrated in Chapter 3 both MTf and NDRG1 were increased after c-Myc silencing, hence 
Chapter 5 will assess if increased NDRG1 and MTf levels have a regulatory effect on these 
proteins. In addition to investigating protein expression, Chapter 5 also investigated the cellular 
localisation of these proteins (i.e., LRP6, RTKs, etc.) after silencing c-Myc, to further determine 
the effects on nuclear translocation of these proteins. Herein, an alteration in signalling was 
demonstrated upon silencing c-Myc, in which proliferating and/or cell survival signalling pathways 
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and proteins, including MTf, c-Met and VEGFR2 were stimulated whereas other pathways were 
depressed e.g. WNT- pathway.  
 
Significantly, using confocal microscopy, an increase of β-catenin on the plasma membrane was 
detected upon c-Myc silencing probably due to the up-regulation of NDRG1. This is of interest, 
since our laboratory and others have demonstrated that inhibition of WNT-signalling via NDRG1 
involves binding and inhibition of the WNT co-receptor, LRP6 (176), as well as the inhibition of 
β-catenin nuclear translocation (194). These novel data indicate an important role of c-Myc in the 
NDRG-MTf regulatory axis and the selectivity of c-Myc in differentially regulating oncogenic 
signalling pathways. 
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5.2 Material and Methods 
5.2.1 Cell Culture  
 
Over-expression of MTf was accomplished by stably transfecting SK-MEL-28 cells with human 
MTf cDNA or with the empty pCMV-Script® (Stratagene, CA, USA) vector alone (195). The over-
expressing clones are termed, hIF and hIE, and their vector control as VA, maintained in the media 
above in G418 (1000 μg/ml; Alexis Biochemicals, Switzerland) (195) and cultured, as described 
in Section 2.1  
 
5.2.2 Gene Silencing by Small Interfering RNA (siRNA)  
 
siRNAs specific for c-Myc (si-c-Myc, Cat.#: 6341S; Cell Signaling) was compared to non-
targeting negative control siRNA (siControl; Life Technologies). The siRNA was reverse 
transiently transfected into SK-MEL-28 cells using Lipofectamine RNAiMAX® (Life 
Technologies) following the manufacturer's instructions and incubated for 72 h/37oC, respectively.  
Western blotting was then performed, as described in Section 2.6.  
 
 
5.2.3 Protein Extractions, Western Blot and Antibodies  
 
Total protein was extracted, and Western analysis were performed, as described previously in 
Section 2.6. The following primary antibodies were used in this study: MTf (Sigma Aldrich Cat#: 
HPA004880; 1:1000, 1:300 for IF), NDRG1 (Abcam, Cambridge, MA, USA; ab37897, 1:2000), 
LRP6 (Cell Signaling Technology, Danvers, MA, USA; Cat#: 2560S; 1:1000; 1:250 for IF), p-
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LRP6 (Ser1490) (Cell Signaling Technology, Danvers, MA, USA Cat#: 2568S; 1:500; 1:100 for 
IF), c-Met (Cell Signaling Technology, Danvers, MA, USA; Cat#: 8198S; 1:3000, 1:300 for IF), 
p-c-Met (Cell Signaling Technology, Danvers, MA, USA; Cat#:  3121S; 1:200, 1:50 for IF), 
VEGFR2 (Cell Signaling Technology, Danvers, MA, USA; Cat#: 9698S; 1:1000), NDRG1 XP 
(Cell Signaling Technology, Danvers, MA, USA; Cat#: 9485S; 1:150), MIG6 (Cell Signaling 
Technology, Danvers, MA, USA; Cat#: 2440S; 1:200), β-catenin (Abcam, Cambridge, MA, USA; 
ab32572, 1:10,000), β-catenin (Abcam, Cambridge, MA, USA; ab22656, 1:250), c-Myc (Cell 
Signaling Technology, Danvers, MA, USA; Cat#: 5605S; 1:1000, 1:300 for IF), cyclin D1 (Cell 
Signaling Technology, Danvers, MA, USA; Cat#: 2922S; 1:1000), and β-actin (Sigma Aldrich; 
1:10,000), which was used as a protein-loading control, was from Sigma-Aldrich. The secondary 
antibodies implemented were anti-goat, anti-rabbit and anti-mouse (Sigma-Aldrich, St. Louis, 
MO; 1:10,000). 
 
 
5.2.4 Immunofluorescence and Confocal Microscopy 
 
Immunofluorescence was performed as described (72) and in Section 2.9. Images were captured 
using a Zeiss LSM 510 Meta Spectral confocal microscope and also a ZEISS LSM 800 plus 
Airyscan Spectral confocal microscope using a 63× objective (Zeiss, Jena, Germany). Raw images 
were analysed using AxioVision (Carl Zeiss, Australia) and ImageJ software (National Institutes 
of Health). Confocal images analysed using the Plot Profile and Co-Masking Analysis functions 
in ImageJ.  
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5.2.5 Statistical Analysis 
 
Densitometry was performed using Quantity One software (Bio-Rad) and normalised using the 
relative β-actin loading control. Experimental data were compared using Student’s paired t-test 
and presented as mean ± SD (3 experiments). Data was considered statistically significant when p 
< 0.05.  
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5.3 Results 
5.3.1 Silencing c-Myc Breaks the MTf-NDRG1 Yin-Yang Relationship 
Resulting in Alterations in Expression of Pro-Oncogenic Signalling Proteins in 
Melanoma Cells 
 
Chapter 3 demonstrated that silencing c-Myc breaks the Yin-Yang relationship between MTf and 
NDRG1 using both MTf over-expressing clones (hIF, hIE) and VA cells. As demonstrated in 
Figure 3.8F-I, silencing c-Myc resulted in a significant (p<0.001-0.01) up-regulation of both MTf 
and NDRG1 vs. their NC in the former mentioned melanoma cell clones (Figure 5.1A). Hence, in 
contrast to cells where c-Myc was endogenously expressed and MTf over-expression down-
regulated NDRG1 (Figure 3.1), the silencing of c-Myc prevented this response (Figure 5.1A). 
Considering these results, studies then investigated the effect of silencing c-Myc on LRP6, p-LRP6 
(Ser1490), c-Met, p-c-Met (Tyr1349), VEGFR2, β-catenin, cyclin D1 and MIG6 expression. First, 
the upstream effectors of c-Myc were examined, namely LRP6 and its activating phosphorylation 
(p-LRP6 (Ser1490)).  Silencing c-Myc resulted in a significant (p<0.001-0.01) decrease of LRP6 
in MTf over-expressing and VA cells versus their NC counterparts (Figure 5.1A). In contrast, c-
Met, p-c-Met (Tyr1349) and VEGFR2 were significantly (p<0.001-0.05) up-regulated upon c-Myc 
silencing vs. the NC (Figure 5.1A).  Generally, the effect of silencing c-Myc on the expression of 
all molecules examined, was greater in the MTf over-expressing cells than the VA, which may be 
explained in terms of effect of MTf potentiating the alteration (Figure 5.1A). 
 
Additionally, examining the effect of c-Myc silencing on its transcriptional activator, β-catenin, 
and one of β-catenin’s oncogene targets, namely cyclin D1, there was a significant (p<0.001-0.05) 
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increase in the expression of both proteins when c-Myc was silenced in the VA and MTf over-
expression clones (Figure 5.1B). Previous studies have demonstrated that NDRG1 stabilises the 
tumour suppressor, MIG6 (191). Furthermore, studies in Chapter 4 demonstrated that upon 
silencing MIG6, c-Myc expression decreased, suggesting a positive feedback loop (Figures 4.12A, 
C). Considering both these facts, silencing of c-Myc resulted in a marked and significant (p<0.001-
0.01) decrease of MIG6 compared to its NC in the VA, with this effect being even more pounced 
in the MTf over-expression clones (Figure 5.1B). It is notable that in the NCs, that MIG6 is 
markedly and significantly (p<0.001) up-regulated upon MTf over-expression (Figure 5.1B). This 
response can be speculated to be due to a potential negative feedback response to negate MTf 
signalling by the tumour suppressor MIG6. 
 
In conclusion, the studies in Figure 5.1 confirm the results in Figure 3.8F-I that c-Myc silencing 
breaks the MTf-NDRG1 Yin-Yang relationship. Importantly, silencing c-Myc resulted in an 
inhibition of WNT pathway (LRP6 and p-LRP6), which was probably due to up-regulation of 
NDRG1. In contrast, c-Myc silencing seemingly and paradoxically increased β-catenin expression, 
but which based on the up-regulation of NDRG1, could result in an increase in plasma membrane 
β-catenin expression (72,194), and this is examined below in Figure 5.7. Considering the 
regulation of RTKs by c-Myc silencing, their expression increased, which can be speculated to be 
a compensatory response to the loss of c-Myc.  Of interest, the tumour suppressor, MIG6, that is 
known to down-regulate RTKs (296) was decreased upon c-Myc silencing and this response could 
lead to the observed up-regulation of the RTKs.  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Silencing of c-Myc in VA, hIF and hIE Cells Up-Regulates c-Met, p-c-Met 
(Tyr1349), β-catenin and cyclin D1, while Decreasing NDRG1, LRP6, p-LRP6 (Ser1490), c-
Myc. The VA, hIF and hIE MTf over-expressing clones of SK-MEL-28 cells were transiently 
transfected with c-Myc siRNA (si-c-Myc) or the negative control siRNA (NC) and western 
analysis performed examining: (A) MTf, NDRG1, c-Myc, LRP6 and p-LRP6 (Ser1490); (B) c-
Met, p-c-Met (Tyr1349) and VEGFR2 expression; and (C) β-catenin, cyclin D1 and MIG6 
expression. Results in (A-C) are mean + SD (3 experiments). *p<0.05, **p<0.01, ***p<0.001 
relative to the respective control. 
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5.3.2 Silencing c-Myc Increases the Nuclear Translocation of MTf and NDRG1 
Within the VA and MTf Over-Expressing Cells 
 
Considering the break in the Yin-Yang relationship between MTf and NDRG1 upon c-Myc 
silencing (Figure 5.1A), studies further investigated the cellular localisation of these proteins 
under this condition using confocal microscopy (Figures 5.2-5.4). To enable examination of the 
proportion of c-Myc, MTf and NDRG1 inside and outside of the nucleus, the Co-Masking Analysis 
tool was implemented (Figure 5.2B-5.4B). A marked and significant (p<0.001-0.01) decrease of 
the total and nuclear of c-Myc (red fluorescence), as well as a decrease in the cytoplasm, after c-
Myc siRNA treatment demonstrated effective silencing in the VA, hIF and hIE cells, compared to 
the NC (Figure 5.2A-B). Examining MTf and NDRG1 (red fluorescence), Figure 5.2 and 5.3 
demonstrated a marked and significant (p<0.001-0.05) increase of MTf and NDRG1 expression in 
all compartments upon c-Myc silencing, when compared to the NC (Figure 5.2A-B; Figure 5.3A-
B). The nuclear localisation of these proteins was further evident upon co-localisation of MTf and 
NDRG1 with the nuclear stain, DAPI (blue fluorescence), respectively, leading to purple 
fluorescence (Figure 5.2A; Figure 5.3A). These results are in good agreement with the western 
data (Figure 5.1A), demonstrating an increase of the protein expression of MTf and NDRG1, as 
well as nuclear translocation upon silencing c-Myc. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Silencing of c-Myc in VA, hIF and hIE Clones of SK-MEL-28 Melanoma Cells 
Decreases Total, Cytoplasmic and Nuclear c-Myc Localisation. (A) Immunofluorescence using 
confocal microscopy was performed to assess c-Myc expression and localisation after transient 
silencing of c-Myc (si-c-Myc) relative to the negative control (NC) siRNA in VA, hIF and hIE 
MTf over-expressing clones. (B) c-Myc localisation examined using ImageJ, Co-Masking 
Analysis. Results are mean + SD (3 experiments). **p<0.01, ***p<0.001 relative to the respective 
control. Image J analysis utilised a total of 28-93 cells over 3 experiments. All images were taken 
using an 63x objective and the scale bar in the bottom left hand corner of the first image in (A) 
represents 30 μm and is the same across all images. 
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Figure 5.3: Silencing of c-Myc in VA, hIF and hIE Clones of SK-MEL-28 Melanoma Cells 
Increases Total, Cytoplasm and Nuclear MTf Localisation. (A) Immunofluorescence using 
confocal microscopy was performed to examine MTf after treatment with c-Myc siRNA (si-c-
Myc) or the negative control (NC) siRNA in VA, hIF and hIE MTf over-expressing clones relative 
to NC. (B) MTf localisation was examined using ImageJ, Co-Masking Analysis. Results are mean 
+ SD (3 experiments). *p<0.05, **p<0.01, ***p<0.001 relative to the respective control. Image J 
analysis utilised a total of 28-54 cells over 3 experiments. All images were taken using an 63x 
objective and the scale bar in the bottom left hand corner of the first image in (A) represents 30 
μm and is the same across all images. 
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Figure 5.4: Silencing of c-Myc in VA, hIF and hIE Clones of SK-MEL-28 Melanoma Cells 
Increases Total, Cytoplasm and Nuclear NDRG1 Localisation. (A) Immunofluorescence using 
confocal microscopy was performed to examine NDRG1 expression and localisation after 
treatment with c-Myc siRNA (si-c-Myc) or negative control (NC) siRNA in VA, hIF and hIE MTf 
over-expressing clones. (B) NDRG1 localisation was examined using ImageJ, Co-Masking 
Analysis. Results are mean + SD (3 experiments). *p<0.05, **p<0.01 relative to the respective 
control. Image J analysis utilised a total of 27-64 cells over 3 experiments. All images were taken 
using an 63x objective and the scale bar in the bottom left hand corner of the first image in (A) 
represents 30 μm and is the same across all images. 
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5.3.3 Silencing c-Myc Decreases the Nuclear Translocation of LRP6, p-LRP6 
(Ser1490) and β-Catenin, and Increases β-Catenin Expression on the Plasma 
Membrane 
 
In order to confirm the previous western analysis (Figure 5.1), the sub-cellular localisation of the 
WNT upstream and downstream targets, LRP6 and β-catenin, after silencing c-Myc was examined 
using confocal microscopy (Figures 5.5-5.7). Assessing the expression of LRP6 (red 
fluorescence), and p-LRP6 (Ser1490) (red fluorescence), via Co-Masking Analysis, a marked and 
significant (p<0.001-0.05) decrease in the total and N-compartment was observed versus the NC 
(Figure 5.5B; Figure 5.6B). A decrease in the levels of LRP6 and p-LRP6 (Ser1490) was detected 
in the C-compartment with a marked and significant (p<0.01-0.05) down-regulation in hIF cells, 
when c-Myc was silenced compared to their NC (Figure 5.5B; Figure 5.6B). 
 
Regarding the increase in total β-catenin expression observed upon western analysis (Figure 
5.1B), it is notable that its cellular localisation is crucial for its function in melanoma cells (216-
218). Therefore, confocal immunofluorescence was performed after silencing c-Myc in the VA, 
hIF, and hIE clones of SK-MEL-28 cells, to: (i) visualise the cell membrane and nucleus (Figure 
5.7A) and (ii) examine the localisation of β-catenin, using ImageJ,  Plot Profile Analysis (213) 
(Figure 5.7Bi-vi) and Co-Masking Analysis (Figure 5.7C). In this study, we have co-localised 
two different β-catenin antibodies, first using an antibody that visualises mainly the plasma 
membrane and cytoplasm (red fluorescence), and another β-catenin antibody (green fluorescence) 
that detects mainly the cytoplasm and nucleus (Figure 5.7A). Yellow fluorescence was observed 
in areas where both antibodies were co-localised in the merge (Figure 5.7A). Using β-catenin 
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antibody (red), the analysis of the plots for c-Myc silenced cells (Figure 5.7Bii, iv, vi) 
demonstrated an increase of β-catenin expression on the plasma membrane (see green arrows at 
outer most edges of plot), with correspondingly less nuclear (DAPI) staining (black asterisk; 
Figure 5.7Bii, iv, vi), relative to their NC (Figure 5.7Bi, iii, v).  
 
Next, to enable examination of the proportion of β-catenin inside and outside of the nucleus in 
Figure 5.7A, β-catenin antibody (green) was used and implemented the Co-Masking Analysis tool 
(Figure 5.7C). Using this analysis, total and C-compartment of β-catenin was significantly 
(p<0.01-0.05) increased upon silencing c-Myc relative to their NC (Figure 5.7C). In contrast, 
nuclear β-catenin was markedly and significantly (p<0.001-0.01) decreased with c-Myc silencing, 
compared to the NC (Figure 5.7C). 
 
In conclusion, the confocal studies are in good agreement with the western analysis in Figure 5.1 
and demonstrate an overall decrease of LRP6 and p-LRP6 (Ser1490) upon c-Myc siRNA treatment 
within the cell. Moreover, a similar effect, as previously shown in Chapter 3, was observed 
regarding β-catenin translocation to the plasma membrane, when NDRG1 was also up-regulated, 
indicating a crucial regulatory role of NDRG1 on the cellular localisation of β-catenin. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Silencing of c-Myc in VA, hIF and hIE Clones of SK-MEL-28 Melanoma Cells 
Decreases Total, Cytoplasmic and Nuclear LRP6 Localisation. (A) Immunofluorescence using 
confocal microscopy was performed after transient silencing of c-Myc (si-c-Myc), or the negative 
control (NC) siRNA, in VA, hIF and hIE MTf over-expressing clones. (B) LRP6 localisation 
examined using ImageJ, Co-Masking Analysis. Results are mean + SD (3 experiments). **p<0.01, 
***p<0.001 relative to the respective control. Image J analysis utilised a total of 13-36 cells over 
3 experiments. All images were taken using an 63x objective and the scale bar in the bottom left 
hand corner of the first image in (A) represents 30 μm and is the same across all images. 
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Figure 5.6: Silencing of c-Myc in VA, hIF and hIE Clones of SK-MEL-28 Melanoma Cells 
Decreases Total, Cytoplasmic and Nuclear p-LRP6 (Ser1490) Localisation. (A) 
Immunofluorescence using confocal microscopy was performed to examine localisation of p-
LRP6 (Ser1490) after treatment with c-Myc siRNA (si-c-Myc) or negative control (NC) siRNA in 
VA, hIF and hIE MTf over-expressing clones relative to NC. (B) p-LRP6 (Ser1490) localisation 
examined using ImageJ, Co-Masking Analysis. Results are mean + SD (3 experiments). *p<0.05, 
**p<0.01, ***p<0.001 relative to the respective control. Image J analysis utilised a total of 20-39 
cells over 3 experiments. All images were taken using an 63x objective and the scale bar in the 
bottom left hand corner of the first image in (A) represents 30 μm and is the same across all images. 
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Figure 5.7: Silencing of c-Myc in VA, hIF and hIE Clones of SK-MEL-28 Melanoma Cells 
Increases β-catenin Expression on the Plasma-Membrane and Cytoplasm, while Decreases 
Nuclear β-catenin Expression. (A) Immunofluorescence using confocal microscopy was 
performed to examine β-catenin expression after transient silencing of c-Myc (si-c-Myc) or the 
negative control (NC) siRNA in VA, hIF and hIE MTf over-expression clones of SK-MEL-28 
cells. (Bi-v) β-catenin (red fluorescence) localisation was examined using ImageJ, Plot Profile 
Analysis and (C) β-catenin (green fluorescence) localisation using Co-Masking Analysis. Results 
are mean + SD (3 experiments). *p<0.05, **p<0.01, ***p<0.001 relative to the respective control. 
Image J analysis utilised a total of 21-26 cells over 3 experiments. All images were taken using an 
63x objective and the scale bar in the bottom left hand corner of the first image in (A) represents 
30 μm and is the same across all images. The white line that crosses the cell body in the merged 
image displays intensities of different channels in the Plot Profile Analysis.
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5.3.4 Silencing c-Myc Increases the Nuclear Translocation of c-Met and its 
Active Form, p-c-Met (Tyr1349) 
 
Finally, the localisation of c-Met and p-c-Met (Tyr1349) upon c-Myc silencing in VA, hIF and hIE 
cells was also assessed using confocal microscopy and the Co-Masking Analysis tool (Figures 5.8 
and 5.9). Interestingly, total c-Met was mainly detected in the cytoplasm, whereas p-c-Met 
(Tyr1349) was predominantly localised in the nucleus (Figure 5.8A; Figure 5.9A). Upon c-Myc 
silencing, c-Met and p-c-Met (Tyr1349) expression was significantly (p<0.001-0.01) increased in 
all compartments relative to their NC (Figure 5.8B; Figure 5.9B). An increase in purple 
fluorescence further confirmed an increase of nuclear localisation of these proteins upon co-
localising c-Met and p-c-Met (Tyr1349) with the nuclear stain, DAPI, respectively (Figure 5.8A; 
Figure 5.9A). Again, these results align with previously shown western results (Figure 5.1A), 
demonstrating a general increase of c-Met and p-c-Met (Tyr1349) levels and an increase of nuclear 
translocation after c-Myc silencing in VA, hIF and hIE cells. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: Silencing of c-Myc in VA, hIF and hIE Clones of SK-MEL-28 Melanoma Cells 
Increases Total, Cytoplasm and Nuclear c-Met Localisation. (A) Immunofluorescence using 
confocal microscopy was performed to examine c-Met localisation after transient silencing of c-
Myc (si-c-Myc) or the negative control (NC) siRNA in VA, hIF and hIE MTf over-expressing 
clones. (B) c-Met localisation examined using ImageJ, Co-Masking Analysis. Results are mean + 
SD (3 experiments). *p<0.05, **p<0.01 relative to the respective control. Image J analysis utilised 
a total of 42-66 cells over 3 experiments. All images were taken using an 63x objective and the 
scale bar in the bottom left hand corner of the first image in (A) represents 30 μm and is the same 
across all images. 
190 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Silencing of c-Myc in VA, hIF and hIE clones of SK-MEL-28 Melanoma Cells 
Increases Total, Cytoplasm and Nuclear p-c-Met (Tyr1349) Localisation. (A) 
Immunofluorescence using confocal microscopy was performed to examine p-c-Met (Tyr1349) 
localisation after transient silencing of c-Myc (si-c-Myc) or the negative control (NC) siRNA in 
VA, hIF and hIE MTf over-expressing clones. (B) p-c-Met (Tyr1349) localisation examined using 
ImageJ, Co-Masking Analysis. Results are mean + SD (3 experiments). *p<0.05, **p<0.01, 
***p<0.001 relative to the respective control. Image J analysis utilised a total of 20-34 cells over 
3 experiments. All images were taken using an 63x objective and the scale bar in the bottom left 
hand corner of the first image in (A) represents 30 μm and is the same across all images. 
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5.4 Discussion 
c-Myc protein is a transcription factor that activates expression of several pro-proliferating genes  
and has a direct role in the regulation of DNA replication (236). Once activated, c-Myc drives 
multiple biological processes, including cell proliferation, cell growth regulation (238), 
differentiation and stem cell self-renewal (239,240). Moreover, c-Myc is known to 
transcriptionally repress the potent metastasis suppressor NDRG1 (205). Chapter 3 demonstrated 
that MTf over-expression induced nuclear translocation of c-Myc where it is transcriptionally 
active (205), and potentially was responsible for the decreased NDRG1 mRNA levels in MTf over-
expressing cells where c-Myc was up-regulated (Figures 3.4A, 3.8A, C). The studies further 
demonstrated that the Yin-Yang relationship between MTf and NDRG1, which is observed under 
control conditions, was broken after c-Myc silencing, suggesting a crucial role of c-Myc in the 
inter-relating regulation of MTf and NDRG1. 
 
Therefore, the aim of Chapter 5 was to assess, if silencing c-Myc had an effect on the WNT 
upstream co-receptor, LRP6, p-LRP6 (Ser1490), and RTK’s, c-Met, p-c-Met (Tyr1349) and 
VEGFR2, as well as the WNT downstream targets β-catenin, cyclin D1 and the tumour suppressor, 
MIG6. Moreover, the cellular localisation of these proteins was investigated after silencing c-Myc 
to further determine whether this procedure had a potential influence on the translocation of these 
proteins. 
 
One interesting observation upon c-Myc silencing was that the increase in β-catenin in the plasma 
membrane and cytoplasm, together with the decrease of nuclear β-catenin may be a consequence 
of NDRG1 up-regulation due to the ablation of c-Myc transcriptional repression (Figure 5.10). 
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This is supported by previous studies from our laboratory demonstrating a NDRG1-dependent 
decrease of nuclear β-catenin and its increase on the plasma membrane in DU145 prostate and 
HT29 colon cancer cells (194). Since, β-catenin is involved in the EMT, the herein observed results 
suggest a reduction in EMT through NDRG1 up-regulation when c-Myc is silenced (Figure 5.10). 
Indeed, decreased levels of the WNT co-receptor LRP6 and its active form p-LRP6 (Ser1490) after 
c-Myc silencing relative to the up-regulation of the RTKs, c-Met and VEGFR2, indicate an 
important role of c-Myc regarding its selective differential effects on signalling pathways (Figure 
5.10).  
 
The tumour suppressor, MIG6, which is known to down-regulate RTKs (296), was down-regulated 
after silencing c-Myc, despite the up-regulation of NDRG1 (Figure 5.10). This was in contrast 
with previous studies that have reported an increase in MIG6 protein half-life with NDRG1 over-
expression (191). However, it is notable that after c-Myc silencing, both the RTKs, c-Met and 
VEGFR2, were up-regulated which could be a consequence of the down-regulation of MIG6 
(Figure 5.10). The positive relationship between c-Myc and MIG6 expression (Figure 5.1B) is 
confirmed by MIG6 silencing, where a decrease in c-Myc expression was demonstrated (Figure 
4.12). Moreover, c-Myc up-regulation occurred in MTf over-expressing cells, resulted in an 
increase in MIG6 expression (see NCs in Figure 5.1B). Hence, a feedback mechanism could be 
speculated to occur in rapidly growing cells, where up-regulation of c-Myc could then result in 
increased levels of MIG6 that then acts to down-regulate RTKs to slow proliferation. The fact that 
MTf over-expression cells grow rapidly (Figure 3.7G) and that c-Met and VEGFR2 remain 
increased relative to the VA control (Figure 4.7A), could mean that the MIG6 levels may not be 
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sufficient to totally regulate the dysfunctional oncogenic signalling in melanoma cells. Supporting 
the later hypothesis, it was notable that the levels of MIG6 were barely detectable in these cells. 
Considering our results demonstrating the up-regulation of pro-proliferative key players, such as 
MTf, c-Met and VEGFR2, when c-Myc is silenced, it is possible to suggest that loss of c-Myc is 
being compensated by up-regulation of MTf expression (Figure 5.10). This could then potentially 
increase c-Met and VEGFR2 expression through their ability to associate and form complexes as 
demonstrated by co-IP and/or confocal microscopy (Figures 4.9A, C, E; 4.10).  This is of 
significance, as c-Met has been demonstrated to synergistically induce angiogenesis and tumour 
progression by up-regulating VEGF expression in various cancers that then may stimulate 
VEGFR2 (280).  As a consequence, the activation of c-Met and the VEGFR2-pathway  may result 
into further activation of MAPK, which finally leads to increased cyclin D1 levels (29,32) (Figure 
5.10). Thus, the observed results may suggest a novel compensatory role of MTf upon loss of c-
Myc (Figure 5.10). Further studies are necessary to determine the explicit mechanism by which 
the cells select signalling pathways and the involvement of MTf under these conditions. 
 
In conclusion, Chapter 5 demonstrated that upon breaking the Yin-Yang relationship via c-Myc 
silencing, NDRG1 up-regulation was able to inhibit WNT signalling and increase β-catenin 
expression on the plasma membrane. In contrast, c-Myc silencing resulted in the up-regulation of 
RTKs and this increased in a MTf-dependent manner potentially to compensate for c-Myc loss. 
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Figure 5.10: Summary Schematic Illustrating the Differential Effect of Silencing c-Myc on 
MTf, NDRG1, c-Met, p-c-Met (Tyr1349), VEGFR2, cyclin D1, LRP6 and p-LRP6 (Ser1490) 
and Their Intracellular Localisation in Melanoma Cells. Silencing of c-Myc (highlighted in 
red) increases the expression of both MTf and NDRG1 and breaks the Yin-Yang inter-relationship 
between these two molecules. The up-regulation of NDRG1 is most likely due to the decrease in 
c-Myc which is a known NDRG1 transcriptional repressor. Upon MTf over-expression, c-Met, p-
c-Met (Tyr1349), VEGFR2 and cyclin D1 levels increase and moreover, the nuclear translocation 
of MTf, NDRG1, c-Met and p-c-Met (Tyr1349) is stimulated. NDRG1 up-regulation increases β-
catenin expression at the cell membrane, which has been previously demonstrated to prevent the 
EMT and metastasis in other tumour cells (72,194). Further, the decrease in LRP6 and p-LRP6 
(Ser1490) levels could be due to NDRG1’s ability to inhibit WNT signalling by binding and 
suppressing LRP6 (176). The tumour suppressor, MIG6, was down-regulated upon c-Myc 
silencing and the loss of tumour suppression could be responsible for the increased MTf, c-Met, 
VEGFR2 and cyclin D1 levels. This hypothesis is suggested as it is already known that binding of 
MIG6 to another RTK, namely EGFR, leads to EGFR lysosomal processing and down-regulation 
(191). 
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CHAPTER 6 
 
 
 
GENERAL DISCUSSION 
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Prelude 
 
Melanoma is undoubtedly one of the most aggressive and treatment-resistant human cancers 
(1,198). Due to the fact that this type of skin cancer can spread to other organs, it is responsible 
for the greatest number of skin cancer-related deaths worldwide (2). One of the first melanoma 
tumour antigens discovered and characterised was melanotransferrin (MTf). MTf, described as an 
oncofoetal antigen, may have an important role in endothelial migration, angiogenesis and 
differentiation (106,112). Interestingly, down-regulation of MTf in melanoma cells resulted in 
noticeably decreased cell proliferation, DNA synthesis, cellular migration and reduced human 
melanoma tumour xenograft initiation and growth in nude mice (105).  
 
On the other hand, NDRG1 was confirmed to function as a potent metastases suppressor in 
numerous neoplasms including prostate, lung, colon, breast and pancreatic cancer (162), but not 
melanoma. NDRG1 was explicitly proven to inhibit the oncogenic PI3K, TGF-β, NF-κB, WNT 
and Ras pathways in pancreatic and prostate cancer, and was demonstrated to inhibit the epithelial-
to-mesenchymal transition (EMT) (162). In fact, NDRG1 expression inhibited WNT signalling 
and prevented loss of β-catenin at the cell membrane and inhibited nuclear β-catenin translocation 
(72,194). Furthermore, NDRG1 inhibits AKT activation that is known to phosphorylate β-catenin 
at Serine 552, thus preventing nuclear β-catenin translocation and promotion of WNT signalling 
(216). This thesis examines a promising therapeutic strategy for inhibiting malignant melanoma 
metastasis, by exploring a new class of di-2-pyridylketone thiosemicarbazone anti-cancer agents, 
namely DpC that is able to up-regulate NDRG1 in tumour cells (192). This agent through its ability 
to up-regulate NDRG1 has the ability to inhibit the EMT and block melanoma metastasis. Indeed, 
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NDRG1 may act to “restore” normal signalling in tumour cells, and hence, may be a critical 
molecular target for cancer therapies (162,186,192).   
 
In recent years, several key molecular pathways have been uncovered that are involved in 
melanoma onset, development and proliferation (26). However, while NDRG1 was found to act 
as a metastasis suppressor in numerous cancers, it has never been examined in melanoma and this 
thesis was the first to assess this.  
 
Herein, Chapter 3 investigated the effect of MTf in melanoma and the possible interaction 
between NDRG1 and MTf in order to determine their influence on each other, and potentially their 
effect on melanoma progression and metastasis. Significantly, this investigation demonstrated that 
an inverse relationship exists between MTf and NDRG1 (a Yin-Yang relationship), which was 
observed in multiple melanoma cell models in vitro, but also in normal human skin and also a 
range of human melanoma patient samples. Furthermore, an assessment of MTf’s effect on critical 
pro-oncogenic signalling pathways involved in melanoma pathogenesis namely, the WNT- and 
PI3K- signalling pathways was also examined. Indeed, an intriguing new function of MTf as a key 
pro-oncogenic signalling protein has been elucidated.  
 
Chapter 4 proposed that MTf associates with and also enhances the expression and activation of 
a group of pro-oncogenic WNT-signalling proteins, including the WNT co-receptor, LRP6 and β-
catenin, as well as members of the RTK family, namely c-Met and VEGFR2. In fact, these 
receptors are master regulators of oncogenesis and the studies in this thesis demonstrated an 
increase of translocation into the cytoplasm and nucleus upon MTf over-expression. This led to a 
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model proposing a novel trafficking mechanism within the cells where MTf and its associated 
oncogenic proteins could act as co-chaperones. In contrast, silencing MTf resulted in up-regulation 
of NDRG1 that then led to a decrease in WNT and RTK-mediated signalling.  
 
Chapter 5 then progressed to dissect the reported Yin-Yang relationship between MTf and 
NDRG1 first observed in Chapter 3 mediated by the NDRG1 transcriptional repressor, c-Myc. 
This was done to further identify by which mechanism MTf promoted oncogenic EMT-like 
changes in melanoma cells (e.g., increased nuclear β-catenin). The Yin-Yang MTf-NDRG1 
mechanism demonstrated that upon MTf over-expression, NDRG1 was suppressed. However, in 
contrast, upon silencing the NDRG1 transcriptional repressor, c-Myc, there was an increase in 
NDRG1 in VA cells and this also occurred upon MTf expression. The studies in Chapter 5 
demonstrated that upon silencing c-Myc, the observed increase in NDRG1 expression led to 
decreased nuclear β-catenin levels and increased levels of membrane-bound β-catenin. 
Furthermore, silencing c-Myc resulted in surprising new insight regarding the selectivity of MTf 
and NDRG1 regulation on signalling pathways in melanoma cells. 
 
Taken together, the findings in this thesis have enhanced the understanding of how the enigmatic 
protein, MTf, increases proliferation and tumour initiation and growth of melanoma cells 
Therefore, these studies are highly significant, considering novel therapeutic approach based on 
targeting the MTf-NDRG1 regulatory axis of pro-oncogenic signalling. This is critical not only for 
understanding the biology of melanoma and potential treatments that have been designed for 
inducing NDRG1 expression, including DpC, but also for the development of a potential 
prognostic markers for this belligerent disease. Currently, there are few useful treatments or 
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prognostic markers for melanoma, underlining the significance of the current results in this thesis. 
A summary of the principle findings from each thesis chapter will be discussed herein, followed 
by avenues for future research, and a conclusion to outline the significance of this thesis. 
 
6.1 Principle Findings 
6.1.1 Summary of Major Discoveries - Chapter 3 
 
More than 50% of human proteins have unknown or unclear functions, yet, ascribing functions to 
such “mystery” proteins could be the key to understanding their molecular pharmacology and 
treating many persistent human diseases. One such protein, melanotransferrin (MTf), is a 
transferrin homologue which was well-characterised at the molecular level (199), yet its functional 
role has remained elusive and a mystery (106). The high homology of MTf to the iron-binding 
protein, transferrin, and its ability to bind iron at a specific high affinity site suggested a role in 
iron metabolism. However, multiple studies indicated that MTf did not play a significant role in 
iron trafficking or homeostasis (105,195,200,203,204). In contrast, MTf was demonstrated to play 
a role in the proliferation and oncogenic capacity of melanoma cells in vitro and in vivo although 
the precise molecular mechanism involved remained unknown (105,113,195) and was the main 
focus of this thesis.  
 
Using 7 different models of MTf and NDRG1 expression and 3 different cell-types, Chapter 3 
demonstrated for the first time, that MTf regulates the expression of the potent metastasis 
suppressor, NDRG1. Moreover, this reciprocal Yin-Yang relationship between MTf and NDRG1 
was also confirmed in melanoma patient samples at both the mRNA and protein levels. In fact, the 
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ratio of NDRG1 to MTf decreases in correlation with the progression from dysplastic nevus stage 
to metastatic melanoma (Figure 3.9). Considering that NDRG1 is down-regulated in multiple 
tumours (187,188), the findings herein underline the significance of the current studies for 
understanding the biology, but also developing treatments and prognostic markers for melanoma 
and other tumours. Moreover, previous studies have also indicated poor patient prognosis with 
decreased NDRG1 levels in non-melanoma tumours (227). Since MTf was shown to be a 
glycosylphosphatidylinositol (GPI)-anchored plasma membrane protein (228), Chapter 3 
demonstrated a surprising observation using confocal microscopy, that MTf was expressed in the 
cytosol and nucleus of SK-MEL-28 in distinct puncta. This was also confirmed by fractionation 
with marker analysis. Notably, nuclear, as well as cytoplasmic MTf expression increased with MTf 
over-expression and the same effect on MTf compartmentalisation was also observed with 
silencing NDRG1, suggesting this alteration of MTf distribution has a pro-oncogenic role. 
Interestingly, our findings further demonstrated that MTf over-expression also decreased the well-
characterised phosphorylation of NDRG1 at Ser330 and Thr346. This is of significance, as these 
phosphorylated forms of NDRG1 have been implicated in its anti-metastatic activity 
(174,193,208).  
 
Notably, our laboratory (194) and others (176) have shown that inhibition of WNT signalling by 
NDRG1 involves: (i) binding with, and inhibition of the WNT co-receptor, LRP6 (176); (ii) the 
up-regulation of the GSK3β-binding protein, FRAT1 (194), which directs β-catenin to the cell 
membrane to prevent metastasis (72); and (iii) the inhibition of p21-activated kinase 4 (PAK4) 
(194) thereby preventing PAK4-mediated translocation of β-catenin to nuclei to initiate pro-
metastatic WNT signalling. 
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Interestingly, the up-regulation of MTf resulted in increased total, cytoplasmic and nuclear β-
catenin expression, whereas MTf silencing led to a prominent and distinct increase of β-catenin 
expression on the plasma membrane. In addition, the phosphorylation of β-catenin at S552, which 
indicates transcriptional activation (216), was also increased by MTf expression, with confocal 
microscopy demonstrating an increase in its nuclear levels (Figure 3.4F-H). In contrast, silencing 
MTf had an opposite effect on β-catenin nuclear translocation. The activation of WNT signalling 
by MTf expression was further evident by the up-regulation of the downstream WNT signalling 
molecules, c-Myc and cyclin D1 (194,219) (Figure 3.4A).  
 
Upon silencing NDRG1 in melanoma cells, there was up-regulation of total, cytoplasmic and 
nuclear β-catenin, with p-β-catenin (Ser552) translocating to the nucleus, where it enhanced the 
expression of the oncogenic WNT downstream targets, c-Myc and cyclin D1. Hence, the 
mechanism responsible for the ability of MTf expression to increase proliferation and 
tumourigenesis in vivo could be related to its ability to down-regulate NDRG1, and therefore, the 
subsequent increase in WNT signalling. Considering that c-Myc is a well-known transcription 
factor, that activates pro-oncogenic target genes (236-240), and also represses NDRG1 expression, 
the findings in Chapter 3 reveal a mechanism by which MTf is able to down-regulate NDRG1 
through c-Myc activation. Moreover, the findings indicate that the Yin-Yang relationship, which 
is observed under control condition is broken after loss of c-Myc, suggesting that c-Myc plays a 
vital role in the inter-relating regulation of MTf and NDRG1. 
 
From a therapeutic aspect, the data from Chapter 3 using DpC demonstrates that its ability to 
pharmacologically up-regulate NDRG1 expression has the same anti-oncogenic effect as genetic 
over-expression of NDRG1, that is, it decreased the expression of MTf and cyclin D1. Hence, the 
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identification of the novel NDRG1-MTf axis of regulation enables a potential therapeutic 
intervention against metastatic melanoma using DpC.  
 
In conclusion, the findings in Chapter 3 are the first to demonstrate that MTf has a pro-oncogenic 
role mediated through its ability to down-regulate the levels and phosphorylation of the potent 
metastasis suppressor, NDRG1. Due to its ability to down-regulate NDRG1, the expression of MTf 
resulted in pro-oncogenic alterations including increased nuclear β-catenin, p-β-catenin (Ser552), 
cyclin D1 and c-Myc. Furthermore, MTf over-expression up-regulated the major PI3K/AKT 
signalling pathway proteins and their activation, including, PI3K p85α, p-PI3K p85 α, p-AKT, 
AKT, p-mTOR and mTOR, again probably due to MTf’s ability to down-regulate NDRG1. This 
is of significance, as p-AKT is known to activate β-catenin phosphorylation at S552, and as such, 
this effect connects PI3K pathway to WNT signalling. In addition, the compelling discovery that 
the novel anti-cancer agent DpC can inhibit MTf and WNT signalling by up-regulating NDRG1, 
contributes to evidence supporting its potential use for inhibiting melanoma metastasis. 
 
6.1.2 Summary of Major Discoveries- Chapter 4 
While the studies in Chapter 3 shed new light into the function of MTf, the precise mechanism 
by which this molecule affects the downstream targets of WNT- and PI3K-signalling was not fully 
elucidated. MTf’s ability to up-regulate major oncogenic signalling pathways appears to be crucial 
to the activation of their downstream activation and oncogenic functions, as such, it was vital to 
identify the mechanism involved. Therefore, Chapter 4 aimed to examine the complex 
interactions of MTf with upstream pro-oncogenic signalling receptors that mediate these pathways 
in order to better understand its pro-proliferating activity by which it potentially promotes 
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melanoma progression. Findings from Chapter 3 showed that NDRG1 had a crucial role in 
counteracting the activation of these signalling pathways, and moreover, a loss of NDRG1 
contributed to increased oncogenic signalling. Chapter 4 intended to additionally investigate the 
role of NDRG1 on expression and/or activation of oncogenic receptors of interest. 
 
Classical WNT signalling requires the binding of secreted WNT ligands to key receptors, such as 
the WNT co-receptor LRP6 at the cell surface that ultimately results in proliferation, metastasis 
and oncogenesis (198,217). Moreover, the WNT pathway in melanoma cells depends on the 
expression level and sub-cellular localisation of β-catenin, which was examined in Chapter 3. In 
fact, these investigations demonstrated for the first time that MTf was able to facilitate WNT 
signalling, leading to the major hypothesis that MTf is pro-oncogenic via its ability to down-
regulate NDRG1, that then enhances WNT signalling and potentially the oncogenic signalling 
mediated through other pathways e.g., RTKs. 
 
Considering the common localisation on the plasma membrane of MTf and the RTKs, such as c-
MET, VEGFR2 and FGFR1, as well as the ability of RTKs to be down-regulated by NDRG1 
(190,191), studies then examined the effect of MTf on the expression of these receptors. Moreover, 
c-Met and VEGFR2 have been demonstrated to up-regulate the PI3K signalling pathway via their 
common downstream effector protein, namely Gab1, in melanoma cells (134,277,278). As such, 
initial studies in Chapter 4 concentrated on the effect of MTf on LRP6, c-Met and VEGFR2 
expression and activation. Of note, previous studies have demonstrated that MTf interacts with, 
and was internalised into cells by a lipoprotein receptor-related protein (LRP) family member, 
although the specific LRP isoform was never identified (112,115). This was of significance, as 
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Chapter 3 demonstrated that MTf was internalised and mainly localised in the nucleus and 
cytoplasm through an unknown mechanism. 
 
The findings in Chapter 4 demonstrated using multiple models of MTf and NDRG1 expression 
in melanoma cells, that MTf had a positive effect on up-regulating LRP6, p-LRP6 (Ser1490), c-
Met, p-c-Met (Tyr1349) and VEGFR2 levels. Additionally, NDRG1 silencing up-regulated the 
receptors in the same manner as MTf over-expression. This is important, as Chapter 3 
demonstrated a reciprocal Yin-Yang relationship between MTf and NDRG1 in vitro and in vivo. 
Furthermore, these previous studies established that NDRG1 was also shown to act as a WNT 
inhibitor (Figures 3.4C-E, 3.5), making its up-regulation an interesting therapeutic target in 
melanoma. The findings presented in Chapter 4 further highlighted the importance of NDRG1 in 
suppressing oncogenic signalling pathways in melanoma cells. In contrast to the up-regulation of 
c-Met and VEGFR2 with MTf over-expression, FGFR1 expression was decreased under these 
conditions in melanoma cells. This negative regulation of MTf expression on FGFR1, while 
positively up-regulating c-Met and VEGFR2, demonstrated that MTf activates only particular 
RTKs, while attenuating others. 
 
Taking into account MTf’s ability to translocate p-β-catenin (Ser552) into the nucleus as shown in 
Chapter 3, it was crucial to determine if a similar relationship exists between MTf expression and 
the nuclear translocation of LRP6, c-Met and VEGFR. Traditionally, it is known that endocytosis 
of cell surface receptors is crucial for regulation of signal transduction of several pathways, such 
as WNT, c-Met and VEGFR2 signalling (259,270,286-288). Several studies have demonstrated 
that LRP6 is internalised via a clathrin-mediated pathway, which plays a crucial role in down-
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regulating transmembrane signalling receptors, which consequently terminates cell signalling 
(286). In contrast, recent studies have uncovered a novel second endocytosis process that occurs 
in a caveolin-dependent manner, which is clathrin-independent and mediated by caveolae (289). 
The findings in Chapter 4 demonstrate via fractionation with marker analysis and also confocal 
immunofluorescence microscopy that total LRP6, p-LRP6 (Ser1490) and β-catenin were 
translocated into the cytoplasm and nucleus upon MTf over-expression, while MTf silencing 
reversed this process. Additionally, findings in Chapter 3 demonstrated that MTf expression up-
regulated WNT downstream targets, including β-catenin, c-Myc and cyclin D1. These data 
demonstrated active WNT signalling, which may be at least in part mediated or facilitated by 
internalisation via clathrin-dependent or independent processes. 
 
Chapter 3 demonstrated that MTf over-expression and NDRG1 silencing in melanoma cells led 
to MTf internalisation into puncta distributed in the cytoplasm, peri-nuclear and nuclear regions 
(Figure 3.1F). This finding was supported by studies demonstrating that GPI-anchored proteins 
are internalised similar to LRP6 via caveolae and lipid rafts (290). This was critical, as findings in 
Chapter 4 demonstrated using co-IP and confocal microscopy that MTf associated with LRP6, β-
catenin and its activated forms and as such, this mechanism may provide an explanation of the 
pro-oncogenic activity of MTf in melanoma patients.  
 
Fractionation and confocal immunofluorescences demonstrated that c-Met and VEGFR2 were 
predominantly localised in the cytoplasm and partly in the nucleus. However, the activated form 
of p-c-Met (Tyr1349) was mainly demonstrated in the nucleus indicating a novel function of this 
protein in melanoma cells. Significantly, these findings in Chapter 4 indicate that the mature and 
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full-length forms of c-Met, VEGFR2 and LRP6 were localised in the nucleus and moreover the 
nuclear expression increased upon MTf over-expression, suggesting a novel mechanism by which 
these receptors translocate to the nucleus. Once in the nucleus, RTKs have been reported to have 
non-canonical functions in transcriptional regulation, DNA repair regulation and DNA replication 
(232,294). It is also known that c-Met’s biological function is not restricted to its signalling role 
from the plasma membrane (294). Moreover, full-length c-Met has been reported to translocate to 
the nucleus in order to rapidly initiate calcium signalling after HGF stimulation in liver cells (271). 
Additionally, VEGFR2 binds to its own promoter and activates it in vivo in endothelial cells, 
suggesting that nuclear VEGFR2 regulates its own transcription and thus, amplifies the angiogenic 
response (131). As such, the demonstrated association between MTf and c-Met, VEGFR2, LRP6 
and β-catenin using co-IP and/or co-localisation by confocal microscopy (Figures 4.3-4.4, 4.6, 
4.9, 4.10), suggests a potential co-chaperone role for these proteins that initiates their transport 
into the cytoplasm and nucleus, where they act in a pro-oncogenic manner. Therefore, this model 
may explain the potential mechanism of how MTf promotes melanoma tumourigenesis and 
proliferation. 
 
Menezes et al. have recently demonstrated a novel association between the tumour suppressor, 
MIG6, and NDRG1 that stabilises MIG6 to promote EGFR processing and down-regulation (191). 
Considering this, Chapter 4 investigated a potential relationship between MIG6 and MTf and 
LRP6, c-Met and VEGFR2. Silencing MIG6 in melanoma cells up-regulated MTf, c-Met, p-c-Met 
(Tyr1349) and cyclin D1, while others, including NDRG1 and the major key players of the WNT 
pathway, LRP6, p-LRP6 (Ser1490), β-catenin and c-Myc decreased. These findings suggest a 
crucial role of MIG6 in regulating cellular signalling in melanoma cells. In particular, the up-
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regulation of MTf, c-Met and cyclin D1 after silencing MIG6 could suggest that it is acting on 
these proteins via its well characterised tumour suppressive function. This could occur by the direct 
binding of MIG6 to MTf, c-Met and cyclin D1 to induce their internalisation and degradation, as 
observed with EGFR (296). On the other hand, this tumour suppressive effect of MIG6 could be 
mediated indirectly via its interactions with other proteins. This is also another possibility, as c-
Met lacks the sequence identified in the EGFR as a MIG6-binding site (297) and appears not to be 
able to bind MIG6 directly (274). Of note, MIG6 has been demonstrated to decrease c-Met 
signalling, distally from c-Met, as part of a potential negative feedback loop (274). In the current 
studies, silencing MIG6 resulted in the down-regulation of key proteins in the WNT pathway, as 
well as, NDRG1. This latter effect can be explained by decreased formation of the MIG6-NDRG1 
complex that stabilises MIG6 (191), but may also increase the stability and half-life of NDRG1 in 
melanoma cells.  
 
Considering that after MIG6 silencing there was a decrease in WNT signalling proteins and/or 
their activation (namely LRP6, p-LRP6 (Ser1490), β-catenin and c-Myc), it can be suggested that 
this may occur through the down-regulation of c-Myc. Previous studies have demonstrated a novel 
model involving c-Myc in a c-Myc-WNT-feedback mechanism that involves DKK1 as an inhibitor 
of LRP6. Therefore, the decrease of LRP6, p-LRP6 (Ser1490) and β-catenin after c-Myc silencing 
suggests an inhibition of WNT-signalling, potentially due to increased levels of DKK1 upon MIG6 
silencing. Of note, under these conditions, NDRG1 was not responsible for the decrease in WNT 
signalling because it was down-regulated by MIG6 silencing.  
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In conclusion, Chapter 4 indicates that the pro-oncogenic role of MTf, which includes activation 
of pro-oncogenic signalling, is a consequence of its ability to increase the internalisation and 
nuclear translocation of the WNT co-receptor LRP6, its downstream targets and the RTKs, namely 
c-Met and VEGFR2. Moreover, the fact that MTf remained associated with LRP6, β-catenin and 
c-Met upon internalisation, suggested the formation of a stable complex that potentially is 
functionally important. In fact, the demonstrated association between MTf and c-Met, VEGFR2, 
LRP6 and β-catenin suggests a potential co-chaperone role for these proteins that initiates their 
transport into the cytoplasm and nucleus for potential pro-oncogenic functions. As such, this model 
may explain the ability of MTf to positively regulate these diverse pathways and cause such broad 
downstream effects.  
 
6.1.3 Summary of Major Discoveries - Chapter 5 
The aim of Chapter 5 was to further advance our understanding how MTf drives proliferation and 
activates certain oncogenic pathways, including WNT- and PI3K-signalling in regards to c-Myc 
expression. Therefore, Chapter 5 integrates the findings in Chapters 3 and 4, with its main focus 
being the effect of c-Myc upon the previously discussed receptors and the oncogenic WNT 
downstream targets. Moreover, it then examined the effect of c-Myc silencing on the translocation 
of these proteins to the nucleus.  
 
c-Myc protein is a well-known transcription factor that represses the potent metastasis suppressor 
NDRG1 (205). Chapter 3 demonstrated that upon MTf over-expression, c-Myc was shown to 
translocate to the nucleus, where it was transcriptionally active (205), and consequently decreased 
NDRG1 levels. In addition, these studies demonstrated that the Yin-Yang relationship between 
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MTf and NDRG1 was broken after c-Myc silencing, suggesting a crucial role for c-Myc in the 
regulation of the MTf-NDRG1 axis. 
 
The findings in Chapter 5 demonstrated that c-Met, p-c-Met (Tyr1349), VEGFR2 and cyclin D1 
increased in melanoma cells upon silencing c-Myc. At the same time, the loss of the transcriptional 
repression of c-Myc resulted in the up-regulation of NDRG1. This latter effect probably accounts 
for the fact that the WNT co-receptor, LRP6 and its active form p-LRP6 (Ser 1490), were 
significantly decreased after c-Myc silencing, suggesting a crucial involvement of NDRG1 on 
LRP6 down-regulation. This was supported by the fact that NDRG1 was previously shown to bind 
and inhibit LRP6, which resulted in the inhibition of WNT signalling (246).  
 
Moreover, Chapter 5 demonstrated that β-catenin expression on the plasma membrane and 
cytoplasm increased, while nuclear β-catenin translocation decreased upon c-Myc silencing. 
Again, this effect is probably due to the up-regulation of NDRG1 due to loss of the transcriptional 
repressor of NDRG1, c-Myc. As such, these studies highlight the ability of NDRG1 to prevent 
EMT and metastasis (194). These novel findings indicate that c-Myc silencing results in signalling 
alterations, where selected pro-oncogenic pathways were increased, while others were attenuated.  
 
Finally, the studies in Chapter 5 demonstrated that c-Myc silencing decreased the expression of 
the tumour suppressor, MIG6, despite the up-regulation of NDRG1. This was in contrast with 
previous studies that have reported an increase in MIG6 protein half-life with NDRG1 over-
expression (191). However, it is notable that after c-Myc silencing, both the RTKs, c-Met and 
VEGFR2, were up-regulated, which could be a consequence of the down-regulation of MIG6, as 
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it is known to down-regulate RTKs (296). The positive relationship between c-Myc and MIG6 
expression was potentially related to previous findings in Chapter 4 demonstrating that silencing 
MIG6 decreased c-Myc expression. Moreover, c-Myc up-regulation occurred in MTf over-
expressing cells, resulted in an increase in MIG6 expression. Hence, a feedback mechanism could 
be speculated to occur in rapidly growing cells, where up-regulation of c-Myc could then result in 
increased levels of MIG6 that then acts to down-regulate RTKs to then slow proliferation. Further 
studies are required to comprehensively investigate this hypothesis.  
 
In conclusion, the studies in Chapter 5 have shed new light onto the relationship between c-Myc, 
MTf and NDRG1 and important players in melanoma proliferation and oncogenesis. In particular, 
upon c-Myc silencing, the resultant up-regulation of NDRG1 then inhibits oncogenic WNT 
signalling despite MTf expression. These results demonstrate the role of c-Myc as key regulator 
of oncogenic signalling in melanoma cells. 
  
6.2 Future Directions 
6.2.1 Exploring the Relationship of MTf and NDRG1 from the Perspective of 
NDRG1 
 
Studies in this thesis were conducted with MTf over-expressing and silenced melanoma cell-types. 
Therefore, the thesis has examined the effect of over-expression or silencing MTf on NDRG1 
expression. In addition, NDRG1 was silenced in melanoma cells to examine its effects on MTf 
levels. Since the studies investigated the effect of MTf on the pro-oncogenic WNT and PI3K/AKT 
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signalling pathways, further studies are necessary to examine how over-expression of NDRG1 in 
melanoma cells could potentially prevent these pathways as a therapeutic mechanism. Moreover, 
the role and function of NDRG1 in melanoma metastasis is still unknown and further studies in 
vitro and in vivo in animal models will be important to examine this relationship. To achieve this, 
SK-MEL-28 and SK-MEL-2 melanoma cells will be stably transfected with an NDRG1 over-
expression vector e.g., the same used to transfect PANC1 cells in our laboratory (162). These cells 
will then be examined via western blotting to determine the effect of NDRG1 over-expression on 
molecules involved in the oncogenic WNT, PI3K and EMT pathways, such as β-catenin, p-β-
catenin (Ser552), c-Myc, cyclin D1, N-myc, p-AKT, p-mTOR, PTEN, E-cadherin as well as the 
WNT-co-receptor, LRP6, and the RTKs, c-MET, VEGFR2 and FGFR1.  
 
Considering that NDRG1 was reported to prevent WNT signalling and EMT in various cancer 
types (72,187-189), it would be of interest to investigate if over-expressed NDRG1 is capable to 
preventing melanoma metastasis by increasing the adherens junction formation at the cell 
membrane using confocal immunofluorescence. These studies would examine whether β-catenin 
and E-cadherin co-localise at the cell membrane, where they form the adherens junction complex 
upon NDRG1 over-expression (38). 
 
Chapter 3 and 5 have demonstrated that the Yin-Yang relationship between MTf and NDRG1 
was broken upon c-Myc silencing in VA, hIF and hIE clones of SK-Mel-28 melanoma cells. To 
determine whether c-Myc decreases NDRG1 levels at the mRNA or protein levels, qPCR and 
western analysis will be performed. The same investigation will also determine if the mRNA of 
MTf and other proteins examined in Chapter 5 are affected by the loss of c-Myc. Moreover, 
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silencing or over-expressing MTf with different incubation timepoints will aid in demonstrating if 
MTf is a potential upstream regulator of c-Myc and NDRG1 mRNA levels. 
 
Studies will also determine whether the observed decrease of NDRG1 expression in MTf over-
expressing melanoma cells is due to transcriptional suppression of c-Myc and/or via a protein 
degradation/inhibition mechanism. To investigate this, studies would inhibit lysosomal and 
proteasomal degradation using established inhibitors, such as chloroquine and MG132, 
respectively (304,305), to determine if MTf expression has an effect on NDRG1 degradation. 
Using the protein synthesis inhibitor, cycloheximide, studies could further test if MTf was altering 
NDRG1 half-life in melanoma cells using standard methodology (306,307). Briefly, control and 
MTf over-expressing cells will be pre-incubated with cycloheximide (10 µg/mL) for 1-8h at 37℃ 
and protein expression determined using western blot analysis. Moreover, future investigations 
could assess whether MTf and/or c-Myc bind and repress NDRG1 on its core promoter in 
melanoma cells (180,222). Co-immunoprecipitation studies will further determine if MTf and/or 
c-Myc are associated with NDRG1 to potentially inhibit its expression and/or mediate its 
degradation. 
 
6.2.2 Investigating the Nuclear Expression and Trafficking of MTf and Other 
Pro-Oncogenic Proteins 
 
As demonstrated in Chapter 3 and 4, MTf, LRP6, p-LRP6 (Ser1490), p-c-Met (Tyr1349), β-
catenin, p-β-catenin (Ser552), c-Myc and cyclin D1 were detected in the nucleus. Moreover, our 
studies showed that NDRG1 expression had an impact on the localisation of MTf, β-catenin and 
p-β-catenin (Ser552), leading to increased nuclear localisation of these proteins when NDRG1 was 
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silenced. Therefore, future studies using confocal immunofluorescence microscopy could examine 
if NDRG1 over-expression is able to re-distribute the localisation of these proteins, e.g. preventing 
their nuclear translocation in melanoma cells.  
 
Furthermore, Chapter 4 established an association of MTf with major oncogenic signalling 
proteins, including LRP6, p-LRP6 (Ser1490), p-c-Met (Tyr1349), β-catenin, p-β-catenin (Ser552) 
and VEGFR2 that potentially act as co-chaperone partners to initiate their transport into the 
cytoplasm and nucleus. To determine whether MTf and these proteins function as transcription 
factors, electrophoretic mobility shift assays (EMSA) could be performed (308). To investigate 
this, double stranded biotinylated oligonucleotides that contain sequences encoding for the specific 
coding regions to MTf, LRP6, p-LRP6 (Ser1490), p-c-Met (Tyr1349), β-catenin, p-β-catenin 
(Ser552) and VEGFR2 for the promoters of oncogenes, such as c-Myc, cyclin D1 and ZEB1 would 
be used. Nuclear extracts from melanoma cells (control vs. MTf over-expressing) would be 
incubated with biotin-end-labelled DNA in a specialised binding buffer to allow binding. The 
protein-DNA complexes would then be separated on a native PAGE gel and transferred onto a 
positively charged nylon membrane. This will demonstrate, if these proteins are capable of binding 
to a given DNA sequence of oncogenes. 
 
Regarding the caveolae trafficking hypothesis mentioned in Chapter 4, co-localisation studies of 
MTf, LRP6, p-LRP6 (Ser1490), β-catenin, p-β-catenin (Ser552) with caveolin or clathrin need to 
establish if both or either of these mechanisms could be involved in internalisation and 
translocation to the cytosol or nucleus. Moreover, inhibiting caveolae formation or endocytosis 
using chemical inhibitors, e.g. Filipin (1 μg/ml; 1h incubation), which binds to cholesterol in the 
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membrane and inhibits clathrin-independent endocytosis or a genetic approach using siRNA of 
clathrin (72h incubation; Thermofisher) to block formation of clathrin pits (309), would be a 
crucial step for dissecting the explicit mechanism(s) involved. Importantly, NDRG1 is known to 
bind to LRP6 and inhibit LRP6-WNT-signalling activity (176). Thus, NDRG1 may regulate the 
endocytic trafficking of MTf in an LRP6-dependent manner. This hypothesis is supported by our 
data that demonstrated an overall decrease in the levels of LRP6 and p-LRP6 with an increase in 
NDRG1 expression, which occurred after transient and stable silencing of MTf (Figure 4.1B-C). 
In contrast, siNDRG1 had the opposite effect on LRP6 and p-LRP6 (Ser1490) levels (Figure 
4.1D). 
 
Chapter 3 and 4 demonstrated that β-catenin and p-β-catenin (Ser552) levels increased at the 
plasma membrane, while nuclear and cytoplasmic levels of these proteins decreased when NDRG1 
was up-regulated in MTf silenced cells (Figure 3.4C, Dv, Eiii, F, Gv, Hiii, Figure 4.2B). Future 
studies will examine the ability of NDRG1 and LRP6 (modulated by silencing or over-expression) 
to regulate the intracellular localisation and endocytosis of MTf, which is relevant to understanding 
MTf’s regulation of WNT signalling. This will be assessed using methods described for other cell 
membrane proteins (310), including co-localisation of MTf with early endosomal (e.g., EEA1) and 
lysosomal (e.g., LAMP1) markers, as well as sub-cellular fractionation experiments.  
 
Chapter 3 demonstrated that MTf expression causes nuclear translocation of β-catenin, which was 
associated with positive regulation of c-Myc and cyclin D1. Both proteins are key β-catenin 
downstream effectors (194,219) and these effects of MTf are probably due to its ability to down-
regulate NDRG1, which is known to have an opposite anti-metastatic effect (186). Once in the 
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nucleus, β-catenin binds to LEF-1/TCF, which then binds to the cyclin D1 and/or c-Myc promoters 
(311). To directly test if MTf causes increased β-catenin DNA-binding activity in the nucleus, 
studies will next assess if MTf expression regulates: (i) cyclin D1 via increased nuclear β-catenin 
expression (EMSAs will be performed using nuclear extracts from MTf-modulated cells); (ii) a 
range of β-catenin-regulated genes (e.g., cyclin D1, c-Myc, DKK1, TCF1, VEGF, etc.) using 
chromatin immunoprecipitation (ChIP)-qPCR assays (312); and (iii) if MTf-mediated downstream 
changes occur through β-catenin/LEF-1 binding to the cyclin D1 promoter. The latter will be 
assessed by the “TOP/FOP” luciferase assay (194,313,314).  
 
Briefly, in the (ChIP)-assay DNA and associated proteins on chromatin in melanoma cells will be 
crosslinked. The DNA-protein complexes will then be trimmed into ~500 bp DNA fragments via 
sonication. Cross-linked DNA fragments associated with the proteins of interest will be selectively 
immunoprecipitated from the cell fragments using an appropriate protein antibody. The associated 
DNA fragments will then be purified and their sequence will be determined.  
 
In the TOP/FOP” luciferase assay, a pair of luciferase reporter constructs, namely TOP-flash and 
FOP-flash will be used to determine β-catenin/LEF1 transcriptional activity in control or MTf 
over-expressing cells. Cells will be transiently transfected in triplicate with one of the luciferase 
reporters and phRG-TK (Promega) using Lipofectamine 3000 (Invitrogen). After a 24 h incubation 
at 37oC, cells will be harvested and cell lysates prepared using the luciferase assay system 
(Promega). Luciferase activity will be measured with the Dual-luciferase reporter assay (Promega) 
and Renilla luciferase activity as an internal control. In summary, these studies will investigate 
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whether MTf increases β-catenin DNA-binding and regulation of key β-catenin-regulated genes 
that are implicated in melanoma progression. 
6.2.3 Further Identification of the Effect of MTf on Canonical and Non-
Canonical WNT Signalling 
 
Considering that this thesis has demonstrated an active role of MTf driving the WNT pathway in 
melanoma cells, future studies will further quantify changes in other key proteins involved in the 
canonical and non-canonical WNT pathways by western analysis via our established methods. 
These WNT proteins include: WNT1/3A/5A, DKKs, NDRG1, Sclerostin, LRP5, ROR2, RYK, 
FZ1/2/5/7, PLC, PKC, DVL, etc., and key down-stream regulated gene products (e.g., MITF). Key 
proteins (e.g., β-catenin, GSK3β active/inactive, DKK1, etc.) will also be assessed using WNT 
pathway ELISA kits (Enzo) to investigate the role of MTf on the activity of WNT pathway. In 
addition, in all studies, relative mRNAs will be extracted, and qPCR performed. Further studies 
will assess changes in mRNA/protein levels after incubation with key WNT ligands (e.g., human 
WNT1/3A, 5-6 h/37°C: 5-100 ng/mL, WNT5A: 100-500 ng/mL, 16 h/37°C; R&D Systems) in a 
range of MTf-modulated melanoma cells and other tumour cell-types. Comparisons of the 
melanoma cells will be made to primary cultures of normal melanocytes obtained from human 
foreskin cultures (315). In these studies, the effects of culturing cells under normoxia (21% O2) or 
hypoxia (1-5% O2) for 24 h/37°C will be compared. In fact, previous studies have demonstrated 
that hypoxia regulates melanoma WNT signalling (316), and thus, hypoxia is important to assess 
in our studies on MTf function in melanoma cells and other tumour cell-types. 
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6.2.4 Discovering the Regulatory Influence of MTf and NDRG1 on Oncogenic 
Signalling Receptors 
 
Chapter 4 and 5 demonstrated a regulatory relationship between NDRG1 and a number of pro-
oncogenic receptors (i.e., LRP6, c-Met and VEGFR2), where there was decreased levels of these 
proteins upon MTf silencing, resulting in NDRG1 up-regulation. Considering this, double silencing 
of MTf and NDRG1 in these cells would provide further insight into the mechanisms involved. 
 
Interestingly, a previous study has established a new positive c-Myc-WNT-feedback mechanism, 
in which c-Myc is capable to up-regulate WNT signalling by repressing the WNT pathway 
inhibitor, Dickkopf-related protein 1 (DKK1) in breast cancer cell lines (298). Indeed, in normal 
mammary epithelial cells, DKK1 is an extracellular WNT inhibitor that targets LRP5/6 for 
degradation, which results in regulated c-Myc gene expression and maintained normal proliferative 
cycles (299-301). Hence, the observed decrease of LRP6, p-LRP6 (Ser1490) upon silencing MIG6 
in Chapter 4 suggests an inhibition of WNT-signalling, potentially as a consequence to increased 
levels of DKK1 and clathrin-mediated lysosomal degradation of LRP6. Therefore, levels of DKK1 
will be investigated using western blot analysis with MIG6 silenced melanoma cells. Moreover, 
co-localisation and co-immunoprecipitation studies with LRP6 and DKK1 in MIG6 silenced cells 
will be conducted to determine a potential association between these two. Further co-localisation 
studies with LRP6 and the lysosomal marker LAMP2 will assess if LRP6 is being degraded via 
clathrin-mediated lysosomal degradation in MIG6 silenced melanoma cells. 
 
Interestingly, FGFR1 was found to be decreased in MTf over-expression SK-MEL-28 cells as 
demonstrated in Chapter 4. However, the mechanism of how FGFR1 is attenuated is poorly 
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understood and varies depending on cell types (281). The current model involves a negative 
feedback mechanism, including receptor internalisation through ubiquitination (282,283) and 
interaction of negative regulators of FGFR1 (133,284). Auto-inhibition is another potential 
mechanism (283,285) and MTf might be involved in this process. In order to understand this 
relationship between MTf and FGFR1, further investigations are required with silencing MTf in 
melanoma cells. Using co-localisation and co-immunoprecipitation studies with MTf and FGFR1 
in MTf over-expressing or MTf silenced cells will assess a potential interaction between these two 
proteins. Moreover, studies would inhibit lysosomal and proteasomal degradation using 
established inhibitors, such as chloroquine and MG132, respectively (304,305), to determine if 
MTf expression has an effect on FGFR1 degradation. Further co-localisation studies with FGFR1 
and LAMP2 will determine if FGFR1 is potentially being degraded via clathrin-mediated 
lysosomal degradation in MTf over-expressing. Finally, studies using the protein synthesis 
inhibitor, cycloheximide, could further assess if MTf was altering FGFR1 half-life in melanoma 
cells using standard methodology (306,307). 
 
6.2.5 The Role of MIG6 in the Regulation of the Receptors and MTf and the 
Potential Link to c-Myc 
 
Considering in Chapter 4 that MTf, c-Met and p-c-Met (Tyr1349) increased significantly with 
silencing of the tumour suppressor, MIG6, it is of importance to further investigate if MTf and c-
Met are potentially degraded via MIG6 by a lysosomal or proteasomal degradation. This will be 
examined using lysosomotropic inhibitors that prevent lysosomal degradation, such as 
chloroquine, methylamine and ammonium chloride (305,317) as well as proteasomal inhibitors 
such as MG132 and Lactacystin (318,319). Control and MTf over-expressing  cells will be treated 
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in the absence and presence of chloroquine (10 µM), methylamine (15 mM), ammonium chloride 
(15 mM), MG132 (2.5 µM) or Lactacystin (5 µM) for 24 h at 37℃. Protein expression will be 
determined using western blot analysis. Furthermore, it will be crucial to asses if NDRG1 and 
MIG6 need to be in a complex to potentially degrade MTf and c-Met, which is the case for EGFR 
degradation (191). This will be investigated by co-localisation studies using confocal microscopy 
and co-immunoprecipitation. 
 
To further investigate the mechanism responsible for the increase in MIG6 levels after c-Myc 
expression demonstrated in Chapter 4 and 5, future studies will perform western blot analysis 
with melanoma cells over-expressing c-Myc followed by assessment of MIG6 expression to 
confirm this relationship. In addition, co-immunoprecipitation studies will further determine if c-
Myc is associated with MIG6 to potentially increase its expression in a positive feedback manner. 
Moreover future studies would use the protein synthesis inhibitor, cycloheximide, to further test if 
c-Myc was altering MIG6 half-life in melanoma cells using standard methodology (306,307). 
 
6.2.6 The Therapeutic Potential of Targeting NDRG1 to Inhibit MTf Activity: 
In Vivo Studies  
 
A critical problem in melanoma is metastasis, which is the major killer (166,181). Indeed, the 
thesis has shown that MTf down-regulates the metastasis suppressor, NDRG1. Based on the 
previously reported studies, NDRG1 inhibits oncogenic WNT signalling (72,176,194) and for the 
first time the thesis has demonstrated that NDRG1 suppresses key aspects of WNT signalling in 
melanoma. Thus, in the context of the central hypothesis that MTf enhances oncogenic WNT 
signalling in melanoma, a novel therapeutic strategy for metastatic melanoma may be to up-
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regulate NDRG1. Future studies will assess the relationship between MTf, which enhances WNT 
signalling, and the WNT inhibitor NDRG1, in regulating metastasis in vivo. Secondly, studies in 
vivo will examine the novel strategy of up-regulating the WNT inhibitor, NDRG1, using DpC to 
inhibit metastasis. Both studies will be discussed in detail below. 
 
6.2.6.1 Cellular Role of MTf and NDRG1 in Melanoma Metastasis in Vivo  
Previous studies showed that a down-regulation of MTf leads to significantly decreased 
proliferation, DNA synthesis, cell migration, melanoma tumour xenograft growth and reduced 
tumour initiation in mice (195,245). Since metastasis is a crucial problem in melanoma, it is 
important to assess the role of both MTf and NDRG1 in melanoma metastasis in vivo. In these 
experiments, VMM12 human melanoma cells with modulated MTf expression will be used, since 
these cells are known to metastasis from the dermis to the lung after dermal injection and this 
model maintains all steps in metastasis from the skin to the circulation and finally seeding in the 
lung (320). As a model of MTf down-regulation, the cells will be stably transfected with siRNA 
targeting MTf mRNA. In addition, as an over-expression model, cells transfected with CMV-
driven expression vector pCMV-Script® alone (control) or this vector containing sense MTf 
cDNA will be used. 
 
To assess metastasis, these cell models will be labelled with green fluorescence protein (GFP) via 
a stable transfection with a GFP-expression vector. These cells will provide sensitive single cell 
detection in tissues (321) and human DNA detection via qPCR of a unique human AluI sequence 
(322). The same studies will be performed using VMM12 cells with up- and down-regulated 
NDRG1 levels with these cells being injected subcutaneous into the dermis on the right flank of 
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nude mice (323). Tumour growth will be measured twice weekly by vernier calipers (323) and 
mice will be sacrificed and all major organs weighted when the tumour reaches 1 cm in diameter 
and/or when VMM12 metastasis to the lung occurs. Previous studies have demonstrated that 
VMM12 metastases to the lung after 8 weeks after the initial subcutaneous tumour cell injection 
in nude mice (320). Lung, liver, lymph nodes and major organs will be dissected and then assessed 
for metastasis. The quantification of metastasis will be done by two methods: (i) Tissues will be 
imaged using Olympus Disc Spinning Unit Inverted Fluorescence Microscope and the La Vision 
BioTec TriM Scope II multiphoton microscope for deep-tissue imaging and each captured frame 
will be analysed using MetaMorph Software (321); and (ii) Quantitation of human DNA using a 
unique human AluI sequence (322) will be assessed via qPCR in mouse tissue. Tumour MTf levels 
will be determined by western analysis at the end of the study in the tumour to ensure stable 
expression. 
 
6.2.6.2 Effect of the Clinically Trialled Anti-Cancer Agent, DpC 
The metastasis suppressor, NDRG1, is a novel melanoma target, as it is strongly induced in a range 
of tumour cells by novel thiosemicarbazone agents (e.g., DpC) (72,190,324,325). Importantly, in 
Chapter 3 and 4, DpC significantly inhibited the expression of pro-oncogenic proteins, such as 
MTf, LRP6, p-LRP6 (Ser1490) and cyclin D1 in melanoma cells, while significantly up-regulating 
NDRG1 and MIG6. These striking results show the potential of this new therapeutic cancer agent. 
While the novel thiosemicarbazones have demonstrated potent and selective anti-cancer activity, 
including inhibiting melanoma xenografts in vivo (72,171,181,324), and up-regulating NDRG1 in 
melanoma tumours in vivo (171), their effects on melanoma metastasis in vivo are unknown and 
is critical to investigate. The effect of DpC in terms of inhibit melanoma metastasis in vivo will be 
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examined in tumours derived from high/low expressing VMM12 NDRG1 clones, which will be 
grown until the tumour volume reaches 120 mm3 (171) followed by treatment of 10 mice/condition 
with: (i) DpC (5 mg/kg, i.v., daily, 5×/week); or (ii) vehicle control (i.v., daily, 5×/week). 
Metastasis/tumour growth, as well as NDRG1/MTf levels, will be assessed in the “primary 
tumour”. Metastasis will be assessed with the methods described in Section 6.2.6.1. 
 
6.3 Concluding Remarks 
In conclusion, the data presented in this thesis has expanded our mechanistic knowledge of how 
MTf drives its pro-oncogenic activity via promotion of major oncogenic signalling pathways. 
Through the ability of pro-oncogenic MTf to down-regulate the metastasis suppressor, NDRG1, 
there is up-regulation of pro-oncogenic effectors including the WNT pathway and RTK receptors, 
including, LRP6, c-Met and VEGFR2. Indeed, this thesis demonstrates that a Yin-Yang 
relationship exists between anti-oncogenic NDRG1 and pro-oncogenic, MTf. Through the use of 
the clinically trialled di-2-pyridylketone thiosemicarbazone, DpC, which up-regulates NDRG1, 
the studies herein demonstrate that NDRG1 can inhibit MTf expression together with key proteins 
involved in WNT and RTK signalling. Collectively, the results indicate a compelling strategy for 
the treatment of metastatic melanoma through the ability of DpC to effectively target the MTf-
NDRG1 Yin Yang axis.  
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Appendix Figure 1: Silencing MTf Expression Up-Regulates NDRG1 and Silencing NDRG1 
with siNDRG1 II in SK-MEL-28 Melanoma Cells Increases MTf, β-catenin and p-AKT, 
While NDRG1 Over-Expression Down-Regulates MTf. (A) Silencing MTf expression using a 
stable siMTf clone (B2) of SK-MEL-28 cells results in the up-regulation of NDRG1 vs. the 
scrambled (SCR) control, as demonstrated by western blotting. (B) Transient silencing of NDRG1 
with an additional NDRG1 siRNA (siNDRG1 II) in SK-MEL-28 cells results in up-regulation of 
MTf, β-catenin and p-AKT vs. the negative control (NC) siRNA, as shown by western blotting. 
(Ci, ii) Immunofluorescence microscopy demonstrating up-regulation of NDRG1 and down-
regulation of MTf in the PANC-1 stable over-expressing NDRG1 clone (N1) relative to vector 
control (VC) cells. Images were taken using a 42× objective with the scale bar in the first image 
in (Ci & ii) representing 30 μm and is the same across all images. Quantitative analysis of NDRG1 
and MTf intensity was performed using ImageJ with results being mean + SD (3 experiments).  
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Appendix Figure 2: Confocal Immunofluorescence Microscopy Demonstrates that MTf 
Over-Expression in SK-MEL-28 Cells Increases Total, Nuclear and Cytoplasmic cyclin D1 
Levels, while MTf Silencing Results in the Opposite. Silencing MTf Expression Up-
Regulates Total β-catenin and Down-Regulates c-Myc and cyclin D1. (A) Confocal 
immunofluorescence microscopy and co-Masking Analysis via ImageJ demonstrates that cyclin 
D1 expression is increased the total, cytoplasmic and nuclear compartments of MTf over-
expressing vector-transfected clones (hIF and hIE) relative to the vector transfected control cells 
(VA), while transient MTf silencing in SK-MEL-28 cells decreases the total, cytoplasmic and 
nuclear cyclin D1 levels vs. the negative control (NC). (B) Silencing MTf expression using a 
stable siMTf clone (B1) of SK-MEL-28 cells results in the up-regulation of total β-catenin, and 
down-regulation of c-Myc and cyclin D1 vs. the scrambled (SCR) control, as demonstrated by 
western blotting. (C) Silencing MTf expression using a stable siMTf clone (B2) of SK-MEL-28 
cells results in down-regulation of c-Myc and cyclin D1 vs. the scrambled (SCR) control, as 
demonstrated by western blotting. Results are mean + SD (3 experiments). (D) Cells were 
stained with secondary antibody (Alexa 594; Alexa 488) only, as a negative control. **p<0.01, 
***p<0.001 vs. the relevant control. ImageJ analysis utilised a total of 11-21 cells over 3 
experiments. All images were taken using an 63x objective and the scale bar in the first image in 
(A) represents 30 μm and is the same across all images. 
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